<SEC-DOCUMENT>0001731122-23-000845.txt : 20230509
<SEC-HEADER>0001731122-23-000845.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509163112
ACCESSION NUMBER:		0001731122-23-000845
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		43
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		23902635

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>e4668_10-q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:avxl="http://anavex.com/20230331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2022_currency -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_avxl_anavex.com_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20221001_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001314052 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wOS0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DDocumentFiscalYearFocus_2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:EntityCentralIndexKey">0001314052</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:CurrentFiscalYearEndDate">--09-30</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-03-31" id="xdx2ixbrl0079" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-09-30" id="xdx2ixbrl0080" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-03-31" id="xdx2ixbrl0090" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-09-30" id="xdx2ixbrl0092" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl0156" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0157" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2021-10-012022-03-31" id="xdx2ixbrl0159" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0172" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2021-10-012022-03-31" id="xdx2ixbrl0174" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0223" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedUnder2023PurchaseAgreement" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-01-012022-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2022-01-012022-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-01to2023-03-31" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-012022-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2021-10-012022-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2021-10-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012022-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0441" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NoncashFinancingRelatedCharges" contextRef="From2021-10-012022-03-31" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:IncreaseDecreaseInDeferredGrantIncome" contextRef="From2021-10-012022-03-31" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2022-10-01to2023-03-31" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="avxl-20230331.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-10-01to2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_custom_MichaelJFoxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_custom_AnavexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_AnavexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-02</xbrli:startDate>
        <xbrli:endDate>2023-02-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_ThirdPartyPayorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 10pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b>&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><b>&#160;SECURITIES AND
EXCHANGE COMMISSION</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_901_edei--DocumentType_c20221001__20230331_zmrXAVWBK0Y"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">(Mark
One)</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Segoe UI Symbol,sans-serif"><b><span id="xdx_90C_edei--DocumentQuarterlyReport_c20221001__20230331_zGBtBrtABfae"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></b></span><b>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">For the quarterly period ended: <b><span style="text-decoration: underline"><span id="xdx_90F_edei--DocumentPeriodEndDate_c20221001__20230331_zrvuH3KYmo4d"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March
31, 2023</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Segoe UI Symbol,sans-serif"><b><span id="xdx_908_edei--DocumentTransitionReport_c20221001__20230331_zMb3LARAhzFj"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></b></span><b>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">For the transition period from _____to _____</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Commission File Number: <span style="text-decoration: underline"><span id="xdx_908_edei--EntityFileNumber_c20221001__20230331_zX2yLtWnxcWj"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:EntityFileNumber">001-37606</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90D_edei--EntityRegistrantName_c20221001__20230331_zaWsenSujCoj"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:EntityRegistrantName">ANAVEX LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>&#160;</b>(Exact name
of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="text-align: center"><span style="font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20221001__20230331_z8zOu4D3Kubf"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></b></span></td>
<td style="width: 50%; text-align: center"><span style="font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20221001__20230331_ztZNhCQki8Li"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:EntityTaxIdentificationNumber">98-0608404</ix:nonNumeric></span></span></b></span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of</span></td>
<td style="text-align: center"><span style="font-size: 10pt">(IRS Employer</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center"><span style="font-size: 10pt">incorporation or organization)</span></td>
<td style="text-align: center"><span style="font-size: 10pt">Identification No.)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_908_edei--EntityAddressAddressLine1_c20221001__20230331_zlInqem8zHNi"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:EntityAddressAddressLine1">630 5th Avenue</ix:nonNumeric></span>,
<span id="xdx_900_edei--EntityAddressAddressLine2_c20221001__20230331_zlIg7MD5ZEWc"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:EntityAddressAddressLine2">20th Floor</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressCityOrTown_c20221001__20230331_z5M60ho0Dvq3"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20221001__20230331" title="Entity Address, State or Province"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressCountry_c20221001__20230331" title="Entity Address, Country"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:EntityAddressCountry">US</ix:nonNumeric></span>A <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20221001__20230331_zKz6AQeZlsSa"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:EntityAddressPostalZipCode">10111</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;(Address of principal
executive offices) (Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span style="text-decoration: underline">1-<span id="xdx_901_edei--CityAreaCode_c20221001__20230331_zQz0bSZv3NJj"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:CityAreaCode">844</ix:nonNumeric></span>-<span id="xdx_901_edei--LocalPhoneNumber_c20221001__20230331_z9DUdIIq7CR2"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:LocalPhoneNumber">689-3939</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>&#160;</b>(Registrant&#8217;s
telephone number, including area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities Registered Pursuant to Section&#160;12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Title of Each Class</span></td>
<td style="vertical-align: top; padding-bottom: 1pt; text-align: center">&#160;</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Trading Symbol</span></td>
<td style="vertical-align: top; padding-bottom: 1pt; text-align: center">&#160;</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Name of Each Exchange on Which Registered</span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="width: 32%; text-align: center"><span style="font-size: 10pt"><span id="xdx_904_edei--Security12bTitle_c20221001__20230331_z1ZuWtZwNy"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:Security12bTitle">Common Stock Par Value $0.001</ix:nonNumeric></span></span></td>
<td style="width: 1%; text-align: center">&#160;</td>
<td style="width: 32%; text-align: center"><span style="font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20221001__20230331_zPhEjLrRvrRb"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:TradingSymbol">AVXL</ix:nonNumeric></span></span></td>
<td style="width: 1%; text-align: center">&#160;</td>
<td style="width: 34%; text-align: center"><span style="font-size: 10pt"><span id="xdx_90D_edei--SecurityExchangeName_c20221001__20230331_zGbHkqFqgj36"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter peri<span style="font: 10pt Times New Roman, Times, Serif">od that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#9746;&#160;<b><span id="xdx_906_edei--EntityCurrentReportingStatus_c20221001__20230331_ztSkv307JvG9"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#9744;
No</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#9746;
<b><span id="xdx_906_edei--EntityInteractiveDataCurrent_c20221001__20230331_z79XlXvuKARb"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9744; No</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 26%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--EntityFilerCategory_c20221001__20230331_zc0LHQwsKVM4"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Large accelerated filer</ix:nonNumeric></span></span></td>
<td style="width: 2%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9746;</span></td>
<td style="width: 44%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 26%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated filer</span></td>
<td style="width: 2%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Non-accelerated filer</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Smaller reporting company</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_edei--EntitySmallBusiness_c20221001__20230331_zjXnHihS1tT6"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" format="ixt:booleanfalse" name="dei:EntitySmallBusiness">&#9744;</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Emerging growth company</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--EntityEmergingGrowthCompany_c20221001__20230331_zFqWERcjEh7b"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Segoe UI Symbol,sans-serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#9744;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;
Yes &#9746; <span id="xdx_901_edei--EntityShellCompany_c20221001__20230331" title="Entity Shell Company"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date: <span id="xdx_903_edei--EntityCommonStockSharesOutstanding_iI_c20230508_zfBF2vuOI2Lf"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-05-08" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,837,723</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of common stock outstanding as of May 8, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b></b></p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 94%"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I&#160;&#160;&#160;FINANCIAL INFORMATION</b></span></a></td>
<td style="text-align: right; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 10pt"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1. FINANCIAL STATEMENTS</b></span></a></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 10pt"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 2. MANAGEMENT&#129;fS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESULTS OF OPERATIONS.</b></span></a></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 10pt"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.</b></span></a></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 10pt"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 4. CONTROLS AND PROCEDURES</b></span></a></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II&#160;&#160;&#160;OTHER INFORMATION</b></span></a></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 10pt"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1. LEGAL PROCEEDINGS</b></span></a></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 10pt"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1A. RISK FACTORS</b></span></a></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 10pt"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></span></a></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 10pt"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 3. DEFAULTS UPON SENIOR SECURITIES</b></span></a></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 10pt"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 4. MINE SAFETY DISCLOSURES</b></span></a></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 10pt"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 5. OTHER INFORMATION</b></span></a></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 10pt"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 6. EXHIBIT</b></span></a></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></a></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase"><span style="text-transform: none"></span></p>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase"><span style="text-transform: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_001"></span>PART I &#8211; FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_002"></span>ITEM 1. FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Anavex Life Sciences Corp.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Condensed Interim Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">March 31, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Unaudited)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10.5pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p>

<p style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Interim Consolidated Balance Sheets</span></p>

<p style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at March 31, 2023 and September 30, 2022</span></p>

<p style="font: 10.5pt/107% Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10.5pt/107% Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_111_zbMS5QfSBvbf" summary="xdx: Statement - Condensed Interim Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20230331" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20220930" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="text-align: center; font-weight: bold">March 31,</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="text-align: center; font-weight: bold">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsAbstract_iB_zhzKZtslzlrd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrentAbstract_i01B_z3NjxajLuDo6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzzh0_zZPCHeugfnP5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; width: 56%; text-align: left; text-indent: -10pt">Cash and cash equivalents</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,466,962</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,157,861</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxesReceivable_i02I_maCzzh0_zbXppceyxCO6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Incentive and tax receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,737,661</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,192,580</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzzh0_zXN2y68pPWDk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">981,774</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">354,162</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Assets_i01TI_mtCzzh0_zL65Uuu5KIx2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total Assets</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,186,397</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,704,603</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z7S2MJ0YzzJ8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Liabilities and Stockholders' Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrentAbstract_i01B_zFD8SUDVdtW7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableCurrent_i02I_maCzEQ3_z5i8dAbILVug" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,281,742</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,824,777</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzEQ3_zy7IqvjVcP39" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued liabilities - Note 4</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,822,838</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,944,953</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredIncomeCurrent_i02I_maCzEQ3_zXNzLZF545lj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt">Deferred grant income - Note 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">916,763</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,831</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Liabilities_i02TI_mtCzEQ3_maCzObk_z5umKapLbjEi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,021,343</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,213,561</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Commitments and Contingencies - Note 6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0079">-</span>&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0080">-</span>&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Capital stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Authorized:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_c20230331_pdd" title="Preferred stock, shares authorized"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_c20220930_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> preferred stock, par value $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_c20230331_pdd" title="Preferred stock, par value"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_c20220930_pdd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PreferredStockValue_iI_pp0p0_c20230331_zf7Q6uSH4T6g" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="color: rgb(204,235,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0090">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PreferredStockValue_iI_pp0p0_c20220930_zn2j9zxQoNm3" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="color: rgb(204,235,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0092">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20230331_pdd" title="Common stock, shares authorized"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_c20220930_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction> common stock, par value $</span></span><span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_c20230331_pdd" title="Common stock, par value"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20220930_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Issued and outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span id="xdx_907_eus-gaap--CommonStockSharesIssued_c20230331_pdd" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20230331_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,235,398</ix:nonFraction></ix:nonFraction></span></span> common shares (September 30, 2022 -<span id="xdx_90A_eus-gaap--CommonStockSharesIssued_c20220930_pdd" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_c20220930_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,942,815</ix:nonFraction></ix:nonFraction></span></span>)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--CommonStockValue_iI_pp0p0_maCzspi_c20230331_zcHrF7OSwwO1" title="Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 80,235,398 common shares (September 30, 2022 - 77,942,815)" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,236</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--CommonStockValue_iI_pp0p0_c20220930_zE0aZdTekH8a" title="Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 80,235,398 common shares (September 30, 2022 - 77,942,815)" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">77,944</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_maCzspi_zEbESgG8o9eg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Additional paid-in capital</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">416,727,598</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,976,881</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maCzspi_zTX2Mpv1JPeb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Accumulated deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">271,642,780</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">245,563,783</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquity_iTI_mtCzspi_maCzObk_zhqxftJ9YkYb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total Stockholders' Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,165,054</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,491,042</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzObk_z1tIQmA06sig" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities and Stockholders' Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,186,397</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,704,603</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Interim Consolidated Financial Statements</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 9.5pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p>

<p style="font: 9.5pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Interim Consolidated Statements of Operations</span></p>

<p style="font: 9.5pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three and six months ended March 31, 2023 and 2022</span></p>

<p style="font: 9.5pt/107% Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_309_113_zhrqLr4Ze3Kj" summary="xdx: Statement - Condensed Interim Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_495_20230101__20230331_zctGI1C6WPu6" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20220101__20220331_zhYgcn74NsQb" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_493_20221001_20230331" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20211001_20220331" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="7" style="text-align: center">Three months ended March 31,</td><td>&#160;</td>
    <td colspan="7" style="text-align: center">Six months ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_zjOrhVwF5Lb5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzWbx_zb2DzYvOLrO5" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; text-indent: -10pt; padding-left: 10pt">General and administrative</td><td style="width: 3%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,882,568</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,915,158</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,199,604</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,982,109</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzWbx_zbMnNKpW2lh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Research and development</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,306,591</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,604,589</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,373,510</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,261,028</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_i01T_mtCzWbx_msCzY72_zwatkH4bF8Wj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total operating expenses</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,189,159</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,519,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,573,114</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,243,137</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingIncomeLoss_i01T_mtCzY72_maCzKzX_zxTPGakwEiS5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating loss</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,189,159</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,519,747</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,573,114</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,243,137</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Other income (expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--NonOperatingIncomeFromGrants_i01_maCz3Xy_zPIzP3UPNBW7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Grant income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0156">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0157">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0159">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ResearchAndDevelopmentIncentiveIncome_i01_maCz3Xy_zJ8HAxLzQru" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development incentive income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">749,681</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">835,513</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,483,271</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,646,243</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InterestIncomeExpenseNet_i01_maCz3Xy_zqOYgItLFHyf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Interest income, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,465,221</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,578</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,732,839</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,488</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OtherFinancingExpense_i01_pp0p0_maCz3Xy_zPwdUEH4bpQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Other financing expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">964,344</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0172">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">964,344</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0174">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_pp0p0_maCz3Xy_zbJ8hFVLXYs8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Foreign exchange (loss) gain</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">118,678</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">268,645</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">247,305</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">324,008</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpense_i01T_mtCz3Xy_maCzKzX_zUoWEySdjbA6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total other income, net</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,131,880</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,111,736</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,524,071</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,982,739</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_mtCzKzX_maCzHeC_zVgNmL2Tzgq1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss before provision for income taxes</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,057,279</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,408,011</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,049,043</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,260,398</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_iN_pp0p0_di_msCzHeC_zRSy6UBKpn83" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Income tax expense, current</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,800</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,954</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">59,780</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_mtCzHeC_zfi0T0AQbauc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net loss and comprehensive loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,107,279</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,437,811</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,078,997</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,320,178</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EarningsPerShareAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Net Loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--NetLossPerShareBasicAndDiluted_i01_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Basic and diluted</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.17</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.14</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.33</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.28</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Weighted average number of shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_i01_pdd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">78,304,363</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">76,248,603</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">78,138,940</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">76,121,792</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Interim Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 8.5pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p>

<p style="font: 8.5pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Interim Consolidated Statements of Changes in Stockholders' Equity</span></p>

<p style="font: 8.5pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2023 and 2022</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_306_114_zjoMeCC4SFA9" summary="xdx: Statement - Condensed Interim Consolidated Statements of Changes in Stockholders&apos; Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zrJbeAnP3Ie7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z6ehgIR8p2c9" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_custom--ShareProceedsReceivableMember_zHniEy7U6dF1" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_ze2g83mmsvf1" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_z54xRZ9CPOf9" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Par Value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Additional Paid-in Capital</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Share proceeds Receivable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_43A_c20230101__20230331_eus-gaap--StockholdersEquity_iS_zVEK0K3VCoR1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-indent: -10pt; padding-left: 10pt">Balance, January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zL5TC8ANKVIe" title="Beginning balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,032,135</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,033</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">393,581,544</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0223">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">258,535,501</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,124,076</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--SharesIssuedUnder2023PurchaseAgreement_zoOcZz2Bv0Pk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Shares issued under 2023 purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--InitialCommitmentShares_zZlt9iz03Woe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt">Initial Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--InitialCommitmentSharesShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWwShAosroKf" title="Initial commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentSharesShares" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">844,425</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0237">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">844,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockRepurchasedDuringPeriodValue_zHjtGNQBnKqg" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt">Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockRepurchasedDuringPeriodShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTdECjRSYbZ7" title="Purchase shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,075,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,075</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,150,425</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0245">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,152,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--CommitmentShares_zj6rmm2s0Ws4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt">Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--CommitmentSharesShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXxE51vsK385" title="Commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,080</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0254">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Shares issued upon exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsInShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zc0mqi4Xbgcf" title="Shares issued upon exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,183</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,149</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,193</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,970,064</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,970,064</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,107,279</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,107,279</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20230101__20230331_eus-gaap--StockholdersEquity_iE_z0eh98oeifsf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance, March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8lsyMW3fmC4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,235,398</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,236</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">416,727,598</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">271,642,780</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,165,054</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20220101__20220331_eus-gaap--StockholdersEquity_iS_zsHHjULRcFHb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Balance, January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzjHInBIu5V6" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">76,155,187</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,156</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">354,759,781</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">208,468,231</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,367,706</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zm8v901eBOu9" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Shares issued upon exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsInShares_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGAPkvAjHYPl" title="Shares issued upon exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,386</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,426</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueOther_iP3custom--SharesIssuedPursuantToExerciseOfStockOptionsInShares_zZ1V9EyTSpVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Shares issued under Sales Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--SharesIssuedUnderSalesAgreementInShares_iP3us-gaap--StockIssuedDuringPeriodValueOther_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKeRYoeXlxq9" title="Shares issued under Sales Agreement, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreementInShares" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">966,801</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">967</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,489,713</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_custom_ShareProceedsReceivableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">403,696</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,086,984</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--LessShareIssueCosts_iP3custom--SharesIssuedUnderSalesAgreementInShares_zCDhAE4ErOuh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Less: share issue costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">374,720</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">374,720</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ziCQWhSWdjI3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,439,456</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,439,456</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_z6Ue2nh5x4B3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,437,811</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,437,811</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_438_c20220101__20220331_eus-gaap--StockholdersEquity_iE_zQCz6HSXa8ff" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance, March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWw9PXSBnErh" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,161,688</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,163</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">371,437,616</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_custom_ShareProceedsReceivableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">403,696</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">218,906,042</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,205,041</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><span style="background-color: lightgrey"><br />
</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Interim Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8.5pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p>

<p style="font: 8.5pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Interim Consolidated Statements of Changes in Stockholders' Equity</span></p>

<p style="font: 8.5pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended March 31, 2023 and 2022</span></p>

<p style="font: 8.5pt/107% Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 8.5pt/107% Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Par Value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Additional Paid-in Capital</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Share proceeds Receivable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_432_c20221001__20230331_eus-gaap--StockholdersEquity_iS_zWHpqtDwSjAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-indent: -10pt; padding-left: 10pt">Balance, October 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20221001__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9vl7NNTdCW1" title="Beginning balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,942,815</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,944</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,976,881</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">245,563,783</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,491,042</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--SharesIssuedUnder2023PurchaseAgreement_zYqjNxzJoxGe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Shares issued under 2023 purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--InitialCommitmentShares_zYAEntGsN7p5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt">Initial Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--InitialCommitmentSharesShares_c20221001__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrIRBPKWQux6" title="Initial commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentSharesShares" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">844,425</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">844,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockRepurchasedDuringPeriodValue_zXR4cgRhFOll" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt">Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockRepurchasedDuringPeriodShares_c20221001__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zigJPkT8crza" title="Purchase shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,075,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,075</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,150,425</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,152,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CommitmentShares_z1nrqCmSKPEb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt">Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--CommitmentSharesShares_c20221001__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYSG5vkgmsP7" title="Commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,080</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zV716PV0uSz5" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Shares issued upon exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsInShares_c20221001__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEnxHLylsmah" title="Shares issued upon exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">133,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">439,304</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">439,437</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z2711UjijVXa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,316,572</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,316,572</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_z3kYwP8xf5p6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,078,997</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,078,997</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_432_c20221001__20230331_eus-gaap--StockholdersEquity_iE_zayYdlTrFK55" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance, March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20221001__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhT3xYY6gysg" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,235,398</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,236</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">416,727,598</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">271,642,780</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,165,054</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20211001__20220331_eus-gaap--StockholdersEquity_iS_z07nVgKr7eU6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Balance, October 1, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20211001__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8YztfLHrBg6" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,918,465</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,920</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,328,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">197,585,864</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,818,104</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueOther_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Shares issued under Sales Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--SharesIssuedUnderSalesAgreementInShares_c20211001__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3RXuF9HB2Db" title="Shares issued under Sales Agreement, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreementInShares" contextRef="From2021-10-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,066,389</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,066</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,802,398</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012022-03-31_custom_ShareProceedsReceivableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">403,696</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,399,768</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--LessShareIssueCosts_zytcrdOkJttk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Less: share issue costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">537,806</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">537,806</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zZxaexb1Xapa" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Shares issued upon exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsInShares_c20211001__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVOd2o2RwlMj" title="Shares issued upon exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares" contextRef="From2021-10-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">176,834</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2021-10-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">177</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2021-10-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">496,746</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">496,923</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zPN8iB6wYJCe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,348,230</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0435">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,348,230</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_zlitzKc6VQjk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0441">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,320,178</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,320,178</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20211001__20220331_eus-gaap--StockholdersEquity_iE_zYT7Z0nxYO38" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance, March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20211001__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zv7j7ccqjkJh" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,161,688</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,163</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">371,437,616</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_custom_ShareProceedsReceivableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">403,696</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">218,906,042</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,205,041</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Interim Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p>

<p style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Interim Consolidated Statements of Cash Flows</span></p>

<p style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended March 31, 2023 and 2022</span></p>

<p style="font: 10.5pt/107% Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10.5pt/107% Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_112_zRUUAEzCv1me" summary="xdx: Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_497_20221001__20230331_zKSqS7SwA6Ia" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20211001__20220331_zww94AHn9had" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_z7Q5mifZf4na" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash Flows used in Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_i01_maCz82f_z3sLFCkZzvnl" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,078,997</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,320,178</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zcujfUoJ4rxh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Adjustments to reconcile net loss to net cash used in operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--NoncashFinancingRelatedCharges_i02_pp0p0_maCz82f_zaZNylEA4ot1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Non-cash financing related charges</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:NoncashFinancingRelatedCharges" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">844,500</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_i02_maCz82f_zNQd5GPwNbT7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Stock-based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,316,572</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,348,230</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_z5wdebW7rOo3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Changes in working capital balances related to operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msCz82f_z2HkUZCGfa8h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Incentive and tax receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,545,081</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,667,844</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCz82f_zVKwjejopk1l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Prepaid expenses and deposits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">627,612</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,056</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCz82f_zlU83ilaePQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,456,965</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,107,893</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCz82f_zduzDr96Y42b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Accrued liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">877,885</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">619,386</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--IncreaseDecreaseInDeferredGrantIncome_i02_maCz82f_z3jAujZCYjVd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Deferred grant income</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:IncreaseDecreaseInDeferredGrantIncome" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">472,932</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCz82f_maCzuLl_zO1rQITQBp3a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net cash used in operating activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,282,836</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,140,439</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zKrjmSH1cJkg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash Flows provided by Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzfED_z2HJB2e90pBl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Issuance of common shares</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,152,500</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,399,768</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsOfFinancingCosts_i01N_di_msCzfED_zHuooaNAMNld" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Share issue costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">521,441</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromStockOptionsExercised_i01_maCzfED_zYzD1W8CuV5h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Proceeds from exercise of stock options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">439,437</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">496,923</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzfED_maCzuLl_zoMIN3VtFXGb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net cash provided by financing activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,591,937</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,375,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_pp0p0_mtCzuLl_za30ijtnNZ4j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Increase in cash and cash equivalents during the period</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,309,101</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,234,811</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zP8p6IJDkvGk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Cash and cash equivalents, beginning of period</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,157,861</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,107,745</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zOdu5ekL5ms4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Cash and cash equivalents, end of period</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,466,962</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,342,556</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zznjxWtHPm1c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Supplemental Cash Flow Information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--CashPaidForStateAndLocalMinimumIncomeTaxes_i01_zJlMaCl5tXu8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Cash paid for state and local minimum income taxes</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,577</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,374</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Interim Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Interim Consolidated Financial Statements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2023</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_808_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zOTbS0vR8uEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#9;<span id="xdx_82A_zwdqtS4RVzRe">Business Description</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp. (&#8220;Anavex&#8221; or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the
development of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with
high unmet need. Anavex analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical
trials for the treatment of neurodegenerative and neurodevelopmental diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73 is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease
and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic
disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;), and Fragile X syndrome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="us-gaap:BasisOfAccounting"><p id="xdx_808_eus-gaap--BasisOfAccounting_zZq4uf2Shwha" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#9;<span id="xdx_82F_z0wmo129n8G2">Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_znYEvP3hVhT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zV0dfSXhuLel">Basis
of Presentation</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying unaudited condensed interim consolidated financial statements have been prepared pursuant to the rules and regulations of
the Securities and Exchange Commission (&#8220;SEC&#8221;) and accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly, certain information and note disclosures normally included in the annual
financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion
of management, the disclosures are adequate to make the information presented not misleading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments,
which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated balance
sheet as of September 30, 2022 was derived from the audited annual financial statements but does not include all disclosures required
by U.S. GAAP. The accompanying unaudited condensed interim consolidated financial statements should be read in conjunction with the audited
consolidated financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K for the year ended September
30, 2022 filed with the SEC on November 28, 2022. The Company follows the same accounting policies in the preparation of interim reports.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
results for the three and six months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the
year ending September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="avxl:LliquidityPolicyTextBlock"><p id="xdx_84C_ecustom--LliquidityPolicyTextBlock_zAiBDyICsCZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_znepwWF4jzGl">Liquidity</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its research
and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical
companies or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business
to continue to experience negative cash flows from operations for the foreseeable future and cannot predict when, if ever, our business
might become profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23E_zn24w7AoiA7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 1 -->
    <div id="xdx_23E_zBNbkNqW5BI" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div id="xdx_23A_zfFLAbxq9cXb" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_236_zr2LUA340u1g" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_z7T6J5GLu8Ya" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Interim Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zxQBMemleL97" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2023</span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zXGN5femSIOi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>


<ix:exclude><p id="xdx_23B_zrtXWTgPz8K" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
condensed interim consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the Sales Agreement
and the Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development
activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_849_eus-gaap--UseOfEstimates_zEswO4DgKpm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_866_zz3cpcMGIZ69">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_ze8RHSFauRVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zJrCBuITl9dc">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23E_zCnQkjLwrjF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 1 -->
    <div id="xdx_233_zBkksEuEBcrc" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div id="xdx_236_zconvEcJFBs3" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zBNjIaayvVB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_z2BcaXnqiJ3d" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_234_z3P9dzR4B4M8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Interim Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zFki5y62qzk7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2023</span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zKSfAdT85eA" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>


<ix:exclude><p id="xdx_237_zB5fqttmuBDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<b><i>&#160;</i></b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zxVD0g3eukN" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_861_zMQJMVFo24xb">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - &#9;quoted prices (unadjusted) in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active &#9;&#9;markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - &#9;assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2023 and September 30, 2022, the Company
did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zFLs6IeSvEY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_86C_z6s1GDvjulTl">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2023 loss per share excludes <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230331_pdd" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,001,613</ix:nonFraction></span>
(March 31, 2022: <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220331_pdd" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,510,319</ix:nonFraction></span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFRCuf4NZQB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_860_zvFoPQmzZ3Ll">Recently Adopted Accounting
Pronouncements</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2021, the FASB
issued ASU 2021-10, &#8220;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&#8221; (&#8220;ASU&#160;2021-10&#8221;).
ASU&#160;2021-10&#160;increases the disclosure requirements for annual reporting periods relating to material government assistance transactions
on the entity&#8217;s financial statements and any significant terms and conditions of the agreements including commitments and contingencies.
The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The
adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company
receives from the Australian Tax Office (&#8220;ATO&#8221;) for its clinical trials in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="avxl:OtherIncomeDisclosureTextBlock"><p id="xdx_805_ecustom--OtherIncomeDisclosureTextBlock_zERf2jW9hKlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 3&#9;<span id="xdx_822_zc1qQrqm7K6d">Other Income</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant Income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of March 31, 2023, the
Company had received $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012023-03-31_custom_MichaelJFoxMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">995,862</ix:nonFraction></span> in a research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant will
be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 related to Parkinson&#8217;s disease.
Of the total, $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230331__dei--LegalEntityAxis__custom--AnavexMember_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012023-03-31_custom_AnavexMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">497,931</ix:nonFraction></span> was received during the six months ended March 31, 2023, and $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20210930__dei--LegalEntityAxis__custom--AnavexMember_z5rWjDX54Ph7" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012021-09-30_custom_AnavexMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">497,931</ix:nonFraction></span> was received during the year ended September
30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:exclude><p id="xdx_23A_zsTcIYlzkhw" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div id="xdx_23F_z7Cl0lHf59r3" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div id="xdx_23F_zb8PDWhuoNAl" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zi3AJVaoJgLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zrpPzQXY8YZi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zIxyuHLX9eL4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Interim Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zwI8byWJbqZ5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2023</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_z5zjFAKU77ni" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>


<ix:exclude><p id="xdx_238_zAQGNDFNunTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income was recorded
to deferred grant income when received and is being amortized to grant income as the related research and development expenditures are
incurred. During the three and six months ended March 31, 2023, the Company recognized $<span id="xdx_907_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20230101__20230331_zXpvre4MlpK" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20221001__20230331_zFOthGqAh2zd" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span>, respectively (2022: $<span id="xdx_901_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20220101__20220331_zXZpFiQ0bYr1" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_c20211001__20220331_pp0p0" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>,
respectively) of this grant on its statements of operations as grant income. At March 31, 2023, an amount of $<span id="xdx_90B_ecustom--DeferredGrantIncome_c20230331_pp0p0" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">916,763</ix:nonFraction></span> (September 30, 2022:
$<span id="xdx_90F_ecustom--DeferredGrantIncome_c20220930_pp0p0" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">443,831</ix:nonFraction></span>) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to
other income. The Company will recognize this income on its statement of operations as the related expenditures are incurred to offset
the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents the income earned by Anavex Australia, of the Australian research and development tax incentive credit (the
&#8220;Tax Incentive Credit&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the three and six
months ended March 31, 2023, the Company recorded research and development incentive income of $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20230101__20230331_z1FOcf6chj13" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">749,681</ix:nonFraction></span> (AUD <span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20230101__20230331__srt--CurrencyAxis__currency--AUD_zVsN0Ahfr2mb" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-01-012023-03-31_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,099,134</ix:nonFraction></span>) and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20230331_zL0yXHqtsWdg" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,483,271</ix:nonFraction></span>
(AUD <span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20230331__srt--CurrencyAxis__currency--AUD_zdVDiI9JGhd5" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012023-03-31_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,215,753</ix:nonFraction></span>), respectively (2022: <span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20220101__20220331_zrupM5QNdMC7" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">835,513</ix:nonFraction></span> (AUD <span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20220101__20220331__srt--CurrencyAxis__currency--AUD_z8Arf3BQHsj4" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-01-012022-03-31_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,146,955</ix:nonFraction></span>) and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20220331_z7wpsblnBmN6" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,646,243</ix:nonFraction></span> (AUD <span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20220331__srt--CurrencyAxis__currency--AUD_znILBhzasKOa" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-10-012022-03-31_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,263,317</ix:nonFraction></span>), respectively) in respect of the Tax Incentive
Credit for eligible research and development expenses incurred during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Although the Company believes that it complies with all the relevant conditions of the program, the Company may be subject
to pre-issue review or audit by the ATO, and the ATO may have different interpretations of certain eligibility requirements. Currently,
the Company&#8217;s tax incentive claims from 2018 to 2022 are open to potential review or audit by the ATO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_801_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zmqY9hLAfjwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 4&#9; &#9; <span id="xdx_82E_zFwrf0lQpAs3">Accrued Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The principal components of accrued liabilities consist of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zE0fQQNmWDSj" summary="xdx: Disclosure - Accrued liabilities (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td id="xdx_8BB_zTXxyNJLU5Ud" style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt">&#160;Schedule of accrued liabilities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49E_20230331_z5Z9pzbGdPYh" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49C_20220930_zt7rlsV1Aj69" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">March 31,</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">September 30,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; text-indent: -10pt">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr id="xdx_403_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued clinical site and patient visits costs</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:AccruedClinicalSiteAndPatientVisitsCosts" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,168,950</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:AccruedClinicalSiteAndPatientVisitsCosts" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,031,105</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedBonusesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,572,500</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,297,337</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--FixedContractAccruals_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed contract accruals</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">82,666</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">417,414</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--MilestoneBasedContractAccruals_iI_pp0p0_zi1lOKAzRrMa" style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">Milestone based contract accruals</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:MilestoneBasedContractAccruals" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,041,930</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:MilestoneBasedContractAccruals" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">137,337</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,956,792</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,061,760</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzEQ3_zRGal2oAj7t1" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt">Total accrued liabilities&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,822,838</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,944,953</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="avxl:EquityOfferingTextBlock"><p id="xdx_80A_ecustom--EquityOfferingTextBlock_zK2pTZF4xKN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 5&#9;&#9;<span id="xdx_82D_zvJt3ZUU0ugc">Equity Offerings</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors (the &#8220;Board&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board has the authority to issue
preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting
any series of the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div id="xdx_234_zuUFpoDB7bLg" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zcxhe83LHx66" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zmI2blUfn4h5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zZUQv28MN6kk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zEIY30rOV8Mk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Interim Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zOcpEqrzvH69" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2023</span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zJJHaIX2rcBk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>


<ix:exclude><p id="xdx_23E_zy15cOvvtQAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company may offer and sell shares of common stock
registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on the Company&#8217;s
instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares by methods deemed to
be an &#8220;at the market offering&#8221; offering, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to
the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company
or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. The Sales
Agents will act as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable
state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has agreed to pay the Sales Agents commissions
for their services of up to <span id="xdx_905_ecustom--PercentageOfGrossProceedsFromSales_dp_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z7Hdr97BdNc1" title="Percentage of gross proceeds from sales"><ix:nonFraction name="avxl:PercentageOfGrossProceedsFromSales" contextRef="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed
to provide the Sales Agents with customary indemnification and contribution rights. During the six months ended March 31, 2023, <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_do_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember_zO2zbhTGAo1j" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> shares
were sold pursuant to the Offering. During the six months ended March 31, 2022, <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_znZ0YhjsDob6" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2021-10-012022-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,066,389</ix:nonFraction></span> shares were sold for gross proceeds of $<span id="xdx_906_ecustom--SoldForGrossProceedsAmount_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zxyLptqoQjQb" title="Sold for gross proceeds amount"><ix:nonFraction name="avxl:SoldForGrossProceedsAmount" contextRef="From2021-10-012022-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,803,464</ix:nonFraction></span>
(net proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z5lqCidGwX49" title="Proceeds from Issuance Public Offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,265,658</ix:nonFraction></span>). At March 31, 2023, an amount of $<span id="xdx_908_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20230331_zoIiPkFxGqHf" title="Sales of agreement amount"><ix:nonFraction name="avxl:SalesOfAgreementAmount" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">142,407,882</ix:nonFraction></span> (September 30, 2022: $<span id="xdx_90B_ecustom--SalesOfAgreementAmount_c20220930_pp0p0" title="Sales of agreement amount"><ix:nonFraction name="avxl:SalesOfAgreementAmount" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">142,407,882</ix:nonFraction></span>) was registered pursuant
to an effective registration statement and remained available to be sold under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into a $150,000,000
purchase agreement (the &#8220;Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant to
which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_pp0p0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zS6yotV9xMtj" title="Value of shares obligated to purchase"><ix:nonFraction name="avxl:ValueOfSharesObligatedToPurchase" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000,000</ix:nonFraction></span> in value
of its shares of common stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the Purchase Agreement,
the Company issued to Lincoln Park <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zHnm5s1hBbxd" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> shares of common stock as a commitment fee (the &#8220;initial commitment shares&#8221;) and
agreed to issue up to an additional <span id="xdx_903_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z1sVAdXIpP6a" title="Pro rata basic number of shares obligated to purchase"><ix:nonFraction name="avxl:NumberOfSharesObligatedToPurchaseProrataBasic" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion, the
$<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zUscKPRLCCv3" title="Proceeds from Issuance or Sale of Equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000,000</ix:nonFraction></span> aggregate commitment. The Company determined the fair value of the initial commitment shares was $<span id="xdx_909_ecustom--FairValueOfInitialCommitment_iI_c20230331_zSDQXyIJt879" title="Fair value of the initial commitment"><ix:nonFraction name="avxl:FairValueOfInitialCommitment" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">844,500</ix:nonFraction></span> with reference
to the closing price of the Company&#8217;s shares on the Purchase Agreement date. In addition, the Company incurred third party expenses
of $<span id="xdx_90E_ecustom--IncurredExpenses_iI_c20230331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__us-gaap--ThirdPartyPayorMember_zKWbQaYjFZA1" title="Incurred expenses"><ix:nonFraction name="avxl:IncurredExpenses" contextRef="AsOf2023-03-31_us-gaap_ThirdPartyPayorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,844</ix:nonFraction></span> in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense on the statement
of operations during the three and six months ended March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended March 31, 2023, the Company
issued to Lincoln Park an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zz6TJrJSBSUf" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,159,080</ix:nonFraction></span> (2022: <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_ziRnUQmbK2T9" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-10-012022-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span>) shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zH5D6LOehDP3" title="Number of shares issued for aggregate purchase price"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,075,000</ix:nonFraction></span>
(2022: <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z64bnbm9d63h" title="Number of shares issued for aggregate purchase price"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2021-10-012022-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span>) shares of common stock for an aggregate purchase price of $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zxsfRggGJ8K6" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,152,500</ix:nonFraction></span>&#160;(2022: $<span id="xdx_906_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z1C6MP1T5iEg" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2021-10-012022-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>) and&#160;<span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zF27NmC8jlp3" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,080</ix:nonFraction></span>&#160;(2022:&#160;<span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zW2CgLvpd8ri" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2021-10-012022-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span>) commitment
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2023, an amount of $<span id="xdx_900_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_do_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z5owmz6IyTGg" title="Amount of shares remain available"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues4" contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">131,847,500</ix:nonFraction></span> (September
30, 2022: $<span id="xdx_908_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_do_c20211001__20220930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zmR1jKfZKYCh" title="Amount of shares remain available"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues4" contextRef="From2021-10-012022-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>) remained available under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_231_z1vcYhlUwFjl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div id="xdx_230_zOeg6AiKPhyl" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zhmliES2eD1i" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zNNxHiOhubLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zwjFbaPQbyR8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zlFCb8Xcsxv3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Interim Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zBdnLk3UbjCc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2023</span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_z74qTY9Su1b4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>


<ix:exclude><p id="xdx_23D_zJhDXwQbDAw8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_804_eus-gaap--CommitmentsDisclosureTextBlock_z1dSsYXExwY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Note 6 &#9;<span id="xdx_82F_zG9sw5dBR2fe">Commitments and Contingencies </span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>Leases </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">During the three
and six months ended March 31, 2023, the Company incurred office lease expense of $<span id="xdx_90E_eus-gaap--CapitalLeaseObligationsIncurred_c20230101__20230331_zZhekqC2spK7" title="Incurred office lease expense"><ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,070</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--CapitalLeaseObligationsIncurred_c20221001__20230331_zERkFiZt4jz" title="Incurred office lease expense"><ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,140</ix:nonFraction></span>, (2022: $<span id="xdx_901_eus-gaap--CapitalLeaseObligationsIncurred_c20220101__20220331_zW0xMJ6LaTn3" title="Incurred office lease expense"><ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,488</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--CapitalLeaseObligationsIncurred_c20211001__20220331_z5qWXxxCyY65" title="Incurred office lease expense"><ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,333</ix:nonFraction></span>) respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company has
a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees.
United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal
Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees.
During the three and six months ended March 31, 2023, the Company made $<span id="xdx_90C_eus-gaap--PensionContributions_pp0p0_c20230101__20230331_zvbghzCNQOK6" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,230</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--PensionContributions_pp0p0_c20221001__20230331_zG5QutkUeVc6" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">99,876</ix:nonFraction></span> (2022: $<span id="xdx_90A_eus-gaap--PensionContributions_pp0p0_c20220101__20220331_zJ0TJ3eI48V3" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,940</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--PensionContributions_pp0p0_c20211001__20220331_zuLN5HQirWg8" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">93,622</ix:nonFraction></span>), respectively,
in matching contributions under the 401(k) plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>Litigation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company is subject
to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be
no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will
not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that any of
such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black; text-align: justify"><span style="font-weight: normal"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>Share Purchase Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2023 and September 30, 2022, the Company
had <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230331_zrRoiO2S0USc" title="Warrants outstanding"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zILBZQ2FOdWe" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></ix:nonFraction></span></span> warrants outstanding at a weighted average exercise price of $<span id="xdx_908_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_c20230331_zOsbPergO0I5" title="Warrants outstanding weighted average exercise"><span id="xdx_909_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_c20220930_z2gRaPqbItTj" title="Warrants outstanding weighted average exercise"><ix:nonFraction name="avxl:WarrantsOutstandingWeightedAverageExercise" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="avxl:WarrantsOutstandingWeightedAverageExercise" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.72</ix:nonFraction></ix:nonFraction></span></span> as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zvfUcIM49MZc" summary="xdx: Disclosure - Commitments and Contingencies (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B7_zvmoXTwM6Uoj" style="display: none">Schedule of share purchase warrants outstanding</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">Number</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td><td>&#160;</td>
    <td style="text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Number" style="padding: 0pt 0pt 0pt 10pt; width: 20%; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2023-03-31_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Exercise Price" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.17</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="text-align: right; width: 40%"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zoTANGKC0ck9" title="Expiry Date"><ix:nonNumeric contextRef="AsOf2023-03-31_custom_PurchaseWarrants1Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 6, 2024</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Number" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2023-03-31_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_ztGbnKtTdM1h" title="Expiry Date"><ix:nonNumeric contextRef="AsOf2023-03-31_custom_PurchaseWarrants2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April 21, 2026</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230331_pdd" title="Number" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A9_z8hNkttuMcZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>Stock&#8211;based Compensation
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2015 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s Board approved
a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_znucd8UstR88" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-03-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,050,553</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_237_z4g2r0CmzOUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 1 -->
    <div id="xdx_23B_zv1xb7pefMil" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div id="xdx_235_zAJEiKRo3IV2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zWTXH5k4ihg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zhneiCjw6GJ2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zSX1WYCm0Jhc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Interim Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zHnr4XFGVUhj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2023</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zG5CNqYX7JS1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>


<ix:exclude><p id="xdx_232_zACqcBT50oCe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zNXFiKqSVkDc" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2022-10-012023-03-31_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">406,453</ix:nonFraction></span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_z3HpFUr6ieje" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2022-10-012023-03-31_custom_StockOptionPlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> additional shares of Common Stock will be available for issuance under the plan. Any awards outstanding under a previous
stock option plan will remain subject to and be paid under such plan, and any shares subject to outstanding awards under a previous plan
that subsequently cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become
available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant and shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date,
then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.
Stock options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such
lesser periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. As at
March 31, 2023, <span id="xdx_90A_ecustom--OptionIssued_c20221001__20230331_zQWtabwz8zea" title="Option issued"><ix:nonFraction name="avxl:OptionIssued" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,916,000</ix:nonFraction></span> options had been issued under the 2022 Plan and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_za2iRI7BF6Ka" title="Option available issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-03-31_custom_StockOptionPlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,557,952</ix:nonFraction></span> options were available for issuance under the 2022
Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the status of Company&#8217;s outstanding
stock options is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zGhmkPXhQ9Gb" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
  <td colspan="3" style="text-align: center"><span id="xdx_8B2_zncDT1zZs2Fd" style="display: none">Schedule of outstanding stock purchase options</span></td>
  <td style="text-align: center">&#160;</td>
  <td colspan="3" style="text-align: center">&#160;</td>
  <td style="text-align: center">&#160;</td>
  <td colspan="3" style="text-align: center">&#160;</td>
  <td style="text-align: center">&#160;</td>
  <td colspan="3" style="text-align: center">&#160;</td>
  <td style="text-align: center">&#160;</td>
  <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
  <td colspan="3" style="text-align: center">&#160; &#160; &#160; &#160;</td>
  <td style="text-align: center">&#160; &#160; &#160; &#160;</td>
  <td colspan="3" style="text-align: center">Number of Shares</td>
  <td style="text-align: center">&#160; &#160; &#160; &#160;</td>
  <td colspan="3" style="text-align: center">Weighted Average Exercise Price<br />
($)</td>
  <td style="text-align: center">&#160; &#160; &#160; </td>
  <td colspan="3" style="text-align: center">Weighted Average Grant Date Fair Value <br />
($)</td>
  <td style="text-align: center">&#160; &#160; &#160; &#160;</td>
  <td colspan="3" style="text-align: center">Aggregate intrinsic value<br />
($)</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 38%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.3pt">Outstanding, September 30, 2021</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuzBCy6iGiC1" title="Options Outstanding at beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,330,903</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3PxdH3c3Bkh" title="Weighted Average Exercise Price Outstanding at beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.74</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#8212;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJrudywlnHWl" title="Aggregate intrinsic value Outstanding at beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">140,132,451</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrl6AoLbahe7" title="Options Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,358,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpR5tlEDrGP5" title="Weighted Average Exercise Price Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXA4H7ikh4S5" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.07</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqzKBxAWarQ8" title="Options Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">118,750</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zU3oWaBTWTdd" title="Weighted Average Exercise Price Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.86</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4IpSXM3CiS7" title="Weighted Average Grant Date Fair Value Forfeited" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqVjeaHJc6G1" title="Options Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,537</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoQtupOyyLAc" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHVz36IBp274" title="Weighted Average Grant Date Fair Value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.88</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zM5qpTwDdW9" title="Aggregate intrinsic value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,201,015</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.25pt">Outstanding, September 30, 2022</span></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFXiw3owsBw8" title="Options Outstanding at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,169,616</ix:nonFraction></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXET1KCwX4ik" title="Weighted Average Exercise Price Outstanding at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.61</ix:nonFraction></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zR1NM0Wrx97g" title="Aggregate intrinsic value Outstanding at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">62,267,309</ix:nonFraction></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxgkgXbaxH9h" title="Options Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,863,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzFsud6fYvaa" title="Weighted Average Exercise Price Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZ7sWM0phDt6" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.64</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJLx97GOqZHg" title="Options Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">133,503</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zU48Vjf8083" title="Weighted Average Exercise Price Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHXv9VJsWv6c" title="Weighted Average Grant Date Fair Value Exercised" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.4pt"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2</ix:nonFraction> 59</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHX4y89O55i" title="Aggregate intrinsic value Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">868,537</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpl3xaiUXDhd" title="Options Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,500</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5OJuXa1uuIl" title="Weighted Average Exercise Price Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.73</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0W6R3TPfm06" title="Weighted Average Grant Date Fair Value Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.09</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.3pt">Outstanding, March 31, 2023</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsT8EkRNCRK5" title="Options Outstanding at ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,841,613</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm5EPX5Pusl1" title="Weighted Average Exercise Price Outstanding at ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.97</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zekX38HHuEIi" title="Aggregate intrinsic value Outstanding at ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,709,206</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.25pt">Exercisable, March 31, 2023</span></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Options Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,937,362</ix:nonFraction></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Exercise Price Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.78</ix:nonFraction></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" title="Aggregate intrinsic value Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,099,822</ix:nonFraction></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>
</ix:nonNumeric><p id="xdx_8A8_zzJUVBBeEePg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at March 31, 2023 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zpLwDuPsADu5" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8BF_z1eKRi0UsXF1" style="display: none">Schedule Of Share-based Payment Arrangement, Option, Activity</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><b>Range of exercises prices</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Number of Outstanding</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Weighted average remaining contractual Me</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Weighted average</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Number of vested</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Weighted average</b></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>From</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>To</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>options</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>(in years)</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>exercise price</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>options</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>exercise price</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Range of exercise prices, lower range limit" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.92</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Range of exercise prices, upper range limit" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Number of outstanding options" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,834,559</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zRaAerWvkkzi" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.60</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Weighted average exercise price" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.29</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Number of vested options" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,834,559</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Weighted average exercise price options vested" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.29</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,022,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z5lJbEpxnPni" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.82</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,017,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.04</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,307,054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zD86a3Np2h0j" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.72</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.89</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,345,720</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.08</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,118,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zbp7pMbGF1mj" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.87</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">312,083</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.94</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Range of exercise prices, lower range limit" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.22</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Range of exercise prices, upper range limit" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.58</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Number of outstanding options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,559,500</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zxeHhqNGWvle" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.99</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Weighted average exercise price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.48</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Number of vested options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">427,500</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Weighted average exercise price options vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.90</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbdo8FSt1zU" title="Number of outstanding options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,841,613</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbdgeOa5UYe7" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.35</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Weighted average exercise price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.97</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Number of vested options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,937,362</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm9PpFXH0seh" title="Weighted average exercise price options vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.78</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A2_zqGnFQPsf3Mg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;&#160;&#160;</p>

<ix:exclude><p id="xdx_23F_zTP84jTmglf6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 1 -->
    <div id="xdx_234_zwVGVx2v9u4l" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div id="xdx_234_zyNAROhnAu77" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zqzfiqgA89U3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zFdhOBJPUkDl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zCu10uTlsARa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Interim Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zuTCq58XjG44" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2023</span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zuJBUtK4Crch" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>


<ix:exclude><p id="xdx_232_z5bvTmsMM0Th" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average grant date fair value of options
vested during the six months ended March 31, 2023 was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20221001__20230331_zgflxeD3c01f" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.67</ix:nonFraction></span> (2022: $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20220331_zWjP57fERXu8" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.20</ix:nonFraction></span>). At March 31, 2023, the weighted average contractual life of
options outstanding was <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331_zp2iDvKN79jb" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.35</ix:nonNumeric></span> years (September 30, 2022: <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zpWFArHrXTxj" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2021-10-012022-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.40</ix:nonNumeric></span> years) and for options exercisable was <span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331_zpFR4PrUC4hh" title="Options exercisable"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">4.92</ix:nonNumeric></span> years (September 30, 2022: <span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zbfkxxCCX355" title="Options exercisable"><ix:nonNumeric contextRef="From2021-10-012022-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5.1</ix:nonNumeric></span>
years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and six months ended March 31, 2023,
the Company recognized stock-based compensation expense of $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331_zwr5bLubUvv6" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,970,064</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20221001__20230331_zONmp8T38Vz2" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,316,572</ix:nonFraction></span> (2022: $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331_znNZBc8riQo8" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,439,456</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220331_zXUB5WrouLN6" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,348,230</ix:nonFraction></span>), respectively,
in connection with the issuance and vesting &#9;of stock options and warrants in exchange for services. These amounts have been included
in general and &#9;administrative expenses and research and development expenses on the Company&#8217;s statement of &#9;operations as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zHd2yF3cv6Yg" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BE_z3eIb511MQDb" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months end March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZcCk1tExeq6" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,256,845</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z88z9XC2Lula" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,577,831</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,999,370</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,249,557</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zs63jaqd34p8" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,713,219</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ztzAhJ2Uak1a" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,861,625</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,317,202</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,098,673</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total stock-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331_zA7bV7COo72e" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,970,064</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331_zI4O267A8sA1" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,439,456</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230331_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,316,572</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220331_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,348,230</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
</table>
</ix:nonNumeric><p id="xdx_8AB_zOSHWMv6YZXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20230331_zduzbrIwAZTd" title="Remaining stock based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,781,736</ix:nonFraction></span> in stock-based
compensation is expected to be recorded over the remaining term &#9;of such options through fiscal 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each option award
granted during the three and six months ended March 31, 2023 and 2022 is estimated on the date of grant using the Black Scholes option
pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2022-10-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zVpUVP5hTl97" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BF_z8iSpRqKAhh4" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20221001__20230331_zxQ8jJ4bCTIk" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.69</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220331_zkCu7YnhAW5k" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.40</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230331_zj9vhfofKnR4" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2022-10-01to2023-03-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.61</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220331_znjpVNeM15Gf" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2021-10-012022-03-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.90</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20221001__20230331_zRr20MOo3PR5" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85.28</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220331_zbUFlI3Ryp71" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95.88</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20221001__20230331_z5M3XiYupIY4" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-10-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220331_zPucHQvEpIdh" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-10-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
</table>
</ix:nonNumeric><p id="xdx_8A0_zOoYGMqz8fc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of stock compensation charges recognized
during the three and six months ended March 31, 2023 and 2022 was determined with reference to the quoted market price of the Company&#8217;s
shares on the grant date.</p>

</ix:nonNumeric><p id="xdx_814_zvxXBc15sOek" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_003"></span>ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Forward-Looking Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Quarterly Report on Form 10-Q includes
forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form
10-Q, including statements regarding our anticipated future clinical and regulatory milestone events, future financial position,
business strategy and plans and objectives of management for future operations, are forward-looking statements. The words &#8220;believe,&#8221;
&#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect&#8221;
&#8220;should,&#8221; &#8220;forecast,&#8221; &#8220;potential,&#8221; &#8220;predict&#8221;, &#8220;could,&#8221; &#8220;would,&#8221;
&#8220;will,&#8221; &#8220;suggest,&#8221; &#8220;plan&#8221; and similar expressions, as they relate to us, are intended to identify
forward-looking statements. Such forward-looking statements include, without limitation, statements regarding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">volatility in our stock price and in the markets in general;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to successfully conduct preclinical studies and clinical trials for our product candidates;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to raise additional capital on favorable terms and the impact of such activities on our stockholders and stock price;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the impact of the COVID-19 outbreak and its effect on us;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to generate any revenue or to continue as a going concern;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to execute our research and development plan on time and on budget; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our products candidates&#8217; ability to demonstrate efficacy or an acceptable safety profile; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain the support of qualified scientific collaborators; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability, whether alone or with commercial partners, to successfully commercialize any of our product candidates that may be approved for sale; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to identify and obtain additional product candidates; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our reliance on third parties in non-clinical studies and clinical trials; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to defend against product liability claims; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to safeguard against security breaches; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain and maintain sufficient intellectual property protection for our product candidates; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to comply with our intellectual property licensing agreements; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to defend against claims of intellectual property infringement; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to comply with the maintenance requirements of the government patent agencies; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to protect our intellectual property rights throughout the world; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">competition; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the anticipated start dates, durations and completion dates of our ongoing and future clinical trials; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the anticipated designs of our future clinical trials; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to attract and retain qualified employees; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the impact of Fast Track designation on receipt of actual FDA approval; </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our anticipated future regulatory submissions and our ability to receive regulatory approvals to develop and market our product candidates, including any orphan drug or Fast Track designations; and </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our anticipated future cash position and ability to obtain funding for our operations.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have based these forward-looking statements
largely on our current expectations and projections about future events, including the responses we expect from the U.S. Food and
Drug Administration, (&#8220;FDA&#8221;), and other regulatory authorities and financial trends that we believe may affect our
financial condition, results of operations, business strategy, preclinical studies and clinical trials, and financial needs. These
forward-looking statements are subject to a number of risks, uncertainties and assumptions including without limitation the risks
described in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange
Commission on November 28, 2022. These risks are not exhaustive. Other sections of this Quarterly Report on Form 10-Q include additional
factors which could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly
changing environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors,
nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking
statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking
statements will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.
Except as required by applicable laws including the securities laws of the United States, we assume no obligation to update or
supplement forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in this Quarterly Report on Form 10-Q,
the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Company&#8221;, and &#8220;Anavex&#8221; mean Anavex Life
Sciences Corp., unless the context clearly indicates otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Current Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. is a clinical stage
biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous
system (&#8220;CNS&#8221;) diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers,
which we use in the analysis of our clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our lead product candidate, ANAVEX<sup>&#174;</sup>2-73,
is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked
gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have two core programs and two
seed programs. Our core programs are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental
diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes key information about our programs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;<img src="img_001.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>* = Orphan Drug Designation by the FDA;
Dashed lines indicate planned clinical trials to-date</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex has a portfolio of compounds varying
in sigma-1 receptor (SIGMAR1) binding activities. The SIGMAR1 gene encodes the SIGMAR1 protein, which is an intracellular chaperone
protein with important roles in cellular communication. SIGMAR1 is also involved in transcriptional regulation at the nuclear envelope
and restores homeostasis and stimulates recovery of cell function when activated. In order to validate the ability of our compounds
to activate quantitatively the SIGMAR1, we performed, in collaboration with Stanford University, a quantitative Positron Emission
Tomography (PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX<sup>&#174;</sup>2-73 target engagement or receptor
occupancy with SIGMAR1 in the brain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="img_002.jpg" alt="" />&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><i>Source:
Reyes S et al., Sci Rep. 2021 Aug 25; 11(1):17150</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cellular Homeostasis</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many diseases are possibly directly caused
by chronic homeostatic imbalances or cellular stress of brain cells. In pediatric diseases, such as Rett syndrome or infantile
spasms, the chronic cellular stress is possibly caused by the presence of a constant genetic mutation. In neurodegenerative diseases,
such as Alzheimer&#8217;s and Parkinson&#8217;s diseases, chronic cellular stress is possibly caused by age-correlated buildup
of cellular insult and hence chronic cellular stress. Specifically, defects in homeostasis of protein or ribonucleic acid (&#8220;RNA&#8221;)
lead to the death of neurons and dysfunction of the nervous system. The spreading of protein aggregates resulting in a proteinopathy,
a characteristic found in Alzheimer&#8217;s and Parkinson&#8217;s diseases that results from disorders of protein synthesis, trafficking,
folding, processing or degradation in cells. The clearance of macromolecules in the brain is particularly susceptible to imbalances
that result in aggregation and degeneration in nerve cells. For example, Alzheimer&#8217;s disease pathology is characterized by
the presence of amyloid plaques, and neurofibrillary tangles, which are aggregates of hyperphosphorylated Tau protein that are
a marker of other diseases known as tauopathies as well as inflammation of microglia. With the SIGMAR1 activation through SIGMAR1
agonists like ANAVEX<sup>&#174;</sup>2-73, our approach is to restore cellular balance (i.e. homeostasis). Therapies that correct
defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental and neurodegenerative disease progression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>ANAVEX</i></b><sup>&#174;</sup><b><i>2-73-specific Biomarkers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of some of our clinical trials, we
have incorporated a genomic analysis to better understand potential populations for whom our clinical programs might benefit. In
our clinical trials, a full genomic analysis of Alzheimer&#8217;s disease patients treated with ANAVEX<sup>&#174;</sup>2-73 has
helped us identify actionable genetic variants. A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>&#174;</sup>2-73
and COMT, a gene involved in memory function, on the drug response level was identified, leading to an early ANAVEX<sup>&#174;</sup>2-73-specific
biomarker hypothesis. We believe that <i>excluding</i> patients with SIGMAR1 identified biomarker variant (approximately 10%-20%
of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically significant
improved functional and cognitive scores. The consistency between the identified DNA and RNA data related to ANAVEX<sup>&#174;</sup>2-73,
which are considered independent of Alzheimer&#8217;s disease pathology, as well as multiple endpoints and time-points, provides
support for the potential precision medicine clinical development of ANAVEX<sup>&#174;</sup>2-73 by using genetic biomarkers identified
within the trial population itself to target patients who are most likely to respond to ANAVEX<sup>&#174;</sup>2-73 treatment. We
may in the future utilize such an approach in Alzheimer&#8217;s disease as well as indications like Parkinson&#8217;s disease dementia
or Rett syndrome in which ANAVEX<sup>&#174;</sup>2-73 is currently being studied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Clinical Trials Overview</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Alzheimer&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial, consisting of Part A and Part B, which lasted a total of 57 weeks, for ANAVEX<sup>&#174;</sup>2-73 in mild-to-moderate Alzheimer&#8217;s
patients. This open-label randomized trial in Australia met both primary and secondary endpoints and was designed to assess the
safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients. ANAVEX<sup>&#174;</sup>2-73 targets sigma-1 and muscarinic
receptors, which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis
and to reverse the pathological hallmarks observed in Alzheimer&#8217;s disease. In October 2017, we presented positive pharmacokinetic
(&#8220;PK&#8221;) and pharmacodynamic (&#8220;PD&#8221;) data from the Phase 2a clinical trial, which established a concentration-effect
relationship between ANAVEX<sup>&#174;</sup>2-73 and trial measurements. These measures obtained from all patients who participated
in the entire 57 weeks include exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally,
the clinical trial appeared to show that ANAVEX<sup>&#174;</sup>2-73 activity was enhanced by its active metabolite (ANAVEX19-144),
which also targets the SIGMAR1 receptor and has a half-life approximately twice as long as the parent molecule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two consecutive trial extensions for the Phase
2a trial have allowed participants who completed the 52-week Part B of the trial to continue taking ANAVEX<sup>&#174;</sup>2-73,
providing an opportunity to gather extended safety data for a cumulative time period of five years. In August 2020, patients completing
these Phase 2a trial extensions were granted continued access to treatment with ANAVEX<sup>&#174;</sup>2-73 through the Australian
Government Department of Health &#8211; Therapeutic Goods Administration&#8217;s compassionate use Special Access Scheme.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A larger Phase 2b/3 double-blind, placebo-controlled
trial of ANAVEX<sup>&#174;</sup>2-73 in Alzheimer&#8217;s disease commenced in August 2018. The Phase 2b/3 trial enrolled 509 patients,
which were treated with a convenient once-daily oral formulation of ANAVEX<sup>&#174;</sup>2-73 for 48 weeks, randomized 1:1:1 to
two different ANAVEX<sup>&#174;</sup>2-73 doses or placebo. The trial took place at 52 sites across North America, Europe and Australia.
Primary and secondary endpoints to assess safety and both cognitive and functional efficacy, were measured through the Alzheimer&#8217;s
Disease Assessment Scale &#8211; Cognitive Subscale test (&#8220;ADAS-Cog&#8221;), Alzheimer&#8217;s Disease Cooperative Study
&#8211; Activities of Daily Living (&#8220;ADCS-ADL&#8221;) and Clinical Dementia Rating &#8211; Sum of Boxes for cognition and
function (&#8220;CDR-SB&#8221;). In addition to the primary endpoints, the ANAVEX<sup>&#174;</sup>2-73 Phase 2b/3 trial design incorporated
pre-specified statistical analyses related to potential genomic precision medicine biomarkers previously identified in the ANAVEX<sup>&#174;</sup>2-73
Phase 2a clinical trial. The trial was completed in mid-2022 and, in December 2022, the Company presented positive topline results
from the Phase 2b/3 clinical trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>2-73 met the co-primary
endpoints ADAS-Cog and ADCS-ADL and key secondary endpoint CDR-SB. ANAVEX<sup>&#174;</sup>2-73 treatment slowed decline of cognition
and function in patients with early Alzheimer&#8217;s disease over 48 weeks. Patients treated with ANAVEX<sup>&#174;</sup>2-73 had
1.84 times higher odds, or likelihood, to improve cognitively compared to placebo, with a ADAS-Cog score threshold change of -0.5
points or better [Odds Ratio = 1.84 (p = 0.015)]. At clinically significant levels of improvement in function (ADCS-ADL score threshold
change of +3.5 points or better), patients treated with ANAVEX<sup>&#174;</sup>2-73 had 2.67 times higher odds, or likelihood, to
improve function compared to placebo [Odds Ratio = 2.67 (p = 0.0255)]. <span style="color: black">Additionally, treatment with
ANAVEX<sup>&#174;</sup>2-73 reduced cognitive decline at end of treatment, measured with the ADAS-Cog, as compared to placebo, by
45%, representing a treatment difference in mean score change of -1.85 points (p=0.033). </span>Compared to placebo, ANAVEX<sup>&#174;</sup>2-73
reduced clinical decline of cognition and function by 27% with mean score difference of -0.42 points (p=0.040) as measured by the
CDR-SB. <span style="color: black">ANAVEX<sup>&#174;</sup>2-73 was generally safe and well tolerated. All statistical analyses were
performed by outside consultancy companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2019, we initiated a long-term open
label extension study of ANAVEX<sup>&#174;</sup>2-73, entitled the ATTENTION-AD trial, for patients who have completed the 48-week
Phase 2b/3 placebo-controlled trial referenced above. This trial extension for an additional two years, which is currently ongoing,
gives patients the opportunity to continue their treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Rett Syndrome </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in Rett syndrome, a rare neurodevelopmental disease. The data demonstrated dose related and
significant improvements in an array of behavioral and gait paradigms in a mouse model with an MECP2-null mutation that causes
neurological symptoms that mimic Rett syndrome. The study was funded by the International Rett Syndrome Foundation (&#8220;Rettsyndrome.org&#8221;).
In January 2017, we were awarded a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs
of a multicenter Phase 2 clinical trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. This award was received
in quarterly instalments which commenced during fiscal 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2019, we commenced the first Phase
2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. The clinical
trials are being conducted in a range of patient age demographics and geographic regions, utilizing an oral liquid once-daily formulation
of ANAVEX<sup>&#174;</sup>2-73.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The first Phase 2 trial, (ANAVEX<sup>&#174;</sup>2-73-RS-001),
which took place in the United States, was completed in December 2020. This trial was a randomized double-blind, placebo-controlled
safety, tolerability, PK and efficacy trial of oral liquid ANAVEX<sup>&#174;</sup>2-73 formulation in 25 adult female patients with
Rett syndrome over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73-specific genomic precision medicine biomarkers.
The primary endpoint of the trial was safety. The dosing of 5 mg ANAVEX<sup>&#174;</sup>2-73 was well-tolerated and demonstrated
dose-proportional PK. All secondary efficacy endpoints of the trial showed statistically significant and clinically meaningful
response in the Rett Syndrome Behaviour Questionnaire (&#8220;RSBQ&#8221;) response, when compared to placebo, in the intent to
treat (&#8220;ITT&#8221;) cohort (all participants, p = 0.011). 66.7% of ANAVEX<sup>&#174;</sup>2-73 treated subjects showed a statistically
significant improvement in RSBQ response as compared to 10% of the subjects on placebo in the ITT cohort (all participants, p =
0.011). ANAVEX<sup>&#174;</sup>2-73 treatment resulted in a sustained improvement in Clinical Global Impression Improvement (CGI-I)
response throughout the 7-week clinical trial, when compared to placebo in the ITT cohort (all participants, p = 0.014). Consistent
with previous ANAVEX<sup>&#174;</sup>2-73 clinical trials, patients carrying the common form of the SIGMAR1 gene treated with ANAVEX<sup>&#174;</sup>2-73
experienced stronger improvements in the prespecified efficacy endpoints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
second, international trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the AVATAR trial, commenced
in June 2019.</span> This trial took place in Australia and the United Kingdom using a higher dose than the U.S. based Phase 2
trial for Rett syndrome. The trial was a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the safety and
efficacy of ANAVEX<sup>&#174;</sup>2-73 in 33 adult patients over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73
specific precision medicine biomarkers. Based upon the input from the successful U.S. Phase 2 Rett syndrome trial (ANAVEX<sup>&#174;</sup>2-73-RS-001),
we updated the endpoints for the AVATAR trial (ANAVEX<sup>&#174;</sup>2-73-RS-002) to appropriately assess the clinically meaningful
outcome following International Conference on Harmonization (ICH) guidelines. These updates were approved by the respective regulatory
authorities in the U.K. and in Australia, respectively, where the AVATAR trial was conducted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The data from the AVATAR trial was released
in February 2022. The clinical trial met all primary and secondary efficacy and safety endpoints, with consistent improvements
in primary efficacy endpoint, RSBQ response (p = 0.037), and secondary efficacy endpoints, ADAMS (p = 0.010) and CGI-I (p = 0.037)
response. Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome symptoms.
Convenient once daily oral liquid doses of up to 30 mg of ANAVEX<sup>&#174;</sup>2-73 were also well tolerated with good medication
compliance. All patients who participated in the trial were eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open
label extension protocol.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the third trial
of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the EXCELLENCE trial. This Phase 2/3 trial in pediatric
patients with Rett syndrome includes trial sites in Australia, the United Kingdom and Canada, and will evaluate the safety and
efficacy of ANAVEX<sup>&#174;</sup>2-73 in approximately 84 pediatric patients, aged 5 to 18, over a 12-week treatment period incorporating
ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers. This trial completed enrollment in February 2023, exceeding
the original enrollment target and topline results are expected in the second half of 2023. All patients who participate in the
trial will be eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label extension protocol, which is currently
ongoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Parkinson&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in an animal model of Parkinson&#8217;s disease, which demonstrated significant improvements
on behavioral, histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J. Fox Foundation. Additional
data announced in October 2017 indicated that ANAVEX<sup>&#174;</sup>2-73 induced robust neurorestoration in experimental Parkinsonism.
We believe the encouraging results we have gathered in this preclinical model, coupled with the favorable profile of this product
candidate in the Alzheimer&#8217;s disease trial, support the notion that ANAVEX<sup>&#174;</sup>2-73 has the potential to treat
Parkinson&#8217;s disease dementia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, we completed a double-blind,
randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia
in Spain and Australia, to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease.
The Phase 2 trial enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73
doses, 30 mg and 50 mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73 Phase 2 Parkinson&#8217;s disease dementia trial design incorporated
genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s disease trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial demonstrated that ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50 mg once daily. The results showed clinically meaningful, dose-dependent, and
statistically significant improvements in the Cognitive Drug Research (&#8220;CDR&#8221;) computerized assessment system analysis.
Treatment with ANAVEX<sup>&#174;</sup>2-73 also resulted in clinically meaningful improvements as measured by the global composite
score of Parkinson&#8217;s disease symptom severity, MDS-Unified Parkinson&#8217;s Disease Rating Scale (&#8220;MDS-UPDRS&#8221;)
total score on top of standard of care including dopaminergic therapy, levodopa and other anti-PD medications after 14 weeks of
treatment, suggesting ANAVEX<sup>&#174;</sup>2-73&#8217;s potential capability of slowing and reversing symptoms that progress in
Parkinson&#8217;s disease. In addition, the trial confirmed the precision medicine approach of targeting SIGMAR1 as a genetic biomarker
in response to ANAVEX<sup>&#174;</sup>2-73 may result in improved clinical outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A 48-week Open Label Extension (&#8220;OLE&#8221;)
ANAVEX2-73-PDD-EP-001 Phase 2 trial was offered to participants after completion of the double-blind placebo-controlled ANAVEX2-73-PDD-001
Phase 2 trial discussed above. The OLE trial assessed safety, tolerability and efficacy, measuring among others, MDS-Unified Parkinson&#8217;s
Disease Rating Scale Parts I, II, III, REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Clinical Global Impression
&#8211; Improvement (CGI-I), as well as cognitive efficacy endpoint Montreal Cognitive Assessment (MoCA) over a 48-week period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2023, we reported the preliminary
ANAVEX2-73-PDD-EP-001 OLE trial data, which demonstrated longitudinal beneficial effects of ANAVEX<sup>&#174;</sup>2-73 on the prespecified
primary and secondary objectives. Preliminary analysis reveals that ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) was found to be generally
safe and well tolerated; and safety findings in this trial were consistent with the known safety profile of ANAVEX<sup>&#174;</sup>2-73.
In respect to efficacy, across all efficacy endpoints, patients performed better while on ANAVEX<sup>&#174;</sup>2-73. While all
patients were on drug holiday due to COVID-19 between the DB EOT and the OLE Baseline, the respective efficacy endpoints, including
the MDS-UPDRS Part II + III and CGI-I, measured at the end of trial of the double-blind study (DB EOT) and the OLE Baseline, were
worsening, as expected in a progressive disease like Parkinson&#8217;s. However, when patients resumed daily oral ANAVEX<sup>&#174;</sup>2-73
treatment, a consistent improvement was observed during the extension phase from OLE Baseline through OLE Week 24, and OLE Week
48, respectively. These results are consistent with the pattern observed for all efficacy measures in the extension phase. The
two endpoints, MDS-UPDRS Part II + III and CGI-I measured in this study are the planned primary and key secondary endpoints in
our forthcoming pivotal 6-month Parkinson&#8217;s disease study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2021, we were awarded a research
grant of $1.0 million from&#160;The Michael J. Fox Foundation for Parkinson&#8217;s Research&#160;to develop ANAVEX<sup>&#174;</sup>2-73
for the treatment of Parkinson&#8217;s disease. The award will explore utilization of PET imaging biomarkers to enable measurement
of target engagement and pathway activation of the SIGMAR1 with clinically relevant doses including in people with Parkinson&#8217;s
disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Frontotemporal Dementia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the First-in-Human
Phase 1 clinical trial of ANAVEX<sup>&#174;</sup>3-71. ANAVEX<sup>&#174;</sup>3-71 was previously granted orphan drug designation
for the treatment of Frontotemporal Dementia (&#8220;FTD&#8221;) by the FDA. ANAVEX<sup>&#174;</sup>3-71 is an orally administered
small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases.
In preclinical studies, <span style="background-color: white">ANAVEX<sup>&#174;</sup>3-71 demonstrated disease-modifying activity
against the major hallmarks of Alzheimer&#8217;s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and
tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Phase
1 clinical trial was a prospective double-blind, randomized, placebo-controlled trial in Australia. A total of 36 healthy male
and female subjects were included. Single escalating doses of ANAVEX<sup>&#174;</sup>3-71 were administered in order to evaluate
the safety, tolerability, and PK of ANAVEX<sup>&#174;</sup>3-71 and the effects of food and gender on its PK in healthy volunteers.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The trial
met its primary and secondary endpoints of safety, with no serious adverse events (&#8220;SAEs&#8221;) or dose-limiting toxicities
observed. ANAVEX<sup>&#174;</sup>3-71 was well tolerated in all cohorts receiving ANAVEX<sup>&#174;</sup>3-71 in single doses ranging
from 5 mg to 200 mg daily with no SAEs and no significant lab abnormalities in any subject. In the trial, ANAVEX<sup>&#174;</sup>3-71
exhibited linear PK. Its pharmacokinetics was also dose proportional for doses up to 160 mg. Gender had no effect on the PK of
the drug and food had no effect on the bioavailability of ANAVEX<sup>&#174;</sup>3-71. The trial also met the secondary objective
of characterizing the effect of ANAVEX<sup>&#174;</sup>3-71 on electrocardiogram (&#8220;ECG&#8221;) parameters. There were no clinically
significant ECG parameters throughout the trial. Participant QTcF measures were normal across all dose groups with no difference
between ANAVEX<sup>&#174;</sup>3-71 and placebo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Based
on these results, and ANAVEX<sup>&#174;</sup>3-71&#8217;s pre-clinical profile, we intend to advance ANAVEX<sup>&#174;</sup>3-71
into a biomarker-driven clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer&#8217;s disease,
evaluating longitudinal effect of treatment with ANAVEX<sup>&#174;</sup>3-71. We believe the results of these clinical trials and
preclinical study could serve as a basis for advancing into respective registration trials in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Pipeline</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development pipeline includes
ANAVEX<sup>&#174;</sup>2-73 currently in three different clinical trial indications, and several other compounds in different stages
of clinical and pre-clinical development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our proprietary SIGMACEPTOR&#8482; Discovery
Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma
receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer&#8217;s
disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate ligands, sigma receptors influence
the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease. Multiple
viruses including SARS-CoV-2 (COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related cellular
processes, in order to ensure survival and replication. Hence, it is possible that SIGMAR1 could play a role in modulating the
cellular response to viral infection and ameliorate pathogenesis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compounds that have been subjects of our research
include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>2-73 <i>(blarcamesine)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe ANAVEX<sup>&#174;</sup>2-73 may offer
a disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of SIGMAR1. ANAVEX<sup>&#174;</sup>2-73
is being developed in an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily
capsule formulation for diseases such as Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Rett syndrome, administration of ANAVEX<sup>&#174;</sup>2-73
in liquid form resulted in both significant and dose related improvements in an array of behavioral paradigms in the MECP2 HET
Rett syndrome disease model. In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX<sup>&#174;</sup>2-73 was
evaluated in automatic visual response and respiration tests in 7-month old mice, an age at which advanced pathology is evident.
Vehicle-treated MECP2 mice demonstrated fewer automatic visual responses than wild-type mice. Treatment with ANAVEX<sup>&#174;</sup>2-73
for four weeks significantly increased the automatic visual response in the MECP2 Rett syndrome disease mice. Additionally, chronic
oral dosing daily for 6.5 weeks of ANAVEX<sup>&#174;</sup>2-73 starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett
syndrome disease mouse model assessed the different aspects of muscular coordination, balance, motor learning and muscular strengths,
some of the core deficits observed in Rett syndrome. Administration of ANAVEX<sup>&#174;</sup>2-73 resulted in both significant
and dose related improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2016 and June 2016, the FDA granted
Orphan Drug Designation to ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome and infantile spasms, respectively. In
November 2019, the FDA granted to ANAVEX<sup>&#174;</sup>2-73 the Rare Pediatric Disease (RPD) designation for the treatment of
Rett syndrome. The RPD designation is intended to encourage the development of treatments for rare pediatric diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, in February 2020, the FDA granted
Fast Track designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the treatment of Rett syndrome. The
FDA Fast Track program is designed to facilitate and expedite the development and review of new drugs to address unmet medical
needs in the treatment of serious and life-threatening conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For Parkinson&#8217;s disease, data demonstrates
significant improvements and restoration of function in a disease modifying animal model of Parkinson&#8217;s disease. Significant
improvements were seen on all measures tested: behavioral, histopathological, and neuroinflammatory endpoints. In October 2020,
we completed a double-blind, randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s
disease dementia, to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease.
The Phase 2 trial enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73
doses, 30mg and 50mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73 Phase 2 Parkinson&#8217;s disease dementia trial design incorporated
genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s disease trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial demonstrated that ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50mg once daily. The results showed clinically meaningful, dose-dependent, and
statistically significant improvements in the CDR computerized assessment system analysis. We anticipate conducting further clinical
trials of ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia after submitting the results of the trial to the FDA
to obtain regulatory guidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Alzheimer&#8217;s disease animal models,
ANAVEX<sup>&#174;</sup>2-73 has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic,
anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to SIGMAR1 and moderate affinities to M1-4 type
muscarinic receptors. In addition, ANAVEX<sup>&#174;</sup>2-73 has shown a potential dual mechanism which may impact amyloid, tau
pathology and inflammation. In a transgenic Alzheimer&#8217;s disease animal model Tg2576, ANAVEX<sup>&#174;</sup>2-73 induced a
statistically significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as significantly
increased the expression of functional and synaptic plasticity markers that is apparently amyloid-beta independent. It also statistically
alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both in terms of spatial working
memory and long-term spatial reference memory.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the results of pre-clinical testing,
we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<sup>&#174;</sup>2-73. In this Phase 1
SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent dose shown
to have positive effects in mouse models of Alzheimer&#8217;s disease. There were no significant changes in laboratory or ECG parameters.
ANAVEX<sup>&#174;</sup>2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some subjects. Observed
adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity
and reversible. These side effects are often seen with drugs that target CNS conditions, including Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial for ANAVEX<sup>&#174;</sup>2-73, for the treatment of Alzheimer&#8217;s disease. The open-label randomized trial was designed
to assess the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients with mild-to-moderate Alzheimer&#8217;s
disease. The Phase 2a trial met both primary and secondary objectives of the trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In July 2018, we presented
the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a clinical trial. More than 33,000 genes were
analyzed using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA and RNA data in patients
treated with ANAVEX<sup>&#174;</sup>2-73. The analysis identified genetic variants that impacted response to ANAVEX<sup>&#174;</sup>2-73,
among them variants related to the SIGMAR1, the target for ANAVEX<sup>&#174;</sup>2-73. Results showed that trial participants with
the common SIGMAR1 wild type gene variant, which is estimated to be about 80% of the population worldwide, demonstrated improved
cognitive (MMSE) and functional (ADCS-ADL) scores. The results from this evaluation supported the continued evaluation of genomic
information in subsequent clinical trials, since these signatures can now be applied to neurological indications tested in future
clinical trials with ANAVEX<sup>&#174;</sup>2-73 including Alzheimer&#8217;s disease, Parkinson&#8217;s disease dementia and Rett
syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">ANAVEX<sup>&#174;</sup>2-73
data met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled trial. On July 2, 2018, the Human Research
Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled 48-week safety
and efficacy trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of early Alzheimer&#8217;s disease. Clinical trial sites in
Canada, the United Kingdom, the Netherlands and Germany were also added. This Phase 2b/3 trial design incorporates inclusion of
genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial completed and, in December 2022,
the Company presented positive topline results from the Phase 2b/3 clinical trial. ANAVEX<sup>&#174;</sup>2-73 met the co-primary
endpoints ADAS-Cog and ADCS-ADL and key secondary endpoint CDR-SB as further described above under <i>Clinical Trials Overview
&#8211; Alzheimer&#8217;s Disease.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe preclinical data from our studies
also supports further research into the use of ANAVEX<sup>&#174;</sup>2-73 as a potential platform drug for other neurodegenerative
diseases beyond Alzheimer&#8217;s disease, Parkinson&#8217;s disease or Rett syndrome, more specifically, epilepsy, infantile spasms,
Fragile X syndrome, Angelman syndrome, multiple sclerosis, and, more recently, tuberous sclerosis complex (TSC). ANAVEX<sup>&#174;</sup>2-73
demonstrated significant improvements in all of these indications in the respective preclinical animal models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a preclinical study sponsored by the Foundation
for Angelman Syndrome, ANAVEX<sup>&#174;</sup>2-73 was assessed in a mouse model for the development of audiogenic seizures. The
results indicated that ANAVEX<sup>&#174;</sup>2-73 administration significantly reduced audiogenic-induced seizures in mice. In
a study sponsored by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>&#174;</sup>2-73
restored hippocampal brain-derived neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed
in many neurodevelopmental and neurodegenerative pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory
synapses. ANAVEX<sup>&#174;</sup>2-73 normalization of BDNF expression could be a contributing factor for the positive preclinical
data observed in both neurodevelopmental and neurodegenerative disorders like Angelman and Fragile X syndromes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data to-date also
indicates that ANAVEX<sup>&#174;</sup>2-73 has the potential to demonstrate protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, may play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data on ANAVEX<sup>&#174;</sup>2-73
related to multiple sclerosis indicates that ANAVEX<sup>&#174;</sup>2-73 may promote remyelination in multiple sclerosis disease.
Further, our data also demonstrates that ANAVEX<sup>&#174;</sup>2-73 has the potential to provide protection for oligodendrocytes
(&#8220;OL&#8217;s&#8221;) and oligodendrocyte precursor cells (&#8220;OPC&#8217;s&#8221;), as well as central nervous system neurons
in addition to helping repair by increasing OPC proliferation and maturation in tissue culture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, we presented preclinical data
of ANAVEX<sup>&#174;</sup>2-73 in a genetic mouse model of tuberous sclerosis complex (&#8220;TSC&#8221;). TSC is a rare genetic
disorder characterized by the growth of numerous benign tumors in many parts of the body with a high incidence of seizures. The
preclinical data demonstrated that treatment with ANAVEX<sup>&#174;</sup>2-73 significantly increased survival and reduced seizures
in those mice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>3-71</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>3-71 is a clinical drug
candidate with a novel mechanism of action via SIGMAR1 activation and M1 muscarinic allosteric modulation, which has been shown
to enhance neuroprotection and cognition in Alzheimer&#8217;s disease models. ANAVEX<sup>&#174;</sup>3-71 is a CNS-penetrable potential
disease modifying treatment for cognitive impairments. We believe it is effective in very small doses against the major Alzheimer&#8217;s
hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects
on inflammation and mitochondrial dysfunctions. ANAVEX<sup>&#174;</sup>3-71 indicates extensive therapeutic advantages in Alzheimer&#8217;s
and other protein-aggregation-related diseases given its ability to enhance neuroprotection and cognition via SIGMAR1 activation
and M1 muscarinic allosteric modulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preclinical study examined the response of
ANAVEX<sup>&#174;</sup>3-71 in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit,
amyloid beta pathology and inflammation with the administration of ANAVEX<sup>&#174;</sup>3-71. In April 2016, the FDA granted Orphan
Drug Designation to ANAVEX<sup>&#174;</sup>3-71 for the treatment of FTD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During pathological conditions ANAVEX<sup>&#174;</sup>3-71
demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number
of astrocytes. In neurodegenerative diseases such as Alzheimer&#8217;s and Parkinson&#8217;s disease, synaptogenesis is believed
to be impaired. Additional preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX<sup>&#174;</sup>3-71
has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if
impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the first Phase
1 clinical trial of&#160;ANAVEX<sup>&#174;</sup>3-71. The trial took place in Australia and was a double-blind, randomized, placebo-controlled,
Phase 1 trial to evaluate safety and tolerability, and PK of oral escalating doses of ANAVEX<span style="background-color: white"><sup>&#174;</sup></span>3-71
including effects of food and gender in healthy volunteers. <span style="background-color: white">The trial met its primary and
secondary endpoints of safety, respectively, with no serious adverse events (SAEs) or dose-limiting toxicities observed, </span>as
more fully described above under <i>Clinical Trials Overview &#8211; Frontotemporal Dementia</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Based
on these results, and ANAVEX<sup>&#174;</sup>3-71 pre-clinical profile, the Company intends to advance ANAVEX<sup>&#174;</sup>3-71
into a biomarker-driven clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer&#8217;s disease,
evaluating longitudinal effect of treatment with ANAVEX<sup>&#174;</sup>3-71. We believe the results of this clinical trial and
preclinical study could serve as a basis for advancing into respective registration trials in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ANAVEX<sup>&#174;</sup>1-41</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1-41 is a sigma-1 agonist.
Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death) through
the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability. In addition,
in animal models, ANAVEX<sup>&#174;</sup>1-41 prevented the expression of caspase-3, an enzyme that plays a key role in apoptosis
(programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning, emotion and memory.
These activities involve both muscarinic and SIGMAR1 systems through a novel mechanism of action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that
ANAVEX<sup>&#174;</sup>1-41 has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological
conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1066</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1066, a mixed sigma-1/sigma-2
ligand, is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>&#174;</sup>1066 was tested in two
preclinical models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic constriction injury
model of neuropathic pain, a single oral administration of ANAVEX<sup>&#174;</sup>1066 dose-dependently restored the nociceptive
threshold in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy was rapid and remained
significant for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory
agent directly into the colon and a single oral administration of ANAVEX<sup>&#174;</sup>1066 returned the nociceptive threshold
to control levels in a dose-dependent manner. Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal
transit with ANAVEX<sup>&#174;</sup>1066 and a favorable safety profile in a battery of behavioral measures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1037 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is designed for
the treatment of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for
SIGMAR1 at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In advanced pre-clinical
studies, this compound revealed antitumor potential. It has also been shown to selectively kill human cancer cells without affecting
normal/healthy cells and also to significantly suppress tumor growth in immune-deficient mice models. Scientific publications highlight
the possibility that these ligands may stop tumor growth and induce selective cell death in various tumor cell lines. Sigma receptors
are highly expressed in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective
apoptosis. In addition, through tumor cell membrane reorganization and interactions with ion channels, we believe our drug candidates
may play an important role in inhibiting the processes of metastasis (spreading of cancer cells from the original site to other
parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is currently in
the pre-clinical and clinical testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical
models will be shown in human testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We continue to identify and initiate discussions
with potential strategic and commercial partners to most effectively advance our programs and increase stockholder value. Further,
we may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further
our goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Target Indications</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are developing compounds with potential
application to two broad categories and several specific indications, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Central Nervous System Diseases</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Alzheimer&#8217;s disease &#8211; In 2023, an estimated 6.7 million Americans age 65 and older are suffering from Alzheimer&#8217;s disease. The Alzheimer&#8217;s Association<sup>&#174;</sup> estimates that the annual number of new cases of Alzheimer&#8217;s and other dementias is projected to double by 2050. Medications on the market today treat only the symptoms of Alzheimer&#8217;s disease and do not have the ability to stop its onset or its progression. We believe that there is an urgent and unmet need for both a disease modifying cure for Alzheimer&#8217;s disease as well as for better symptomatic treatments.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Parkinson&#8217;s disease &#8211; Parkinson&#8217;s disease is a progressive disease of the nervous system marked by tremors, muscular rigidity, and slow, imprecise movement. It is associated with degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter dopamine. Parkinson&#8217;s disease currently is estimated to afflict more than 10 million people worldwide, typically middle-aged and elderly people. The Parkinson&#8217;s disease market is expected to reach $11.5 billion by 2029, according to GlobalData.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rett syndrome &#8211; Rett syndrome is a rare
        X-linked genetic neurological and developmental disorder that affects the way the brain develops, including protein transcription,
        which is altered and as a result leads to severe disruptions in neuronal homeostasis. It is considered a rare, progressive neurodevelopmental
        disorder and is caused by a single mutation in the MECP2 gene. Because males have a different chromosome combination from females,
        boys who have the genetic MECP2 mutation are affected in devastating ways. Most of them die before birth or in early infancy. For
        females who survive infancy, Rett syndrome leads to severe impairments, affecting nearly every aspect of the child&#8217;s life;
        severe mental retardation, their ability to speak, walk and eat, sleeping problems, seizures and even the ability to breathe easily.
        Rett syndrome affects approximately 1 in every 10,000-15,000 females.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
</table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 22.5pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Fragile X &#8211; Fragile X syndrome (FXS) is the most prevalent genetic form of intellectual disability
and autism spectrum disorder, primarily affecting boys. As with most neurodevelopmental disorders, FXS is considered a condition
of synaptic development and function. The disease has a range of clinical presentations depending on the specific genetic changes
associated with an &#8220;expansion&#8221; of the FMR1 gene. The disease is characterized by deficits in long-term potentiation
and homeostatic plasticity. FXS has been detected in all populations and ethnic groups. Researchers do not know the exact number
for how many Americans could have full mutation FXS. Studies estimate that the disease affects approximately 1:4,000 males and
1:6,000-8,000 females. Worldwide, more than 1,400,000 people could be affected by FXS.&#160;</td></tr></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Depression &#8211; Depression is a major cause of morbidity worldwide according to the World Health Organization. The global antidepressant drug market is projected to reach $21 Billion by 2030 according to Allied Market Research. Pharmaceutical treatment for depression has been historically dominated by blockbuster brands. However, the dominance of the leading brands is waning, largely due to an increase in the number of approvals for antidepressant drugs.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Epilepsy &#8211; Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures are transient signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain. According to the Centers for Disease Control and Prevention, in 2015 epilepsy affected 3.4 million Americans. Today, epilepsy is often controlled, but not cured, with medication that is categorized as older traditional anti-epileptic drugs and second generation anti-epileptic drugs. Because epilepsy afflicts sufferers in different ways, there is a need for drugs used in combination with both traditional anti-epileptic drugs and second generation anti-epileptic drugs.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Neuropathic Pain &#8211; We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal pain medications. Special medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Cancer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Malignant Melanoma &#8211; Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant melanoma accounts for a large majority of skin cancer deaths. The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy. According to iHealthcareAnalyst, Inc. the worldwide malignant melanoma market is expected to grow to $7.5 billion by 2029.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Prostate Cancer &#8211; Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. Cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes. Drug therapeutics for prostate cancer are expected to increase to nearly $10.1 billion by the end of 2030 according to Market Research Future.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pancreatic Cancer &#8211; Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States, approximately 62,000 new cases of pancreatic cancer will be diagnosed this year and approximately 50,000 patients will die as a result of their cancer, according to the American Cancer Society. Sales predictions by Market Data Forecast predict that the market for the global pharmaceutical treatment of pancreatic cancer will increase to $3.73 billion by 2027.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Patents, Trademarks and Intellectual
Property </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights to eighteen
U.S. patents, twenty-one U.S. patent applications, and various PCT or ex-U.S. patent applications relating to our drug candidates, methods
associated therewith, and to our research programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own one issued U.S. patent entitled &#8220;ANAVEX<sup>&#174;</sup>2-73
and certain anticholinesterase inhibitors composition and method for neuroprotection&#8221; claims a composition of matter of ANAVEX<sup>&#174;</sup>2-73
directed to a novel and synergistic neuroprotective compound combined with donepezil and other cholinesterase inhibitors. This patent
is expected to expire in June 2034, absent any patent term extension for regulatory delays. We own one issued U.S. patent entitled &#8220;A2-73
crystalline polymorph compositions of matter and methods of use thereof&#8221;. It claims crystals of A2-73 freebase or its fumarate salt,
dosage forms and pharmaceutical formulations. This patent is expected to expire in July 2039, absent any patent term extension for regulatory
delays. We own three issued U.S. patents each with claims directed to crystalline forms of ANAVEX<sup>&#174;</sup>2-73. The first of these
three patents claims crystalline forms of ANAVEX<sup>&#174;</sup>2-73, dosage forms and compositions containing crystalline ANAVEX<sup>&#174;</sup>2-73,
and methods of treatment for Alzheimer&#8217;s disease using them. This patent is expected to expire in July 2036, absent any patent term
extension for regulatory delays. The second of these three patents claims pharmaceutical compositions containing a crystalline form of
ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s disease using the compositions. This patent is expected to
expire in June 2037, absent any patent term extension for regulatory delays. The third of these three patents claims pharmaceutical compositions
containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s disease using the compositions.
This patent is expected to expire in June 2037, absent any patent term extension for regulatory delays. We also own two issued U.S. patents
for seizure treatment. The first of these two patents claims methods and dosage forms for treating seizures, the dosage forms containing
a low-dose anti-epilepsy drug combined with either: (i) ANAVEX<sup>&#174;</sup>2-73 and its active metabolite ANAVEX<sup>&#174;</sup>19-144;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">or (ii) ANAVEX<sup>&#174;</sup>19-144. The second of these two patents further claims a combination seizure treatment involving
administration of an anti-epilepsy drug combined with (i) ANAVEX<sup>&#174;</sup>19-144, or (ii) ANAVEX 19-144<sup>&#174;</sup> and
ANAVEX 2-73<sup>&#174;</sup>. Both patents are expected to expire in October 2035, absent any patent term extension for regulatory
delays. We also own three issued U.S. patents with claims directed to treating neurodevelopmental disorders. These patents claim
methods for treating a neurodevelopmental disorder, multiple sclerosis, or their related biochemical and functional abnormalities
by administering ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144, and/or ANAVEX<sup>&#174;</sup>1-41 (another sigma receptor
ligand similar to ANAVEX<sup>&#174;</sup>2-73), or compositions thereof. All three patents are expected to expire in January 2037,
absent any patent term extension for regulatory delays. In addition, we own one issued U.S. Patent with claims directed to methods
of treating melanoma with a compound related to ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in February 2030,
absent any patent term extension for regulatory delays. We also own an issued U.S. patent that claims crystalline forms of ANAVEX<sup>&#174;</sup>19-144,
dosage forms and compositions containing the crystalline forms of ANAVEX<sup>&#174;</sup>19-144, and methods of treatment for Alzheimer&#8217;s
disease. This patent is expected to expire in July 2036, absent any patent term extension for regulatory delays. Further, we own
one issued U.S. Patent with claims directed to methods of treating cardiac dysfunction with ANAVEX<sup>&#174;</sup>2-73. This patent
is expected to expire in July 2038, absent any patent term extension for regulatory delays. Additionally, we own one issued U.S.
Patent with claims directed to methods of treating insomnia or anxiety with ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
and/or ANAVEX<sup>&#174;</sup>1-41. This patent is expected to expire in September 2038, absent any patent term extension for regulatory
delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own two issued U.S. patents related
to ANAVEX<sup>&#174;</sup>1066. The first of these two patents claims methods for treating or preventing pain using (+) ANAVEX<sup>&#174;</sup>1066
isomer. The second patent claims methods for treating or preventing pain using (-) ANAVEX<sup>&#174;</sup>1066 isomer. Both patents
are expected to expire in November 2036, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
ANAVEX<sup>&#174;</sup>1-41, and ANAVEX<sup>&#174;</sup>1066, we also have granted or pending applications in Australia, Canada,
China, Europe, Japan, and Hong Kong, which are expected to expire after 2035.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With regard to ANAVEX<sup>&#174;</sup>3-71,
we own exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX<sup>&#174;</sup>3-71 compound
and methods of treating various diseases including Alzheimer&#8217;s with the same. These patents are expected to expire in April
2030, and January 2030, respectively, absent any patent term extension for regulatory delays. We also own exclusive rights to related
patents or applications that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and
South Africa, which are expected to expire in January 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own other patent applications directed
to enantiomers, crystals, formulations, uses, and patient selection methods that may provide additional protection for one or more
of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We regard patents and other intellectual property
rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual property in developing our business strategy
including the selective development, protection, and exploitation of our intellectual property rights. In addition to filings made
with intellectual property authorities, we protect our intellectual property and confidential information by means of carefully
considered processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure agreements
and provisions for the same in contractor&#8217;s agreements. While no agreement offers absolute protection, such agreements provide
some form of recourse in the event of disclosure, or anticipated disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Our
intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical questions
for which important legal principles are unresolved. For more information regarding challenges to our existing or future patents,
see &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange Commission
on November 28, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Financial Overview </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The following discussion should be read
in conjunction with our condensed interim consolidated financial statements and related notes thereto contained elsewhere in this
report. Past operating results are not necessarily indicative of results that may occur in future periods. The discussion contains
forward-looking statements, which involve a number of risks and uncertainties. See &#8220;Forward Looking Statements&#8221; included
elsewhere in this report.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are in the development stage and have not
earned any revenue since our inception in 2004. We do not anticipate earning any revenues until we can establish an alliance with
other companies to develop, co-develop, license, acquire or market our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operating costs consist primarily of research
and development activities including the cost of clinical trials and clinical supplies as well as clinical drug manufacturing and
formulation. Research and development expenses also include personnel related costs such as salaries and wages, and third-party
contract research organization (CRO) expenses in support of these clinical trials. Personnel costs include salaries and wages,
benefits, and non-cash stock-based compensation charges associated with options and other equity awards granted to employees and
consultants who are directly engaged in support of our research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses consist
of personnel costs, expenses for outside professional services and expenses associated with operating as a public company. Personnel
costs consist of salaries and wages, benefits and stock-based compensation for general and administrative personnel. Outside professional
services and public company expenses include expenses related to compliance and reporting, additional insurance expenses, audit
and SOX compliance, expenses associated with patent research, applications and filings, investor and stockholder relations activities
and other administrative expenses and professional services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Comparison of the three and six months ended
March 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total operating expenses for the quarter ended
March 31, 2023 were $14.2 million, compared to $11.5 million for the comparable quarter ended March 31, 2022. Total operating expenses
for the six months ended March 31, 2023 were $29.6 million, compared to $23.2 million for the comparable six month period ended
March 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development expenses for the
three months ended March 31, 2023 were $11.3 million, as compared to $8.6 million for the three months ended March 31, 2022. The
increase in research and development expenses is primarily related to (i) an increase in personnel costs of $0.5 million as a result
of the expansion of our team engaged in research and development activities, (ii) an increase of approximately $1.0 million over
the comparable period, relating to the manufacture of additional clinical trial supply for ANAVEX<sup>&#174;</sup>2-73 and ANAVEX<sup>&#174;</sup>2-73
manufacturing development activities, (iii) an increase of approximately $0.40 million over the comparable period relating to the
manufacture and associated Phase 1 activities for ANAVEX<sup>&#174;</sup>3-71 tablets and (iv) an increase in clinical site costs
associated with expanded enrollment in our EXCELLENCE trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development expenses for the
six months ended March 31, 2023 were $23.4 million, as compared to $17.3 million for the six months ended March 31, 2022. The increase
in research and development expenses is primarily related to (i) an increase in personnel costs of $1.2 million and an increase
in stock-based compensation expense of $1.2 million as a result of the expansion of our team engaged in research and development
activities, (ii) an increase of approximately $2.1 million over the comparable period, relating to manufacturing activities for
both our ANAVEX<sup>&#174;</sup>2-73 and ANAVEX<sup>&#174;</sup>3-71 programs and (iii) an increase in costs associated with expanded
enrollment in our EXCELLENCE trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes our research
and development expenses for the three and six months ended March 31, 2023 and 2022 (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended<br />
March
    31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended<br />
March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Cost of external service providers</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">6,165</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,823</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">12,219</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">8,081</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Personnel costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,407</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,557</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,713</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,862</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,317</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,099</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">License fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other common costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">50</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total research and development costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,307</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,605</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,374</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,261</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and six months ended March
31, 2023 and 2022, external service providers cost by product candidate was as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended<br />
March 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended<br />
March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left"><span style="font-size: 10pt">ANAVEX<sup>&#174;</sup>2-73</span></td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5,510</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,135</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">10,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">7,043</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">ANAVEX<sup>&#174;</sup>3-71</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">528</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">590</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,240</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">914</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">All other product candidates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other external service provider costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">124</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">40</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">226</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">64</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total external service provider costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,165</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,823</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,219</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,081</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses were $2.9
million for the three months ended March 31, 2023, as compared to $2.9 million for the same quarter of fiscal 2022. General and
administrative expenses were consistent between both periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses were $6.2 million
for the six months ended March 31, 2023, as compared to $6.0 million for the same six-month period of fiscal 2022, an increase of $0.2
million mostly relating to an increase in professional and IP related costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the first half of fiscal 2023, we utilized cash and
cash equivalents of $14.3 million to fund our operations, compared to $13.1 million during the same period of fiscal 2022. Our cash position
was $153.5 million at March 31, 2023 compared to $149.2 million at our fiscal year ended September 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect to continue an increase in our research
and development expenditures as we advance our ANAVEX<sup>&#174;</sup>2-73 clinical trials, including planned advancement of ANAVEX<sup>&#174;</sup>2-73
for Parkinson&#8217;s disease program, planned initiation of a Fragile X clinical program, ongoing extension trials of our current
clinical programs, continued advancement of our other pipeline compounds such as ANAVEX<sup>&#174;</sup>3-71, and as we continue
to add additional staffing to manage and support these clinical initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other income (net)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The net amount of other income for the three
months ended March 31, 2023 was $1.1 million as compared to $1.1 million for the comparable three months ended March 31, 2022.
An increase in interest income on excess cash invested was offset by a one time financing expense of $964,344 associated with entering
into the 2023 Purchase Agreement (as described below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The net amount of other income for the six
months ended March 31, 2023 was $3.5 million as compared to $2.0 million for the comparable six-months ended March 31, 2022. The
increase in other income for the quarter is primarily related to an increase in return on excess cash invested in cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Net loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net loss for the three months ended March 31,
2023, was $13.1 million, or $0.17 per share, as compared to $10.4 million, or $0.14 per share in the comparative quarter of fiscal
2022. The increase in net loss for the quarter is primarily related to increased research and development fees as discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net loss for the six months ended March 31,
2023, was $26.1 million, or $0.33 per share, as compared to $21.3 million, or $0.28 per share in the comparative period of fiscal
2022. The increase in net loss for the six-month period is primarily related to increased research and development fees as discussed
above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Liquidity and Capital Resources </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Working Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">March 31, 2023</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">September 30, 2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Current Assets</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">159,186,397</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">152,704,603</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,021,343</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,213,561</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Working Capital</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">145,165,054</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">142,491,042</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2023, we had current assets of
$159.2 million, an increase of $6.5 million from September 30, 2022. The increase in current assets primarily relates to an increase
in cash and cash equivalents of $4.3 million mainly due to $18.0 million in net proceeds received from issuance of common shares
under the 2023 Purchase Agreement, described below, offset by cash used in operations of $14.3 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2023, we had current liabilities of
$14.0 million, an increase of $3.8 million from September 30, 2022. A portion of this increase relates to an increase in deferred grant
income of $0.5 million relating to amounts received during the quarter for a research grant awarded by the Michael J. Fox Foundation
for Parkinson&#8217;s Research. Other increases in current liabilities relate to amounts owed at period end for manufacturing activities
and programs and laboratory and analysis work relating to the <span style="background-color: white">ANAVEX<sup>&#174;</sup>2-73 </span>Phase
2b/3 clinical trial in Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">We intend to continue to use our capital resources
to advance our clinical trials for ANAVEX<sup>&#174;</sup>2-73 and ANAVEX<sup>&#174;</sup>3-71, and to perform work necessary to prepare
for future development of our pipeline compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following
table summarizes cash flows during the six months ended March 31, 2023 and 2022: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Net cash flows used in operating activities</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(14,282,836</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(13,140,439</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash flows from financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,591,937</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,375,250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Increase in cash and cash equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,309,101</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,234,811</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash flow used in operating activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities for the six
months ended March 31, 2023 was $14.3 million, compared to $13.1 million during the comparable period ended March 31, 2022. The principal
reason for this increase in net cash used in operating activities in the current period is due to the increase in net loss over the comparable
quarter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash flow provided by financing activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash provided by financing activities for the
six months ended March 31, 2023 was $18.6 million, mainly attributable to the issuance of common shares under the 2023 Purchase
Agreement, described below, while <span style="background-color: white">cash provided by financing activities for the six months
ended March 31, 2022 was </span>$14.4 million, primarily attributable to the sale of common shares at various market prices under
the Sales Agreement, described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other Financings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Purchase Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into
a $150,000,000 purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln
Park&#8221;), pursuant to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase,
up to $150,000,000 in value of its shares of common stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On any business day and subject to certain
customary conditions, the Company may direct LPC to purchase up to 200,000 shares of Common Stock (such purchases, &#8220;<span style="text-decoration: underline">Regular
Purchases</span>&#8221;). The amount of a Regular Purchase may increase under certain circumstances based on the market price of the
Common Stock; provided, however, that LPC&#8217;s committed obligation under any Regular Purchase shall not exceed $4,000,000.
The purchase price of shares of Common Stock will be based on the then prevailing market prices of such shares at the time of sales
as described in the Purchase Agreement. There are no limits on the price per share that LPC may pay to purchase Common Stock under
the Purchase Agreement. In addition, if the Company has directed LPC to purchase the full amount of Common Stock available as a
Regular Purchase on a given day, it may direct LPC to purchase additional amounts as &#8220;accelerated purchases&#8221; and &#8220;additional
accelerated purchases&#8221; as set forth in the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Purchase Agreement limits the Company&#8217;s
sale shares of Common Stock to LPC to 15,606,426 shares of Common Stock, representing 19.99% of the shares of the Common Stock
outstanding on the date of the Purchase Agreement unless (i)&#160;shareholder approval is obtained to issue more than such amount
or (ii)&#160;the average price of all applicable sales of Common Stock to LPC under the Purchase Agreement equals or exceeds the
lower of (A) the closing price of the Common Stock on the Nasdaq Capital Market immediately preceding the Execution Date or (B)
the average of the closing price of the Common Stock on the Nasdaq Capital Market for the five Business Days immediately preceding
the Execution Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Purchase Agreement also prohibits the Company
from directing LPC to purchase any shares of Common Stock if those shares, when aggregated with all other shares of Common Stock
then beneficially owned by Lincoln Park and its affiliates, would result in LPC and its affiliates having beneficial ownership,
at any single point in time, of more than 4.99% of the then total outstanding shares of Common Stock, as calculated pursuant to
Section&#160;13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2023
Purchase Agreement, the Company issued to Lincoln Park 75,000 shares of common stock as a commitment fee (the &#8220;initial commitment
shares&#8221;) during the six months ended March 31, 2023 and agreed to issue up to 75,000 shares pro rata, when and if, Lincoln
Park purchased, at the Company&#8217;s discretion, the $150,000,000 aggregate commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended March 31, 2023, the Company issued to Lincoln Park
an aggregate of 2,159,080 (2022: Nil) shares of common stock under the 2023 Purchase Agreement, including 2,075,000 (2022: Nil) shares
of common stock for an aggregate purchase price of $18.2 million (2022: $Nil) and 9,080 (2022: Nil) commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of&#160;March 31, 2023, an amount of $131.8
million in shares of our common stock remain available for purchase by Lincoln Park under the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Controlled Equity Offering Sales Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2020, we entered into an Amended
and Restated Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and SVB Leerink LLC (the &#8220;Sales
Agents&#8221;), pursuant to which we may offer and sell shares of common stock registered under an effective registration statement
from time to time through the Sales Agents (the &#8220;At-the-Market Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on
our instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell shares of common stock
by methods deemed to be an &#8220;at the market offering&#8221;, in negotiated transactions at market prices prevailing at the
time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated
transactions, subject to our prior written consent. We are not obligated to make any sales of shares under the Sales Agreement.
We or the Sales Agents may suspend or terminate the At-the-Market Offering upon notice to the other party, subject to certain conditions.
The Sales Agents will act as agents on a commercially reasonable efforts basis consistent with their normal trading and sales practices,
applicable state and federal law, and rules and regulations and the rules of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have agreed to pay the Sales Agents&#8217; commissions
for their services of 3.0% of the gross proceeds from the sale of shares of common stock pursuant to the Sales Agreement. We have also
agreed to provide the Sales Agents with customary indemnification and contribution rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No shares were sold during the six months ended
March 31, 2023 under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended March 31, 2022,
1,066,389 shares were sold under the Sales Agreement for gross proceeds of $14.8 million (net proceeds of $14.3 million after deducting
commissions and offering expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Off-Balance Sheet
Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have no off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in
financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are
material to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>CRITICAL ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We prepare our condensed
interim consolidated financial statements in accordance with accounting principles generally accepted in the United States of America
and make estimates and assumptions that affect our reported amounts of assets, liabilities, revenue and expenses, and the related
disclosures of contingent liabilities. We base our estimates on historical experience and other assumptions that we believe are
reasonable in the circumstances. Actual results may differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">There have been no
significant changes in the critical accounting policies and estimates described in our Annual Report on Form 10-K for the year
ended September 30, 2022, as filed with the SEC on November 28, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>RECENT ACCOUNTING
PRONOUNCEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Please refer to Note
2 &#8220;Recent Accounting Pronouncements&#8221; in notes to our Condensed Interim Consolidated Financial Statements included in
this Form 10-Q.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_004"></span>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISKS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Not applicable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_005"></span>ITEM 4. CONTROLS AND PROCEDURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Disclosure Controls
and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We maintain disclosure
controls and procedures that are designed to provide reasonable assurance that material information required to be disclosed in
our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified
in the SEC&#8217;s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to
our management, our chief executive officer and our principal financial officer, to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We carried out an
evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal
financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule
13a 15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation,
our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective
as of March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Changes in Internal
Control over Financial Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the quarter
ended March 31, 2023, there were no changes to our internal control over financial reporting identified in management&#8217;s evaluation
pursuant to Rules 13a 15(d) or 15d 15 (d) of the Exchange Act that materially affected, or are reasonably likely to materially
affect, our internal controls over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_006"></span>PART II &#8211; OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_007"></span>ITEM 1. LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">We
know of no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our
Company or our subsidiaries are a party or of which any of their property is subject. There are no proceedings in which any of
our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse
party or has a material interest adverse to our or our subsidiaries&#8217; interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_008"></span>ITEM 1A. RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been no material changes to the
risk factors discussed in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended
September 30, 2022, filed with the SEC on November 28, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_009"></span>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period covered by this Quarterly
Report on Form 10-Q, we have not sold any equity securities that were not registered under the Securities Act of 1933 that were
not previously reported in a Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_010"></span>ITEM 3. DEFAULTS UPON SENIOR SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_011"></span>ITEM 4. MINE SAFETY DISCLOSURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_012"></span>ITEM 5. OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_013"></span>ITEM 6. EXHIBIT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border: black 1pt solid; width: 11%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Exhibit </b></span><br /> <span style="font-size: 10pt"><b>Number </b></span></td>
<td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 89%; padding-right: 5.75pt; padding-left: 5.75pt"><br /><span style="font-size: 10pt"><b>Description</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(3) </b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Articles of Incorporation and Bylaws </b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">3.1</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/e3306_ex3-1.htm"><span style="font-size: 10pt">Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Annual Report on Form 10-K for the year ended September 30, 2021 filed on November 24, 2021)</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">3.2</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm"><span style="font-size: 10pt">Bylaws (incorporated by reference to our Current Report on Form 8-K filed on April 14, 2023)</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(4)</b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Instruments Defining the Rights of Security Holders</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">4.1</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112223000152/e4385_ex4-1.htm"><span style="font-size: 10pt">Registration Rights Agreement, dated February 3, 2023, by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 4.1 to our Quarterly Report on Form 10-Q for the period ended December 31, 2022 filed on February 7, 2023)</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(10)</b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Material Contracts</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">10.1</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112223000152/e4385_ex10-1.htm"><span style="font-size: 10pt">Purchase Agreement dated February 3, 2023 by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the period ended December 31, 2022 filed on February 7, 2023)</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(31) </b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Rule 13a-14(a)/15(d)-14(a)Certifications</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">31.1*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e4668_ex31-1.htm"><span style="font-size: 10pt">Certification of Christopher Missling, PhD.</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">31.2*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e4668_ex31-2.htm"><span style="font-size: 10pt">Certification of Sandra Boenisch</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(32) </b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Section 1350 Certifications</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">32.1**</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e4668_ex32-1.htm"><span style="font-size: 10pt">Certification of Christopher Missling, PhD and Sandra Boenisch.</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(101)</b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>XBRL</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.INS*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL INSTANCE DOCUMENT</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.SCH*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION SCHEMA</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.CAL*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.DEF*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.LAB*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION LABEL LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.PRE*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">* Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">** Furnished herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 100%; font-weight: normal; text-align: center; font-family: Calibri Light; color: #2F5496"><span style="font: 10pt Times New Roman, Times, Serif; color: windowtext"><b><span id="a_014"></span>SIGNATURES</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: center; text-indent: -36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX LIFE SCIENCES CORP. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 50%"><span style="font-size: 10pt">/s/Christopher Missling, PhD</span></td>
<td style="width: 50%">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: black 1pt solid">&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">Christopher Missling, PhD</span></td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">Chief Executive Officer</span></td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">(Principal Executive Officer)</span></td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">Date: May 9, 2023</span></td>
<td>&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 50%"><span style="font-size: 10pt">/s/Sandra Boenisch</span></td>
<td style="width: 50%">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: black 1pt solid">&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">Sandra Boenisch, CPA, CGA</span></td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">Principal Financial Officer</span></td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">Date: May 9, 2023</span></td>
<td>&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>e4668_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&nbsp;<B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Christopher Missling, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on
Form 10-Q for the three and six months ended March 31, 2023 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f)
and 15d&ndash;15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(c) evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(d) disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) all significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: May 9, 2023</FONT></TD>
<TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/Christopher Missling, PhD</FONT></TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">Christopher Missling, PhD</FONT></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">Chief Executive Officer, President and Secretary</FONT></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>e4668_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right; text-indent: 0.5in">&nbsp;<B>Exhibit
31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Sandra Boenisch, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on
Form 10-Q for the three and six months ended March 31, 2023 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f)
and 15d&ndash;15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(c) evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(d) disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) all significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: May 9, 2023</FONT></TD>
<TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/Sandra Boenisch</FONT></TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">Principal Financial Officer, Treasurer</FONT></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>e4668_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly Report of
Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-Q for the three and six months ended March 31, 2023 as filed with
the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, in the capacities and on the
date indicated below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that to the best of our knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(1) the Report fully complies with
the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(2) the information contained in
the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">Date: May 9, 2023</FONT></TD>
<TD STYLE="width: 50%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/Christopher Missling, PhD </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Christopher Missling, PhD</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer, President, Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer) </FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
<TD STYLE="width: 50%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/Sandra Boenisch</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Principal Financial Officer, Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing certification is being furnished
solely to accompany the Report pursuant to 18 U.S.C. &sect; 1350, and is not being filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before
or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement
required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed
form within the electronic version of this written statement required by Section 906, has been provided to the Company and will
be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $U G$# 2(  A$! Q$!_\0
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MLJOC@L,@?AD57\N__P"?FW_[\-_\70!:HJKY=_\ \_-O_P!^&_\ BZ/+O_\
MGYM_^_#?_%T -O[[[&8$6(RRSOL1=P4< L22?8&L?_A-=.(#+'(R>8\>\%2,
MAE"]_P"(."/RZUJSV=Q=1^7</9RIG.V2U+#/K@M33I\IZ_83P!_QZ=AR!][M
M@8^E &</%D97;]AE\X*'9/,7 787SG.#\HZ>M*/%EO,)6M;=IEBE:-SO X"%
M]P'I\KCURM7?[*_=K'Y>G>6IRJ_8^ ?8;JE^Q3XQNLNF/^/4].>/O>Y_,T 3
MV-R;RQAN3&8S(H;8>HJQ5**VNX(EBAEM(XUX54MB /P#T_R[_P#Y^;?_ +\-
M_P#%T 6J*J^7?_\ /S;_ /?AO_BZ/+O_ /GYM_\ OPW_ ,70!:HJKY=__P _
M-O\ ]^&_^+H\N_\ ^?FW_P"_#?\ Q= %JBJOEW__ #\V_P#WX;_XNCR[_P#Y
M^;?_ +\-_P#%T 6J*J^7?_\ /S;_ /?AO_BZ/+O_ /GYM_\ OPW_ ,70!:HJ
MKY=__P _-O\ ]^&_^+H\N_\ ^?FW_P"_#?\ Q= %JBJOEW__ #\V_P#WX;_X
MNCR[_P#Y^;?_ +\-_P#%T 6J*J^7?_\ /S;_ /?AO_BZ/+O_ /GYM_\ OPW_
M ,70!:JO?W7V+3[FZV;_ "8FDV^N!G%-\N__ .?FW_[\-_\ %T>7?'K<6W_?
M@_\ Q= &#_PE=RMT+>;3/)<LBYDD(&6QGMV!!QU&1G%3Q^*49-S10Y9 Z(D^
M6 +A=K#'##.2.<5JM!>.,--:L/>W)_\ 9Z3[-=[MWFVF<YS]F/7_ +[H Q+?
MQ?\ :2D?V-()CM5_/FVI&Q4-@MCIAA@]\CUJ[IOB2#4;XVPC$>6<(S/CS%&W
M:RY R&R<8_NU?:"\8$--:D'J#;G_ .+H,%X2"9K4E>G^CGC_ ,?H N455\N_
M_P"?FW_[\-_\71Y=_P#\_-O_ -^&_P#BZ +5%5?+O_\ GYM_^_#?_%T>7?\
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M_P#OPW_Q= %JBJOEW_\ S\V__?AO_BZ/+O\ _GYM_P#OPW_Q= %JBJOEW_\
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M_P"^Z ,Z/Q S:?I]VUN@%W.L102Y*!C@'ISC(S6[5(6UV,8EM!@Y'^C'@_\
M?=/\N_\ ^?FW_P"_#?\ Q= %JBJOEW__ #\V_P#WX;_XNCR[_P#Y^;?_ +\-
M_P#%T 6J*J^7?_\ /S;_ /?AO_BZLC.!D@GOB@!:*** "BBB@ K%\3;C8VT8
M=T$EU&C%&P<'-;58OB3_ (]K+_K\B_F:Y<;_ +O(WPO\:(G_  B]E_S\7O\
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MI<L/?1P_ I1Q%M5/\2*#Q!XMG(QKCA6565O+4[LJ6P %ZC!!]ZDMM=\4W,D
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MQ@@[@<\GVK+$3I>QE[-QYNFQIAX5?:Q]HI<O7<ZHZ.4^_P"*M6!/0>>A)_\
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MT;1FW!5U56S<(<A3E<G/8T]O!GC1F<_9(AO)+[98EWD@@YQUZGKZTN:AWC^
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M:!E3M/!X/7TJ!=7 D9_^$2UUMR;<&$\=<]_?]*0ZK&49/^$1UXAQALQGD
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M:]_T!K__ ,!V_P */^$:U[_H#7__ (#M_A1['"]H_@'ML5WE^)N?\+-\2_\
M/6U_[\?_ %Z/^%F^)?\ GK:_]^/_ *]8?_"-:]_T!K__ ,!V_P */^$:U[_H
M#7__ (#M_A1['"]H_@'ML5WE^)N?\+-\2_\ /6U_[\?_ %Z/^%F^)?\ GK:_
M]^/_ *]8?_"-:]_T!K__ ,!V_P */^$:U[_H#7__ (#M_A1['"]H_@'ML5WE
M^)N?\+-\2_\ /6U_[\?_ %Z/^%F^)?\ GK:_]^/_ *]8?_"-:]_T!K__ ,!V
M_P */^$:U[_H#7__ (#M_A1['"]H_@'ML5WE^)N?\+-\2_\ /6U_[\?_ %Z/
M^%F^)?\ GK:_]^/_ *]8?_"-:]_T!K__ ,!V_P */^$:U[_H#7__ (#M_A1[
M'"]H_@'ML5WE^)N?\+-\2_\ /6U_[\?_ %Z/^%F^)?\ GK:_]^/_ *]8?_"-
M:]_T!;__ ,!V_P */^$:U[_H"W__ (#M_A1['"]H_@'ML5WE^)N?\+-\2_\
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M\+VWAC3C#&WF7,N&GF_O$=@.P':MZOFZJ@IM4]CZ2DYN"=3<****S- HHHH
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M^A% "Z)?W,\8@OUG%X5,CAX-BIT!4$<$9)P>X!K8HHH **** "BBB@ HHHH
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MH^YY)Z] >G89_.FCQ3X24-C4;LLRA2QA.0 ",].3SU]A6?LJ_P#SX_\ 2O\
M,GVU/_G[^,?\CKO[<US_ *%>;_P-A_QJMJ'BO4]*L9;V]\-7$=O%C>_VJ(XR
M0!P#GJ:YT^+?"+%"+^Z0IZ1'G@<GCKQ61X@\1Z->:-=06FKW<\DB_P"KF1L,
M=R_@, $UK1H5)32G2LK_ -[_ #)J8B$8-QJZV_N_Y&W_ ,+=M/\ H#W/_?U:
M/^%NVG_0'N?^_JUY3O7^\/SHWK_>'YUZ_P#9N'_E_%GD_P!I8C^;\$>K?\+=
MM/\ H#W/_?U:/^%NVG_0'N?^_JUY3O7^\/SHWK_>'YT?V;A_Y?Q8?VEB/YOP
M1ZM_PMVT_P"@/<_]_5H_X6[:?] >Y_[^K7E.]?[P_.C>O]X?G1_9N'_E_%A_
M:6(_F_!'JW_"W;3_ * ]S_W]6C_A;MI_T![G_OZM>4[U_O#\Z-Z_WA^=']FX
M?^7\6']I8C^;\$>K?\+=M/\ H#W/_?U:/^%NVG_0'N?^_JUY3O7^\/SHWK_>
M'YT?V;A_Y?Q8?VEB/YOP1ZM_PMVT_P"@/<_]_5H_X6[:?] >Y_[^K7E.]?[P
M_.C>O]X?G1_9N'_E_%A_:6(_F_!'JW_"W;3_ * ]S_W]6C_A;MI_T![G_OZM
M>4[U_O#\Z-Z_WA^=']FX?^7\6']I8C^;\$>K?\+=M/\ H#W/_?U:/^%NVG_0
M'N?^_JUY3O7^\/SHWK_>'YT?V;A_Y?Q8?VEB/YOP1ZM_PMVT_P"@/<_]_5H_
MX6[:?] >Y_[^K7E.]?[P_.C>O]X?G1_9N'_E_%A_:6(_F_!'JW_"W;3_ * ]
MS_W]6C_A;MI_T![G_OZM>4[U_O#\Z-Z_WA^=']FX?^7\6']I8C^;\$>K?\+=
MM/\ H#W/_?U:/^%NVG_0'N?^_JUY3O7^\/SHWK_>'YT?V;A_Y?Q8?VEB/YOP
M1ZM_PMVT_P"@/<_]_5H_X6[:?] >Y_[^K7E.]?[P_.MBWU2Q@L8+?:Q>-O,9
MCC#%LAU]?NGK[5,LOPZVC^+*CF&(>\OP1WW_  MVT_Z ]S_W]6C_ (6[:#_F
M#W/_ ']6N#?5-/%M<6\9D <;8I. 4" >6?7).2<'^+O3FUBRF-WY[RR?:46+
M<<?NU"#GG_;YXQT]ZGZA0_D_%E?7Z_\ /^".Z_X6[:?] >Y_[^K1_P +>M/^
M@/<_]_5K@[O5K&[O[2=]WE0%BR=2V.5Y/3)XQT'XU-_;>G,7W*P$K/,WR@F.
M0QA>/4$[L_7VH^H4/Y'][#Z_7_G7W([;_A;UI_T![G_OZM'_  MVT_Z ]S_W
M]6N&.JZ4[11LD@@C3RB, EE7#(?^^@0?9C2KK=J7MIIY/,"1D36^#AV)/')V
MXYSD#/%'U"A_(_O8_K]?^=?<CN?^%N6N ?[&NL'H?,7FD_X6[:'IH]S_ -_5
MK@UUYIGM[6XO"EI;R,ZS1IB1LYZX/&<\XJO%JD4%W/<Q.R2,'/R-A9')^7Y>
MP&2<'/2C^SZ/\GXL7]H5OY_P1Z WQ5TUIA,V@RF7;M#ETW;?3..E1)\3M)CN
M9;A?#T@FE $C[UR0  !].!Q7$2:E9,-/#NTS6Y^9\D8Y4]#G/0\# ]*L7.LV
M=U'<;Y&59$ \I<ABP)Q\^>00>0<X[=*/J%#^3\6'U^O_ #_@CLS\5-,:02'0
M)"^"H8LF>>2,XI9/BKILR;)=!E=-V[:SH1GUZ=:XJ#5[&.U$:RO%F/8BXW>2
M_P W[P'N?F'3G\A4-]J-K/9S)'=,SR2JWENN  HQN'8%CDG\J%@*%[<GXL'C
MZ]K\_P"".[D^*NFS+MET&5QNW89T//KTZU2@^(&@VRW2Q>'9@MTI28&<'<I+
M$CGH,LQP/4UYUO7^\/SHWK_>'YUI_9N'_E_%F?\ :6(_F_!'J ^*>F!BPT&7
M<P 9BZ$D#ID]\4L'Q+T-[BW270W@B27>)!M/ED]6P*\NWK_>'YTZ,&618XP7
MD<A55>2Q/8"D\MP_;\6-9EB._P""/I&&'3[RV,T,-M-!<@.65 5D[@GUJ:*V
MAAFFECC"R3$&1AU8@ #]!7-> ] O] T0QW]PQ>9MXM\Y6#V!]3W[5U5?/58Q
MA-QB[H^AI2E."E)684445F:!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!F^(-1@TG0KJ^NK?[1#$ 6BP#NRP'?CO7!?\+)T#_H7&
M_P"^(ZZKQ_\ \B-JG^XO_H:UXI9:E):0R6P\OR)G0R90$X!SP>U>O@,-"K2<
MI+6_>W8\C'XF=*JHQ>ENWJ>@?\+)\/\ _0N-_P!\1TO_  LGP_\ ]"XW_?$=
M<FFL:=O5F4AHRFU@GWE\PL0?IV/N14%OJ=AY0$XD$C3+.SGY]K*1A<GD_*#_
M -]>U=?U.E_*_O9Q_7:O\R^Y'9_\+)\/_P#0N-_WQ'1_PLGP_P#]"XW_ 'Q'
M7&2ZQ#Y;FV9X6D@D#HHP!*S9&/;&3[9Q4@U&P-W'<"<)M25-OEL#ELX.1_\
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MY/Q_X(?6:G\_X?\  .@F\=WMNNZ;PQI:+N*Y,?<=?Y'\JA_X6/+_ -"]I/\
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M-_SQE_[X-='U2AV_%F'UNOW_  1V7_"QY?\ H7M)_P"^#1_PL>7_ *%[2?\
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MUC"/YB[85&UO[PXX/O5RB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#.UW4SHVAWFHK$)3;Q[]A;&[\:\_'Q:NB<
M#0@3[3G_ .)KL?''_(E:M_UP/\Q7C4&M0VSI/'Y@GVH#TPI2-D!'/.20:];
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M6+5X)D9Y6EDC56E*#D@G'RAN..X_*L3</4?G51P&'>\/Q9$L?B%M/\$>E_\
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M)D;0+S@COD[./RI__"U7W18T,;2!YA^U\KSSCY.>/7%>;[U$K1%@)5!+)_$
M!DY'7I0+B'RO-\U/+W;=^X;<^F?6E_9^%_IA_:&*_I'I ^*DA,F=#&!_J_\
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M]SP1D<=/6E]1_O\ X?\ !']>_N?C_P  ^@/LL_\ U#_^_!_^*H^RS_\ 4/\
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M&YO[[?\ ?1I_V<_Y_P /^"']H+^3\?\ @'TU]EG_ .H?_P!^#_\ %4?99_\
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MMG% T&T\J&0S2D&$R2 ,.#M1L$[3M^]TP>!FCEJ_S_@'-2_D_$ZO_A4^I_\
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M_P""#VE'^3\6>C_\*@O?^@Y9?]^S_C1_PJ"]_P"@Y9?]^S_C7G%%/V=;^?\
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M! &2.A /3K7JE>7BJ<X5'SN[/5PM2$Z:Y%9=@HHHKG.@**** "BBB@ HHHH
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M_P#G^MO^_P O^-17.IV!M9@+ZVR4;_EJOI]::B[["<E;<P_AK_R3_2O]U_\
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MJ\SWO_??_OHT;W_OO_WT:/9U_P#GY^"#VE#^3\6>F?\ "F[O_H.6_P#WX/\
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MX5:I5?Y_P,95:7\GXGJ@^%D220#_ (2:VV.!N!@&7.>=OS_EUJ5/AHJ^>/\
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M (1/6?\ H<=2_P"_:47_ .GO_I7^06_Z=?D1?\(;X)_Z :_]^9:/^$-\$_\
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MA_S[?WEU/AMJD;[TU]E8Y^86LX/;_ ?D*9_PK'4,@_VWT((_T2;@CH?PK/\
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M\7_@%-_A7MM%'UZOW_ /J-'M^)XE_P *LNO^@O%_X!3?X4?\*LNO^@O%_P"
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M!ST_Y?Q-_P#X19O^@[H/_@</\*/^$6;_ *#N@_\ @</\*P**.2I_-^ <]/\
ME_$W_P#A%F_Z#N@_^!P_PH_X19O^@[H/_@</\*P**.2I_-^ <]/^7\3?_P"$
M6;_H.Z#_ .!P_P */^$6;_H.Z#_X'#_"L"BCDJ?S?@'/3_E_$Z>P\&->W\%M
M_;NC?O'"GRKH.^/]E<<GVKV?2-(L]$TZ.QL8MD2=3W8]V)[DU\X@E6#*2&!R
M"#@@U[AX UK4]:T+S-1@;]T=D=T>//'KCU'3/0_G7EYG3J\BDY72^1Z>65*7
M.XJ-G]YUE%%%>(>X%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5R?C[_D'Z3_V%;?\ F:ZRL3Q/H<VO:=!!;W2VTT-PEPDC)O&5SCC\:VP\
ME&JG+8QQ$7*FU'<VZ*Y/^Q_&7_0TV_\ X +1_8_C+_H:;?\ \ %I^QC_ #K\
M?\A>VE_(_P /\SK**Y/^Q_&7_0TV_P#X +1_8_C+_H:;?_P 6CV,?YU^/^0>
MVE_(_P /\SK**Y/^Q_&7_0TV_P#X +1_8_C+_H:;?_P 6CV,?YU^/^0>VE_(
M_P /\SK**Y/^Q_&7_0TV_P#X +1_8_C+_H:;?_P 6CV,?YU^/^0>VE_(_P /
M\SK**Y/^Q_&7_0TV_P#X +1_8_C+_H:;?_P 6CV,?YU^/^0>VE_(_P /\SK*
MBN?^/6;_ '&_E7,?V/XR_P"AIM__   6D;1?&+HRMXHM\,,'_0%IJC'^=?C_
M )"=:7\C_#_,F^'G_(BZ9_NO_P"AM73UE^'-(.@Z!:Z:9A,8 07"[<Y8GI^-
M:E17DI5926S;+H1<:48O=)!11161J<;\2$TY]"MAJ4UU%%]I&TV\:NQ;:W4$
MCCK7F/V?PGG/]H:QG_KUC_\ BJ]#^+'_ "+=I_U]K_Z U>:Z2-.>,I>^6K-.
MFUV/W5 ).?\ 9/0_45[^ B_J][OY'S^/DOK%K+YD_P!G\)_]!#6/_ 6/_P"*
MH^S^$_\ H(:Q_P" D?\ \53)XK.6)8X?LRLULNQBRC]Y\N<GJ#][[U6"=&?Y
M0(!B4L">!MW$#GKC[O'IS79KW?X?Y')IV7X_YD7V?PF.FH:Q_P" L?\ \52^
M1X4_Z".L?^ L?_Q5+$MEL7SEL/.RGV@ C:%RV[9@_>QM^[WQ2%;#='Y8MO\
M4+LWE.6^7=GG[V,XW<9HU[O\/\@T[+\?\P\CPI_T$=8_\!8__BJ/(\*?]!'6
M/_ 6/_XJGD:9$\!VVLT2O*9,%5WXW;1UW#^'';I37CTQ( L#02#=%EV*AMN!
MNSGG/7..]+7N_P /\@T[+\?\Q/(\*?\ 01UC_P !8_\ XJCR/"G_ $$=8_\
M 6/_ .*ITB:/*\SAX8Q-'Y<0Q]QQDEB!PO(4>A!-1)+82J!-%:KNCB4E%"E6
M8$,>/3@_A3U[O\/\@NNR_'_,?Y'A3_H(ZQ_X"Q__ !5'D>%/^@CK'_@+'_\
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M_'/\:/MGB+_GQ;_QS_&NDHH]I#^1?C_F'LY_SO\ #_(YO[9XB_Y\6_\ '/\
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M<FG)?JLJ_-)Y8E0X]5"X/'ZUMROS^\QYEY?<.SI&<?9[W/IN%)OT;_GC>?\
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M=/E:E<[L)4YDXV+%%%%<9V!1110 4444 %%%% !1110 4444 %%%% !1110
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MZ;_OH?X4?\(W8_WIO^^A_A113]O4_F%["G_*'_"-V/\ >F_[Z'^%'_"-V/\
M>F_[Z'^%%%'MZG\P>PI_RA_PC=C_ 'IO^^A_A1_PC=C_ 'IO^^A_A111[>I_
M,'L*?\H?\(W8_P!Z;_OH?X4?\(W8_P!Z;_OH?X444>WJ?S!["G_*'_"-V/\
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0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &@ G # 2(  A$! Q$!_\0
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MMO'&8(8@Q"AU929"0,GD=<#&*[2>[,]M<0:=>6;:@(V\L.VY5?IEE!SC/44
M7J*XOP3J%]#:^)O[<U9KS^SM3D1KJ55C58UBC8X X51ECBL?P_XIUBX\5ZMJ
M.I/(FE2:/_:-E8D;3%")&56;_:=4W'TW =J /3**\N\%^(8M7OM*O=2\3:N-
M2OT,JV36QALGRI/E1EH\,5!ZALG;GD5T/Q&U*;3_  [:26^IOIZRZE;03743
MJICB>0!SN((''>@#L**\=O\ Q-J5KX8\6C3_ !'<ZAIUA)9K::N C2*7D431
MAU7:^T$<@<;L5TVB:?::]9W2Z9XU\2SJDB;Y'(C9#@\#=$.#GGKT% '>45PG
MPTMK^\T&TUS4-?U2]FG65&@N)$,0Q*R@@!0<X4=^YHO_ !>F@7_B:X:'4K_[
M+>6=N+4.A ,JH (A@'JV2">3Z4 =W17!R_$+4H9;^U?PA??;=.B%S=QBYB*)
M 02&#YPS'#?*!_">:OZQXTGL-.BU.QT.>^TUK1;QKG[1'"-A!;"JQRS[1G''
M;F@#K:*XG5OB$+597TK1KC4XK?3DU.ZD$J1"*%P2OWN68A6.!Z=>U59?&PLI
M-1UB>"^Q!H=OJ#6'G(8E#N^-I ^_@<G.,8H ] HKC[?QYY<UU'K6C7>E>5I[
MZG'YCI(9($^_D*?E<9'R^_6DT3QK?ZKXBMM)NO#D]C]ILC?)*]U&_P"YR ,@
M?Q9(!';- '8T5S6K^*;FUUIM'T?19]6OH8!<7"I,D20HQ(7+-U9MK8'MSBN,
MU_Q%=>+=5\*0Z=I^H/I5_'<321Q7PM)'DCPK(Q!!!C.21G!.,9Q0!ZQ17/>,
MM4GT?PO,;%C_ &A<LEG99Y/G2,$4^^,[O^ FN2NO$.L0_"/6A)?NFOZ1*UA/
M= ?,7610LF/]I&5OQH ].HKS:/Q5JMPGAJTN)C;ZI!K8TW5HT  D(AD8'_=<
M!7'U]J=JOBC5(/B ES#.1X<L+J'2KU,?*T\RD[\^B,T*G_?- 'H]%<%;>*+C
MP_9>,8=6G>XGT:1KFW9^LL$J[H5]_FW1_@*YV\O[W3-8TG2?$GBS6+(KHB7$
MTEFNYI+DRMOSB-N .!P.@H ]?HKSKQ!KNI>"?L&J0W%UK&E7UJEG'%<,!(+K
M!,+DD# DY#<<'!KG?B#8^,K/0=&M?[3OIY-C27-S!N"-<$EBK[!D( =J#VYY
MQ0![/17$:7I>L:KX0TTZEKFJZ4(A*\I!1+AX]Q\OS78':0N,^IZGBK?@?7)K
MSP987FLWT;2RF417$VV)KB)781R$>K(%/'K0!UE%>>>.["^L+.2]T[Q-K::A
MJ%REM86D<T8A$LAP!C9G:HW,>>BGFJ/C_4Y/#D32'QCJ46K);Q?V?91Q((I)
M/NYE)7!#,#DLP '2@#U&BF0EV@C:3;O*@MM.1G'.*?0 4444 %%%% !1110
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MV=+:%(59SDD*H )]^*LT44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M )^;'_P%%>844 >G_P#"_?'7_/S8_P#@**/^%^^.O^?FQ_\  45YA10!Z?\
M\+]\=?\ /S8_^ HH_P"%^^.O^?FQ_P# 45YA10!Z?_POWQU_S\V/_@**/^%^
M^.O^?FQ_\!17F%% 'I__  OWQU_S\V/_ ("BC_A?OCK_ )^;'_P%%>844 >G
M_P#"_?'7_/S8_P#@**/^%^^.O^?FQ_\  45YA10!Z?\ \+]\=?\ /S8_^ HH
M_P"%^^.O^?FQ_P# 45YA10!Z?_POWQU_S\V/_@**/^%^^.O^?FQ_\!17F%%
M'I__  OWQU_S\V/_ ("BC_A?OCK_ )^;'_P%%>844 >G_P#"_?'7_/S8_P#@
M**/^%^^.O^?FQ_\  45YA10!Z?\ \+]\=?\ /S8_^ HH_P"%^^.O^?FQ_P#
M45YA10!Z?_POWQU_S\V/_@**/^%^^.O^?FQ_\!17F%% 'I__  OWQU_S\V/_
M ("BC_A?OCK_ )^;'_P%%>844 >G_P#"_?'7_/S8_P#@**/^%^^.O^?FQ_\
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M/$7@72=7ORANKF$M(8UVJ2&(X'X5\25]E_"3_DE7A_\ Z]S_ .AM0!VE%%%
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MDXI*DB&9!]:TI1YII";LCT#X?^#QJLWVN[C)MU/R@CJ:]L6QTO18[>*8&,R
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MI7;Z5'IC3$V<4S3I%@8#L "<]>0J_E0!W%OX=TS7XM+FNKR[FU?7]2EMH[E
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M_P"AFJ% !1110 5K:?X6U_5K/[7IVBW]W;;BOFP6[.N1U&0.M9->J:%:K/\
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M#]YO#^8-WSYV\ ].U<-XXT^VTKQOJ]E90^3;17!$<0)(0'G SV&: .?HHHH
M*44E36D<,URD<]P+>)C\TI0MM_ <FG'<!JUJ:1*T%]$ZG&#4PTK1?^ACC_\
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M][*H>TQ*E;8X.3EC4=2/]ZHS7SE=>\V?=QV TE%%<S*"BBBD 4444 %**2G
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M25>'_P#KW/\ Z&U8,9VE%%%(#X/ULYU_43ZW4O\ Z$:H5>UK_D/:C_U\R?\
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MB6WG6V\M&C:UECW2/]V,,P )X8_12>E.UK7[4ZG?23IIGB![J-1'=^5/"MJ
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MU?&U?9/PA_Y)3H'_ %Q?_P!&-0!VU%%% 'P=K7_(>U'_ *^9/_0C5&KVM?\
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ME.@?]<7_ /1C5\;5]D_"'_DE.@?]<7_]&-0!VU%%% 'P=K7_ "'M1_Z^9/\
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M)+FZ9P&\W<-KR;#L="&^7 R",<4 >OUYN_C;55CN;L'8D[3PV<4UJ!'N281
MAPV21RS @ \[>G/I%8Y\*Z*TUS(]DK?:5D616=BG[PY?:N<*6(!)4 DT -T"
M]O)IM3L+Z9;B:PN1$)UCV>8K1HXR!P"-^./05J2'%Q%P3\K=/PJ'3M,M-*@>
M&TC95=S([.[.SL>K,S$DG@#D] *G?_CYB_W6_I0 [>?^>;?I1O/_ #S;]*?1
M0 S>?^>;?I1O/_/-OTI]% #-Y_YYM^E-E<E/N-U'IZU+3)?]6?J/YT &\_\
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MC>?^>;?I3Z* (I7/EGY&ZCT]:=O/_/-OTHE_U9^H_G3Z &;S_P \V_2C>?\
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MD;S)C_$>WL!V%3T45<8J*LB6V]PHHHJA!1110 R'_5"GTR'_ %0I] !1110
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M=/\ +_VW_.B'_5"GT ,\O_;?\Z/+_P!M_P Z?10 SR_]M_SH\O\ VW_.GT4
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MC^=/H **** "BBB@ ID7^J6GTR+_ %2T /HHHH **** "BBB@ HHHH ****
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M\@_\]I?S'^% $U%0^0?^>TOYC_"CR#_SVE_,?X4 345#Y!_Y[2_F/\*/(/\
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>avxl-20230331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +KNZs7xRiXhun8uAY3RMWa+LqcP9z5B3yekxvWp6bfn6jyYoGBEXvCd2uNY2YQQG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:avxl="http://anavex.com/20230331" elementFormDefault="qualified" targetNamespace="http://anavex.com/20230331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://anavex.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimConsolidatedBalanceSheets" id="InterimConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Interim Consolidated Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimConsolidatedBalanceSheetsParenthetical" id="InterimConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Interim Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfOperations" id="InterimConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Interim Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity" id="InterimConsolidatedStatementsOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement - Condensed Interim Consolidated Statements of Changes in Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows" id="InterimConsolidatedStatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescription" id="BusinessDescription">
	  <link:definition>00000007 - Disclosure - Business Description</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BasisOfPresentation" id="BasisOfPresentation">
	  <link:definition>00000008 - Disclosure - Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
	  <link:definition>00000009 - Disclosure - Other Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/AccruedLiabilities" id="AccruedLiabilities">
	  <link:definition>00000010 - Disclosure - Accrued Liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferings" id="EquityOfferings">
	  <link:definition>00000011 - Disclosure - Equity Offerings</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000012 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BasisOfPresentationPolicies" id="BasisOfPresentationPolicies">
	  <link:definition>00000013 - Disclosure - Basis of Presentation (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
	  <link:definition>00000014 - Disclosure - Accrued Liabilities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000015 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" id="BasisOfPresentationDetailsNarrative">
	  <link:definition>00000016 - Disclosure - Basis of Presentation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
	  <link:definition>00000017 - Disclosure - Other Income (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" id="AccruedLiabilitiesDetails">
	  <link:definition>00000018 - Disclosure - Accrued liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" id="EquityOfferingsDetailsNarrative">
	  <link:definition>00000019 - Disclosure - Equity Offerings (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000020 - Disclosure - Commitments and Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
	  <link:definition>00000021 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" id="CommitmentsAndContingenciesDetails2">
	  <link:definition>00000022 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" id="CommitmentsAndContingenciesDetails3">
	  <link:definition>00000023 - Disclosure - Commitments and Contingencies (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" id="CommitmentsAndContingenciesDetails4">
	  <link:definition>00000024 - Disclosure - Commitments and Contingencies (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000025 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="avxl_ShareProceedsReceivableMember" name="ShareProceedsReceivableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_MichaelJFoxMember" name="MichaelJFoxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AnavexMember" name="AnavexMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingSalesAgreementMember" name="EquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement1Member" name="PurchaseAgreement1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2022Member" name="StockOptionPlan2022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants2Member" name="PurchaseWarrants2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice1Member" name="OptionPrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice2Member" name="OptionPrice2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice3Member" name="OptionPrice3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice4Member" name="OptionPrice4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice5Member" name="OptionPrice5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrants" name="NonOperatingIncomeFromGrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherFinancingExpense" name="OtherFinancingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NetLossPerShareBasicAndDiluted" name="NetLossPerShareBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" name="WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUnder2023PurchaseAgreement" name="SharesIssuedUnder2023PurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_InitialCommitmentShares" name="InitialCommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_InitialCommitmentSharesShares" name="InitialCommitmentSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentShares" name="CommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesShares" name="CommitmentSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptions" name="SharesIssuedPursuantToExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" name="SharesIssuedPursuantToExerciseOfStockOptionsInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUnderSalesAgreementInShares" name="SharesIssuedUnderSalesAgreementInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LessShareIssueCosts" name="LessShareIssueCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NoncashFinancingRelatedCharges" name="NoncashFinancingRelatedCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncreaseDecreaseInDeferredGrantIncome" name="IncreaseDecreaseInDeferredGrantIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" name="CashPaidForStateAndLocalMinimumIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureOtherIncomeAbstract" name="DisclosureOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureEquityOfferingsAbstract" name="DisclosureEquityOfferingsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingTextBlock" name="EquityOfferingTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LliquidityPolicyTextBlock" name="LliquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredGrantIncome" name="DeferredGrantIncome" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AccruedClinicalSiteAndPatientVisitsCosts" name="AccruedClinicalSiteAndPatientVisitsCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FixedContractAccruals" name="FixedContractAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_MilestoneBasedContractAccruals" name="MilestoneBasedContractAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PercentageOfGrossProceedsFromSales" name="PercentageOfGrossProceedsFromSales" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SoldForGrossProceedsAmount" name="SoldForGrossProceedsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SalesOfAgreementAmount" name="SalesOfAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" name="NumberOfSharesObligatedToPurchaseProrataBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FairValueOfInitialCommitment" name="FairValueOfInitialCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncurredExpenses" name="IncurredExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues4" name="StockIssuedDuringPeriodSharesNewIssues4" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues3" name="StockIssuedDuringPeriodValueNewIssues3" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues3" name="StockIssuedDuringPeriodSharesNewIssues3" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues4" name="StockIssuedDuringPeriodValueNewIssues4" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WarrantsOutstandingWeightedAverageExercise" name="WarrantsOutstandingWeightedAverageExercise" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionIssued" name="OptionIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>avxl-20230331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedBalanceSheets" xlink:href="avxl-20230331.xsd#InterimConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20230331.xsd#InterimConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfOperations" xlink:href="avxl-20230331.xsd#InterimConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="avxl-20230331.xsd#InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows" xlink:href="avxl-20230331.xsd#InterimConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescription" xlink:href="avxl-20230331.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentation" xlink:href="avxl-20230331.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20230331.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20230331.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20230331.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationPolicies" xlink:href="avxl-20230331.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20230331.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:href="avxl-20230331.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20230331.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20230331.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20230331.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Condensed Interim Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Interim Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - Condensed Interim Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OtherFinancingExpense" xlink:label="loc_avxlOtherFinancingExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlOtherFinancingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Interim Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_NoncashFinancingRelatedCharges" xlink:label="loc_avxlNoncashFinancingRelatedCharges" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlNoncashFinancingRelatedCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:label="loc_avxlIncreaseDecreaseInDeferredGrantIncome" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlIncreaseDecreaseInDeferredGrantIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescription" xlink:title="00000007 - Disclosure - Business Description" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000010 - Disclosure - Accrued Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationPolicies" xlink:title="00000013 - Disclosure - Basis of Presentation (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000014 - Disclosure - Accrued Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000015 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000016 - Disclosure - Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000017 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000018 - Disclosure - Accrued liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000019 - Disclosure - Equity Offerings (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>avxl-20230331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedBalanceSheets" xlink:href="avxl-20230331.xsd#InterimConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20230331.xsd#InterimConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfOperations" xlink:href="avxl-20230331.xsd#InterimConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="avxl-20230331.xsd#InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows" xlink:href="avxl-20230331.xsd#InterimConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescription" xlink:href="avxl-20230331.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentation" xlink:href="avxl-20230331.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20230331.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20230331.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20230331.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationPolicies" xlink:href="avxl-20230331.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20230331.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:href="avxl-20230331.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20230331.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20230331.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20230331.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Condensed Interim Consolidated Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Interim Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - Condensed Interim Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Interim Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ShareProceedsReceivableMember" xlink:label="loc_avxlShareProceedsReceivableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_avxlShareProceedsReceivableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:label="loc_avxlSharesIssuedUnder2023PurchaseAgreement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnder2023PurchaseAgreement_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_InitialCommitmentShares" xlink:label="loc_avxlInitialCommitmentShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentShares_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_InitialCommitmentSharesShares" xlink:label="loc_avxlInitialCommitmentSharesShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentSharesShares_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_CommitmentShares" xlink:label="loc_avxlCommitmentShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentShares_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsInShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsInShares_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SharesIssuedUnderSalesAgreementInShares" xlink:label="loc_avxlSharesIssuedUnderSalesAgreementInShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreementInShares_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_LessShareIssueCosts" xlink:label="loc_avxlLessShareIssueCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlLessShareIssueCosts_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescription" xlink:title="00000007 - Disclosure - Business Description" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000010 - Disclosure - Accrued Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationPolicies" xlink:title="00000013 - Disclosure - Basis of Presentation (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000014 - Disclosure - Accrued Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000015 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000016 - Disclosure - Basis of Presentation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000017 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_MichaelJFoxMember" xlink:label="loc_avxlMichaelJFoxMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_AnavexMember" xlink:label="loc_avxlAnavexMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlAnavexMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="loc_currencyAUD_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlDeferredGrantIncome_140" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000018 - Disclosure - Accrued liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000019 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaapThirdPartyPayorMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_us-gaapThirdPartyPayorMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SoldForGrossProceedsAmount" xlink:label="loc_avxlSoldForGrossProceedsAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSoldForGrossProceedsAmount_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SalesOfAgreementAmount" xlink:label="loc_avxlSalesOfAgreementAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSalesOfAgreementAmount_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_FairValueOfInitialCommitment" xlink:label="loc_avxlFairValueOfInitialCommitment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlFairValueOfInitialCommitment_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_IncurredExpenses" xlink:label="loc_avxlIncurredExpenses_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlIncurredExpenses_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4_110" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaapCapitalLeaseObligationsIncurred_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCapitalLeaseObligationsIncurred_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPensionContributions_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="loc_avxlWarrantsOutstandingWeightedAverageExercise_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWarrantsOutstandingWeightedAverageExercise_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_130" xlink:type="arc" order="13" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>avxl-20230331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ShareProceedsReceivableMember" xlink:label="avxl_ShareProceedsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareProceedsReceivableMember" xlink:to="avxl_ShareProceedsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareProceedsReceivableMember_lbl" xml:lang="en-US">Share Proceeds Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_MichaelJFoxMember" xlink:label="avxl_MichaelJFoxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MichaelJFoxMember" xlink:to="avxl_MichaelJFoxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MichaelJFoxMember_lbl" xml:lang="en-US">Michael J Fox [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_AnavexMember" xlink:label="avxl_AnavexMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AnavexMember" xlink:to="avxl_AnavexMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AnavexMember_lbl" xml:lang="en-US">Anavex [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="avxl_EquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="avxl_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald And Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_PurchaseAgreement1Member" xlink:label="avxl_PurchaseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement1Member_lbl" xml:lang="en-US">2019 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ThirdPartyPayorMember" xlink:to="us-gaap_ThirdPartyPayorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ThirdPartyPayorMember_lbl" xml:lang="en-US">Third-Party Payor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">Stock Option Plan 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">Stock Option Plan 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockOptionPlan2022Member" xlink:label="avxl_StockOptionPlan2022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2022Member" xlink:to="avxl_StockOptionPlan2022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2022Member_lbl" xml:lang="en-US">Stock Option Plan 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">Purchase Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_PurchaseWarrants2Member" xlink:label="avxl_PurchaseWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants2Member_lbl" xml:lang="en-US">Purchase Warrants 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionPrice1Member" xlink:label="avxl_OptionPrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice1Member" xlink:to="avxl_OptionPrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice1Member_lbl" xml:lang="en-US">Option Price 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionPrice2Member" xlink:label="avxl_OptionPrice2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice2Member" xlink:to="avxl_OptionPrice2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice2Member_lbl" xml:lang="en-US">Option Price 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionPrice3Member" xlink:label="avxl_OptionPrice3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice3Member" xlink:to="avxl_OptionPrice3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice3Member_lbl" xml:lang="en-US">Option Price 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionPrice4Member" xlink:label="avxl_OptionPrice4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice4Member" xlink:to="avxl_OptionPrice4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice4Member_lbl" xml:lang="en-US">Option Price 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionPrice5Member" xlink:label="avxl_OptionPrice5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice5Member" xlink:to="avxl_OptionPrice5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice5Member_lbl" xml:lang="en-US">Option Price 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities - Note 4</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Deferred grant income - Note 3</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 6</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 80,235,398 common shares (September 30, 2022 - 77,942,815)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="avxl_NonOperatingIncomeFromGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrants" xlink:to="avxl_NonOperatingIncomeFromGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrants_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OtherFinancingExpense" xlink:label="avxl_OtherFinancingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherFinancingExpense" xlink:to="avxl_OtherFinancingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherFinancingExpense_lbl" xml:lang="en-US">Other financing expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange (loss) gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_NetLossPerShareBasicAndDiluted" xlink:label="avxl_NetLossPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NetLossPerShareBasicAndDiluted" xlink:to="avxl_NetLossPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NetLossPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:label="avxl_SharesIssuedUnder2023PurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:to="avxl_SharesIssuedUnder2023PurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUnder2023PurchaseAgreement_lbl" xml:lang="en-US">Shares issued under 2023 purchase agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_InitialCommitmentShares" xlink:label="avxl_InitialCommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_InitialCommitmentShares" xlink:to="avxl_InitialCommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_InitialCommitmentShares_lbl" xml:lang="en-US">Initial Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_InitialCommitmentSharesShares" xlink:label="avxl_InitialCommitmentSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_InitialCommitmentSharesShares" xlink:to="avxl_InitialCommitmentSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_InitialCommitmentSharesShares_lbl" xml:lang="en-US">Initial commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Purchase shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_CommitmentShares" xlink:label="avxl_CommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentShares" xlink:to="avxl_CommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentShares_lbl" xml:lang="en-US">Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_CommitmentSharesShares" xlink:label="avxl_CommitmentSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesShares" xlink:to="avxl_CommitmentSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesShares_lbl" xml:lang="en-US">Commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xml:lang="en-US">Shares issued upon exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares_lbl" xml:lang="en-US">Shares issued upon exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued under Sales Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SharesIssuedUnderSalesAgreementInShares" xlink:label="avxl_SharesIssuedUnderSalesAgreementInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUnderSalesAgreementInShares" xlink:to="avxl_SharesIssuedUnderSalesAgreementInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUnderSalesAgreementInShares_lbl" xml:lang="en-US">Shares issued under Sales Agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_LessShareIssueCosts" xlink:label="avxl_LessShareIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LessShareIssueCosts" xlink:to="avxl_LessShareIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LessShareIssueCosts_lbl" xml:lang="en-US">Less: share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_NoncashFinancingRelatedCharges" xlink:label="avxl_NoncashFinancingRelatedCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NoncashFinancingRelatedCharges" xlink:to="avxl_NoncashFinancingRelatedCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NoncashFinancingRelatedCharges_lbl" xml:lang="en-US">Non-cash financing related charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:label="avxl_IncreaseDecreaseInDeferredGrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:to="avxl_IncreaseDecreaseInDeferredGrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncreaseDecreaseInDeferredGrantIncome_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Increase in cash and cash equivalents during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:label="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:to="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes_lbl" xml:lang="en-US">Cash paid for state and local minimum income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="avxl_DisclosureOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureOtherIncomeAbstract" xlink:to="avxl_DisclosureOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="avxl_DisclosureEquityOfferingsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureEquityOfferingsAbstract" xlink:to="avxl_DisclosureEquityOfferingsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureEquityOfferingsAbstract_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_EquityOfferingTextBlock" xlink:label="avxl_EquityOfferingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_EquityOfferingTextBlock_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_LliquidityPolicyTextBlock" xlink:label="avxl_LliquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LliquidityPolicyTextBlock" xlink:to="avxl_LliquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LliquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:to="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding stock purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule Of Share-based Payment Arrangement, Option, Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_DeferredGrantIncome" xlink:label="avxl_DeferredGrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_DeferredGrantIncome_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_AccruedClinicalSiteAndPatientVisitsCosts" xlink:label="avxl_AccruedClinicalSiteAndPatientVisitsCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccruedClinicalSiteAndPatientVisitsCosts" xlink:to="avxl_AccruedClinicalSiteAndPatientVisitsCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AccruedClinicalSiteAndPatientVisitsCosts_lbl" xml:lang="en-US">Accrued clinical site and patient visits costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued compensation and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_FixedContractAccruals" xlink:label="avxl_FixedContractAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FixedContractAccruals" xlink:to="avxl_FixedContractAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FixedContractAccruals_lbl" xml:lang="en-US">Fixed contract accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_MilestoneBasedContractAccruals" xlink:label="avxl_MilestoneBasedContractAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MilestoneBasedContractAccruals" xlink:to="avxl_MilestoneBasedContractAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MilestoneBasedContractAccruals_lbl" xml:lang="en-US">Milestone based contract accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">All other accrued liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued liabilities&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="avxl_PercentageOfGrossProceedsFromSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PercentageOfGrossProceedsFromSales_lbl" xml:lang="en-US">Percentage of gross proceeds from sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of common stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SoldForGrossProceedsAmount" xlink:label="avxl_SoldForGrossProceedsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SoldForGrossProceedsAmount" xlink:to="avxl_SoldForGrossProceedsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SoldForGrossProceedsAmount_lbl" xml:lang="en-US">Sold for gross proceeds amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from Issuance Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SalesOfAgreementAmount" xlink:label="avxl_SalesOfAgreementAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SalesOfAgreementAmount" xlink:to="avxl_SalesOfAgreementAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SalesOfAgreementAmount_lbl" xml:lang="en-US">Sales of agreement amount</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Value of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Share issued for offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_FairValueOfInitialCommitment" xlink:label="avxl_FairValueOfInitialCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FairValueOfInitialCommitment" xlink:to="avxl_FairValueOfInitialCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FairValueOfInitialCommitment_lbl" xml:lang="en-US">Fair value of the initial commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_IncurredExpenses" xlink:label="avxl_IncurredExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncurredExpenses" xlink:to="avxl_IncurredExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncurredExpenses_lbl" xml:lang="en-US">Incurred expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price, value</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xml:lang="en-US">Number of shares issued for commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xml:lang="en-US">Amount of shares remain available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiry Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, lower range limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, upper range limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of outstanding options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of vested options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US">Incurred office lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions" xlink:label="us-gaap_PensionContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionContributions" xlink:to="us-gaap_PensionContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionContributions_lbl" xml:lang="en-US">Contribution amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="avxl_WarrantsOutstandingWeightedAverageExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WarrantsOutstandingWeightedAverageExercise" xlink:to="avxl_WarrantsOutstandingWeightedAverageExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WarrantsOutstandingWeightedAverageExercise_lbl" xml:lang="en-US">Warrants outstanding weighted average exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionIssued" xlink:label="avxl_OptionIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionIssued" xlink:to="avxl_OptionIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionIssued_lbl" xml:lang="en-US">Option issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Option available issue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value of options vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted average contractual life of options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PercentageOfGrossProceedsFromSales_doc" xml:lang="en-US">Represents information related to percentage of gross proceeds from sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingSalesAgreementMember_doc" xml:lang="en-US">Represents information related to equity offering sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Represents information related to cantor fitzgerald and co.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2015Member_doc" xml:lang="en-US">Information related to type of plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ValueOfSharesObligatedToPurchase_doc" xml:lang="en-US">Information related to value of shares obligated to purchase initially.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreement1Member_doc" xml:lang="en-US">Represents the information pertaining to purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Information related to type of legal entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xml:lang="en-US">Information related to number of shares obligated to purchase prorata basic.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xml:lang="en-US">OtherIncomeDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingTextBlock_2_lbl" xml:lang="en-US">EquityOfferingTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_2_lbl" xml:lang="en-US">NonOperatingIncomeFromGrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredGrantIncome_2_lbl" xml:lang="en-US">DeferredGrantIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>avxl-20230331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedBalanceSheets" xlink:href="avxl-20230331.xsd#InterimConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20230331.xsd#InterimConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfOperations" xlink:href="avxl-20230331.xsd#InterimConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="avxl-20230331.xsd#InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows" xlink:href="avxl-20230331.xsd#InterimConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescription" xlink:href="avxl-20230331.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentation" xlink:href="avxl-20230331.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20230331.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20230331.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20230331.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationPolicies" xlink:href="avxl-20230331.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20230331.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:href="avxl-20230331.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20230331.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20230331.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20230331.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Condensed Interim Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Interim Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - Condensed Interim Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OtherFinancingExpense" xlink:label="loc_avxlOtherFinancingExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlOtherFinancingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_NetLossPerShareBasicAndDiluted" xlink:label="loc_avxlNetLossPerShareBasicAndDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_avxlNetLossPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="loc_avxlWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_avxlWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Interim Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ShareProceedsReceivableMember" xlink:label="loc_avxlShareProceedsReceivableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_avxlShareProceedsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:label="loc_avxlSharesIssuedUnder2023PurchaseAgreement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnder2023PurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_InitialCommitmentShares" xlink:label="loc_avxlInitialCommitmentShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_InitialCommitmentSharesShares" xlink:label="loc_avxlInitialCommitmentSharesShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_CommitmentShares" xlink:label="loc_avxlCommitmentShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsInShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SharesIssuedUnderSalesAgreementInShares" xlink:label="loc_avxlSharesIssuedUnderSalesAgreementInShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreementInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_LessShareIssueCosts" xlink:label="loc_avxlLessShareIssueCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlLessShareIssueCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_NoncashFinancingRelatedCharges" xlink:label="loc_avxlNoncashFinancingRelatedCharges" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_avxlNoncashFinancingRelatedCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:label="loc_avxlIncreaseDecreaseInDeferredGrantIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_avxlIncreaseDecreaseInDeferredGrantIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:label="loc_avxlCashPaidForStateAndLocalMinimumIncomeTaxes" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_avxlCashPaidForStateAndLocalMinimumIncomeTaxes" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescription" xlink:title="00000007 - Disclosure - Business Description">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaapBasisOfAccounting" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccounting" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000010 - Disclosure - Accrued Liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings">
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_EquityOfferingTextBlock" xlink:label="loc_avxlEquityOfferingTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_avxlEquityOfferingTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationPolicies" xlink:title="00000013 - Disclosure - Basis of Presentation (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_LliquidityPolicyTextBlock" xlink:label="loc_avxlLliquidityPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_avxlLliquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000014 - Disclosure - Accrued Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000015 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000016 - Disclosure - Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000017 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_MichaelJFoxMember" xlink:label="loc_avxlMichaelJFoxMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_AnavexMember" xlink:label="loc_avxlAnavexMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlAnavexMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlDeferredGrantIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000018 - Disclosure - Accrued liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_AccruedClinicalSiteAndPatientVisitsCosts" xlink:label="loc_avxlAccruedClinicalSiteAndPatientVisitsCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlAccruedClinicalSiteAndPatientVisitsCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_FixedContractAccruals" xlink:label="loc_avxlFixedContractAccruals" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlFixedContractAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_MilestoneBasedContractAccruals" xlink:label="loc_avxlMilestoneBasedContractAccruals" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlMilestoneBasedContractAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000019 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaapThirdPartyPayorMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_us-gaapThirdPartyPayorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SoldForGrossProceedsAmount" xlink:label="loc_avxlSoldForGrossProceedsAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSoldForGrossProceedsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_SalesOfAgreementAmount" xlink:label="loc_avxlSalesOfAgreementAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSalesOfAgreementAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_FairValueOfInitialCommitment" xlink:label="loc_avxlFairValueOfInitialCommitment" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlFairValueOfInitialCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_IncurredExpenses" xlink:label="loc_avxlIncurredExpenses" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlIncurredExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaapCapitalLeaseObligationsIncurred" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCapitalLeaseObligationsIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPensionContributions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="loc_avxlWarrantsOutstandingWeightedAverageExercise" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWarrantsOutstandingWeightedAverageExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230331.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206937041088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0608404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">630 5th Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">20th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-3939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock Par Value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVXL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,837,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206941294032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Interim Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 153,466,962<span></span>
</td>
<td class="nump">$ 149,157,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">4,737,661<span></span>
</td>
<td class="nump">3,192,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">981,774<span></span>
</td>
<td class="nump">354,162<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">159,186,397<span></span>
</td>
<td class="nump">152,704,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,281,742<span></span>
</td>
<td class="nump">3,824,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities - Note 4</a></td>
<td class="nump">6,822,838<span></span>
</td>
<td class="nump">5,944,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred grant income - Note 3</a></td>
<td class="nump">916,763<span></span>
</td>
<td class="nump">443,831<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">14,021,343<span></span>
</td>
<td class="nump">10,213,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies - Note 6</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 80,235,398 common shares (September 30, 2022 - 77,942,815)</a></td>
<td class="nump">80,236<span></span>
</td>
<td class="nump">77,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">416,727,598<span></span>
</td>
<td class="nump">387,976,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(271,642,780)<span></span>
</td>
<td class="num">(245,563,783)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">145,165,054<span></span>
</td>
<td class="nump">142,491,042<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 159,186,397<span></span>
</td>
<td class="nump">$ 152,704,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206936948752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Interim Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">80,235,398<span></span>
</td>
<td class="nump">77,942,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">80,235,398<span></span>
</td>
<td class="nump">77,942,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206938440544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Interim Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 2,882,568<span></span>
</td>
<td class="nump">$ 2,915,158<span></span>
</td>
<td class="nump">$ 6,199,604<span></span>
</td>
<td class="nump">$ 5,982,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">11,306,591<span></span>
</td>
<td class="nump">8,604,589<span></span>
</td>
<td class="nump">23,373,510<span></span>
</td>
<td class="nump">17,261,028<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">14,189,159<span></span>
</td>
<td class="nump">11,519,747<span></span>
</td>
<td class="nump">29,573,114<span></span>
</td>
<td class="nump">23,243,137<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(14,189,159)<span></span>
</td>
<td class="num">(11,519,747)<span></span>
</td>
<td class="num">(29,573,114)<span></span>
</td>
<td class="num">(23,243,137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrants', window );">Grant income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">749,681<span></span>
</td>
<td class="nump">835,513<span></span>
</td>
<td class="nump">1,483,271<span></span>
</td>
<td class="nump">1,646,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">1,465,221<span></span>
</td>
<td class="nump">7,578<span></span>
</td>
<td class="nump">2,732,839<span></span>
</td>
<td class="nump">12,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OtherFinancingExpense', window );">Other financing expense</a></td>
<td class="num">(964,344)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(964,344)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (loss) gain</a></td>
<td class="num">(118,678)<span></span>
</td>
<td class="nump">268,645<span></span>
</td>
<td class="nump">247,305<span></span>
</td>
<td class="nump">324,008<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,131,880<span></span>
</td>
<td class="nump">1,111,736<span></span>
</td>
<td class="nump">3,524,071<span></span>
</td>
<td class="nump">1,982,739<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(13,057,279)<span></span>
</td>
<td class="num">(10,408,011)<span></span>
</td>
<td class="num">(26,049,043)<span></span>
</td>
<td class="num">(21,260,398)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense, current</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="num">(29,800)<span></span>
</td>
<td class="num">(29,954)<span></span>
</td>
<td class="num">(59,780)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (13,107,279)<span></span>
</td>
<td class="num">$ (10,437,811)<span></span>
</td>
<td class="num">$ (26,078,997)<span></span>
</td>
<td class="num">$ (21,320,178)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NetLossPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">$ 78,304,363<span></span>
</td>
<td class="nump">$ 76,248,603<span></span>
</td>
<td class="nump">$ 78,138,940<span></span>
</td>
<td class="nump">$ 76,121,792<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NetLossPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NetLossPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherFinancingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherFinancingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206938761328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Interim Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Share Proceeds Receivable [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 75,920<span></span>
</td>
<td class="nump">$ 348,328,048<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (197,585,864)<span></span>
</td>
<td class="nump">$ 150,818,104<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Sep. 30, 2021</a></td>
<td class="nump">75,918,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued upon exercise of stock options</a></td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">496,746<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">496,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares', window );">Shares issued upon exercise of stock options, shares</a></td>
<td class="nump">176,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued under Sales Agreement</a></td>
<td class="nump">$ 1,066<span></span>
</td>
<td class="nump">14,802,398<span></span>
</td>
<td class="num">(403,696)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,399,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUnderSalesAgreementInShares', window );">Shares issued under Sales Agreement, shares</a></td>
<td class="nump">1,066,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_LessShareIssueCosts', window );">Less: share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(537,806)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(537,806)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,348,230<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,348,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(21,320,178)<span></span>
</td>
<td class="num">(21,320,178)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 77,163<span></span>
</td>
<td class="nump">371,437,616<span></span>
</td>
<td class="num">(403,696)<span></span>
</td>
<td class="num">(218,906,042)<span></span>
</td>
<td class="nump">152,205,041<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="nump">77,161,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 76,156<span></span>
</td>
<td class="nump">354,759,781<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(208,468,231)<span></span>
</td>
<td class="nump">146,367,706<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">76,155,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued upon exercise of stock options</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">123,386<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">123,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares', window );">Shares issued upon exercise of stock options, shares</a></td>
<td class="nump">39,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued under Sales Agreement</a></td>
<td class="nump">$ 967<span></span>
</td>
<td class="nump">12,489,713<span></span>
</td>
<td class="num">(403,696)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,086,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUnderSalesAgreementInShares', window );">Shares issued under Sales Agreement, shares</a></td>
<td class="nump">966,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_LessShareIssueCosts', window );">Less: share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(374,720)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(374,720)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,439,456<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,439,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,437,811)<span></span>
</td>
<td class="num">(10,437,811)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 77,163<span></span>
</td>
<td class="nump">371,437,616<span></span>
</td>
<td class="num">(403,696)<span></span>
</td>
<td class="num">(218,906,042)<span></span>
</td>
<td class="nump">152,205,041<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="nump">77,161,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 77,944<span></span>
</td>
<td class="nump">387,976,881<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(245,563,783)<span></span>
</td>
<td class="nump">142,491,042<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Sep. 30, 2022</a></td>
<td class="nump">77,942,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_InitialCommitmentShares', window );">Initial Commitment shares</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">844,425<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">844,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_InitialCommitmentSharesShares', window );">Initial commitment shares, shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Purchase shares</a></td>
<td class="nump">$ 2,075<span></span>
</td>
<td class="nump">18,150,425<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,152,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase shares, shares</a></td>
<td class="nump">2,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentShares', window );">Commitment shares</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">9,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued upon exercise of stock options</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">439,304<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">439,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares', window );">Shares issued upon exercise of stock options, shares</a></td>
<td class="nump">133,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,316,572<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,316,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(26,078,997)<span></span>
</td>
<td class="num">(26,078,997)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 80,236<span></span>
</td>
<td class="nump">416,727,598<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(271,642,780)<span></span>
</td>
<td class="nump">145,165,054<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2023</a></td>
<td class="nump">80,235,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 78,033<span></span>
</td>
<td class="nump">393,581,544<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(258,535,501)<span></span>
</td>
<td class="nump">135,124,076<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">78,032,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUnder2023PurchaseAgreement', window );">Shares issued under 2023 purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_InitialCommitmentShares', window );">Initial Commitment shares</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">844,425<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">844,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_InitialCommitmentSharesShares', window );">Initial commitment shares, shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Purchase shares</a></td>
<td class="nump">$ 2,075<span></span>
</td>
<td class="nump">18,150,425<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,152,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase shares, shares</a></td>
<td class="nump">2,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentShares', window );">Commitment shares</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">9,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued upon exercise of stock options</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">181,149<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">181,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares', window );">Shares issued upon exercise of stock options, shares</a></td>
<td class="nump">44,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,970,064<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,970,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,107,279)<span></span>
</td>
<td class="num">(13,107,279)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 80,236<span></span>
</td>
<td class="nump">$ 416,727,598<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (271,642,780)<span></span>
</td>
<td class="nump">$ 145,165,054<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2023</a></td>
<td class="nump">80,235,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_InitialCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_InitialCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_InitialCommitmentSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_InitialCommitmentSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_LessShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_LessShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUnder2023PurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUnder2023PurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUnderSalesAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUnderSalesAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206938722000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,078,997)<span></span>
</td>
<td class="num">$ (21,320,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NoncashFinancingRelatedCharges', window );">Non-cash financing related charges</a></td>
<td class="nump">844,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,316,572<span></span>
</td>
<td class="nump">8,348,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="num">(1,545,081)<span></span>
</td>
<td class="nump">2,667,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="num">(627,612)<span></span>
</td>
<td class="num">(109,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,456,965<span></span>
</td>
<td class="num">(2,107,893)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">877,885<span></span>
</td>
<td class="num">(619,386)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncreaseDecreaseInDeferredGrantIncome', window );">Deferred grant income</a></td>
<td class="nump">472,932<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,282,836)<span></span>
</td>
<td class="num">(13,140,439)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="nump">18,152,500<span></span>
</td>
<td class="nump">14,399,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(521,441)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">439,437<span></span>
</td>
<td class="nump">496,923<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">18,591,937<span></span>
</td>
<td class="nump">14,375,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase in cash and cash equivalents during the period</a></td>
<td class="nump">4,309,101<span></span>
</td>
<td class="nump">1,234,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">149,157,861<span></span>
</td>
<td class="nump">152,107,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">153,466,962<span></span>
</td>
<td class="nump">153,342,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CashPaidForStateAndLocalMinimumIncomeTaxes', window );">Cash paid for state and local minimum income taxes</a></td>
<td class="nump">$ 139,577<span></span>
</td>
<td class="nump">$ 141,374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CashPaidForStateAndLocalMinimumIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CashPaidForStateAndLocalMinimumIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncreaseDecreaseInDeferredGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncreaseDecreaseInDeferredGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NoncashFinancingRelatedCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NoncashFinancingRelatedCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206942703600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Description</a></td>
<td class="text"><p id="xdx_808_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zOTbS0vR8uEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 	<span id="xdx_82A_zwdqtS4RVzRe">Business Description</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp. (&#8220;Anavex&#8221; or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the
development of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with
high unmet need. Anavex analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical
trials for the treatment of neurodegenerative and neurodevelopmental diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73 is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease
and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic
disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;), and Fragile X syndrome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206942532816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_808_eus-gaap--BasisOfAccounting_zZq4uf2Shwha" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 	<span id="xdx_82F_z0wmo129n8G2">Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_znYEvP3hVhT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zV0dfSXhuLel">Basis
of Presentation</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying unaudited condensed interim consolidated financial statements have been prepared pursuant to the rules and regulations of
the Securities and Exchange Commission (&#8220;SEC&#8221;) and accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly, certain information and note disclosures normally included in the annual
financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion
of management, the disclosures are adequate to make the information presented not misleading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments,
which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated balance
sheet as of September 30, 2022 was derived from the audited annual financial statements but does not include all disclosures required
by U.S. GAAP. The accompanying unaudited condensed interim consolidated financial statements should be read in conjunction with the audited
consolidated financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K for the year ended September
30, 2022 filed with the SEC on November 28, 2022. The Company follows the same accounting policies in the preparation of interim reports.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
results for the three and six months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the
year ending September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_ecustom--LliquidityPolicyTextBlock_zAiBDyICsCZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_znepwWF4jzGl">Liquidity</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its research
and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical
companies or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business
to continue to experience negative cash flows from operations for the foreseeable future and cannot predict when, if ever, our business
might become profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>












<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
condensed interim consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the Sales Agreement
and the Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development
activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_849_eus-gaap--UseOfEstimates_zEswO4DgKpm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_866_zz3cpcMGIZ69">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_ze8RHSFauRVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zJrCBuITl9dc">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


















<p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zxVD0g3eukN" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_861_zMQJMVFo24xb">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2023 and September 30, 2022, the Company
did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zFLs6IeSvEY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_86C_z6s1GDvjulTl">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2023 loss per share excludes <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230331_pdd" title="Loss per share for potentially dilutive common shares">15,001,613</span>
(March 31, 2022: <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220331_pdd" title="Loss per share for potentially dilutive common shares">11,510,319</span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFRCuf4NZQB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_860_zvFoPQmzZ3Ll">Recently Adopted Accounting
Pronouncements</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2021, the FASB
issued ASU 2021-10, &#8220;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&#8221; (&#8220;ASU&#160;2021-10&#8221;).
ASU&#160;2021-10&#160;increases the disclosure requirements for annual reporting periods relating to material government assistance transactions
on the entity&#8217;s financial statements and any significant terms and conditions of the agreements including commitments and contingencies.
The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The
adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company
receives from the Australian Tax Office (&#8220;ATO&#8221;) for its clinical trials in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206942730416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><p id="xdx_805_ecustom--OtherIncomeDisclosureTextBlock_zERf2jW9hKlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 3	<span id="xdx_822_zc1qQrqm7K6d">Other Income</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant Income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of March 31, 2023, the
Company had received $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_pp0p0" title="Research and development incentive income">995,862</span> in a research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant will
be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 related to Parkinson&#8217;s disease.
Of the total, $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230331__dei--LegalEntityAxis__custom--AnavexMember_pp0p0" title="Research and development incentive income">497,931</span> was received during the six months ended March 31, 2023, and $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20210930__dei--LegalEntityAxis__custom--AnavexMember_z5rWjDX54Ph7" title="Research and development incentive income">497,931</span> was received during the year ended September
30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income was recorded
to deferred grant income when received and is being amortized to grant income as the related research and development expenditures are
incurred. During the three and six months ended March 31, 2023, the Company recognized $<span id="xdx_907_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20230101__20230331_zXpvre4MlpK" title="Grant income">0</span> and $<span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20221001__20230331_zFOthGqAh2zd" title="Grant income">25,000</span>, respectively (2022: $<span id="xdx_901_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20220101__20220331_zXZpFiQ0bYr1" title="Grant income">0</span> and $<span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_c20211001__20220331_pp0p0" title="Grant income">0</span>,
respectively) of this grant on its statements of operations as grant income. At March 31, 2023, an amount of $<span id="xdx_90B_ecustom--DeferredGrantIncome_c20230331_pp0p0" title="Deferred grant income">916,763</span> (September 30, 2022:
$<span id="xdx_90F_ecustom--DeferredGrantIncome_c20220930_pp0p0" title="Deferred grant income">443,831</span>) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to
other income. The Company will recognize this income on its statement of operations as the related expenditures are incurred to offset
the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents the income earned by Anavex Australia, of the Australian research and development tax incentive credit (the
&#8220;Tax Incentive Credit&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the three and six
months ended March 31, 2023, the Company recorded research and development incentive income of $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20230101__20230331_z1FOcf6chj13" title="Research and development incentive income">749,681</span> (AUD <span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20230101__20230331__srt--CurrencyAxis__currency--AUD_zVsN0Ahfr2mb" title="Research and development incentive income">1,099,134</span>) and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20230331_zL0yXHqtsWdg" title="Research and development incentive income">1,483,271</span>
(AUD <span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20230331__srt--CurrencyAxis__currency--AUD_zdVDiI9JGhd5" title="Research and development incentive income">2,215,753</span>), respectively (2022: <span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20220101__20220331_zrupM5QNdMC7" title="Research and development incentive income">835,513</span> (AUD <span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20220101__20220331__srt--CurrencyAxis__currency--AUD_z8Arf3BQHsj4" title="Research and development incentive income">1,146,955</span>) and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20220331_z7wpsblnBmN6" title="Research and development incentive income">1,646,243</span> (AUD <span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20220331__srt--CurrencyAxis__currency--AUD_znILBhzasKOa" title="Research and development incentive income">2,263,317</span>), respectively) in respect of the Tax Incentive
Credit for eligible research and development expenses incurred during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Although the Company believes that it complies with all the relevant conditions of the program, the Company may be subject
to pre-issue review or audit by the ATO, and the ATO may have different interpretations of certain eligibility requirements. Currently,
the Company&#8217;s tax incentive claims from 2018 to 2022 are open to potential review or audit by the ATO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206942693696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p id="xdx_801_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zmqY9hLAfjwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 4	 	 <span id="xdx_82E_zFwrf0lQpAs3">Accrued Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The principal components of accrued liabilities consist of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zE0fQQNmWDSj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td id="xdx_8BB_zTXxyNJLU5Ud" style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt">&#160;Schedule of accrued liabilities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49E_20230331_z5Z9pzbGdPYh" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49C_20220930_zt7rlsV1Aj69" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">March 31,</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">September 30,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; text-indent: -10pt">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr id="xdx_403_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued clinical site and patient visits costs</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">2,168,950</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">2,031,105</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedBonusesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,572,500</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,297,337</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--FixedContractAccruals_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed contract accruals</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">82,666</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">417,414</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--MilestoneBasedContractAccruals_iI_pp0p0_zi1lOKAzRrMa" style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">Milestone based contract accruals</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,041,930</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">137,337</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">1,956,792</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">2,061,760</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzEQ3_zRGal2oAj7t1" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt">Total accrued liabilities&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">6,822,838</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">5,944,953</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206942683120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureEquityOfferingsAbstract', window );"><strong>Equity Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_EquityOfferingTextBlock', window );">Equity Offerings</a></td>
<td class="text"><p id="xdx_80A_ecustom--EquityOfferingTextBlock_zK2pTZF4xKN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 5		<span id="xdx_82D_zvJt3ZUU0ugc">Equity Offerings</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors (the &#8220;Board&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board has the authority to issue
preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting
any series of the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company may offer and sell shares of common stock
registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on the Company&#8217;s
instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares by methods deemed to
be an &#8220;at the market offering&#8221; offering, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to
the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company
or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. The Sales
Agents will act as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable
state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has agreed to pay the Sales Agents commissions
for their services of up to <span id="xdx_905_ecustom--PercentageOfGrossProceedsFromSales_dp_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z7Hdr97BdNc1" title="Percentage of gross proceeds from sales">3.0</span>% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed
to provide the Sales Agents with customary indemnification and contribution rights. During the six months ended March 31, 2023, <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_do_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember_zO2zbhTGAo1j" title="Number of common stock sold">no</span> shares
were sold pursuant to the Offering. During the six months ended March 31, 2022, <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_znZ0YhjsDob6" title="Number of common stock sold">1,066,389</span> shares were sold for gross proceeds of $<span id="xdx_906_ecustom--SoldForGrossProceedsAmount_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zxyLptqoQjQb" title="Sold for gross proceeds amount">14,803,464</span>
(net proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z5lqCidGwX49" title="Proceeds from Issuance Public Offering">14,265,658</span>). At March 31, 2023, an amount of $<span id="xdx_908_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20230331_zoIiPkFxGqHf" title="Sales of agreement amount">142,407,882</span> (September 30, 2022: $<span id="xdx_90B_ecustom--SalesOfAgreementAmount_c20220930_pp0p0" title="Sales of agreement amount">142,407,882</span>) was registered pursuant
to an effective registration statement and remained available to be sold under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into a $150,000,000
purchase agreement (the &#8220;Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant to
which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_pp0p0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zS6yotV9xMtj" title="Value of shares obligated to purchase">150,000,000</span> in value
of its shares of common stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the Purchase Agreement,
the Company issued to Lincoln Park <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zHnm5s1hBbxd" title="Share issued for offering, shares">75,000</span> shares of common stock as a commitment fee (the &#8220;initial commitment shares&#8221;) and
agreed to issue up to an additional <span id="xdx_903_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z1sVAdXIpP6a" title="Pro rata basic number of shares obligated to purchase">75,000</span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion, the
$<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zUscKPRLCCv3" title="Proceeds from Issuance or Sale of Equity">150,000,000</span> aggregate commitment. The Company determined the fair value of the initial commitment shares was $<span id="xdx_909_ecustom--FairValueOfInitialCommitment_iI_c20230331_zSDQXyIJt879" title="Fair value of the initial commitment">844,500</span> with reference
to the closing price of the Company&#8217;s shares on the Purchase Agreement date. In addition, the Company incurred third party expenses
of $<span id="xdx_90E_ecustom--IncurredExpenses_iI_c20230331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__us-gaap--ThirdPartyPayorMember_zKWbQaYjFZA1" title="Incurred expenses">119,844</span> in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense on the statement
of operations during the three and six months ended March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended March 31, 2023, the Company
issued to Lincoln Park an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zz6TJrJSBSUf" title="Share issued for offering, shares">2,159,080</span> (2022: <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_ziRnUQmbK2T9" title="Share issued for offering, shares">0</span>) shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zH5D6LOehDP3" title="Number of shares issued for aggregate purchase price">2,075,000</span>
(2022: <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z64bnbm9d63h" title="Number of shares issued for aggregate purchase price">0</span>) shares of common stock for an aggregate purchase price of $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zxsfRggGJ8K6" title="Number of shares issued for aggregate purchase price, value">18,152,500</span>&#160;(2022: $<span id="xdx_906_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z1C6MP1T5iEg" title="Number of shares issued for aggregate purchase price, value">0</span>) and&#160;<span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zF27NmC8jlp3" title="Number of shares issued for commitment">9,080</span>&#160;(2022:&#160;<span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zW2CgLvpd8ri" title="Number of shares issued for commitment">0</span>) commitment
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2023, an amount of $<span id="xdx_900_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_do_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z5owmz6IyTGg" title="Amount of shares remain available">131,847,500</span> (September
30, 2022: $<span id="xdx_908_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_do_c20211001__20220930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zmR1jKfZKYCh" title="Amount of shares remain available">0</span>) remained available under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureEquityOfferingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureEquityOfferingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206942504976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_804_eus-gaap--CommitmentsDisclosureTextBlock_z1dSsYXExwY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Note 6 	<span id="xdx_82F_zG9sw5dBR2fe">Commitments and Contingencies </span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>Leases </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">During the three
and six months ended March 31, 2023, the Company incurred office lease expense of $<span id="xdx_90E_eus-gaap--CapitalLeaseObligationsIncurred_c20230101__20230331_zZhekqC2spK7" title="Incurred office lease expense">30,070</span> and $<span id="xdx_90D_eus-gaap--CapitalLeaseObligationsIncurred_c20221001__20230331_zERkFiZt4jz" title="Incurred office lease expense">60,140</span>, (2022: $<span id="xdx_901_eus-gaap--CapitalLeaseObligationsIncurred_c20220101__20220331_zW0xMJ6LaTn3" title="Incurred office lease expense">16,488</span> and $<span id="xdx_902_eus-gaap--CapitalLeaseObligationsIncurred_c20211001__20220331_z5qWXxxCyY65" title="Incurred office lease expense">21,333</span>) respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company has
a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees.
United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal
Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees.
During the three and six months ended March 31, 2023, the Company made $<span id="xdx_90C_eus-gaap--PensionContributions_pp0p0_c20230101__20230331_zvbghzCNQOK6" title="Contribution amount">56,230</span> and $<span id="xdx_90A_eus-gaap--PensionContributions_pp0p0_c20221001__20230331_zG5QutkUeVc6" title="Contribution amount">99,876</span> (2022: $<span id="xdx_90A_eus-gaap--PensionContributions_pp0p0_c20220101__20220331_zJ0TJ3eI48V3" title="Contribution amount">70,940</span> and $<span id="xdx_90A_eus-gaap--PensionContributions_pp0p0_c20211001__20220331_zuLN5HQirWg8" title="Contribution amount">93,622</span>), respectively,
in matching contributions under the 401(k) plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>Litigation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company is subject
to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be
no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will
not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that any of
such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black; text-align: justify"><span style="font-weight: normal"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>Share Purchase Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2023 and September 30, 2022, the Company
had <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230331_zrRoiO2S0USc" title="Warrants outstanding"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zILBZQ2FOdWe" title="Warrants outstanding">160,000</span></span> warrants outstanding at a weighted average exercise price of $<span id="xdx_908_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_c20230331_zOsbPergO0I5" title="Warrants outstanding weighted average exercise"><span id="xdx_909_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_c20220930_z2gRaPqbItTj" title="Warrants outstanding weighted average exercise">3.72</span></span> as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zvfUcIM49MZc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B7_zvmoXTwM6Uoj" style="display: none">Schedule of share purchase warrants outstanding</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">Number</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td><td>&#160;</td>
    <td style="text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="padding: 0pt 0pt 0pt 10pt; width: 20%; text-align: right; text-indent: -10pt" title="Number">150,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 20%; text-align: right" title="Exercise Price">3.17</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="text-align: right; width: 40%"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zoTANGKC0ck9" title="Expiry Date">May 6, 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="text-align: right" title="Exercise Price">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_ztGbnKtTdM1h" title="Expiry Date">April 21, 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230331_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number">160,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  </table>



<p id="xdx_8A9_z8hNkttuMcZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>Stock&#8211;based Compensation
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2015 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s Board approved
a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_znucd8UstR88" title="Maximum number of common shares reserved for future issuance">6,050,553</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zNXFiKqSVkDc" title="Additional shares of common stock available for issuance">6,000,000</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Option granted">406,453</span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_z3HpFUr6ieje" title="Additional shares of common stock available for issuance">10,000,000</span> additional shares of Common Stock will be available for issuance under the plan. Any awards outstanding under a previous
stock option plan will remain subject to and be paid under such plan, and any shares subject to outstanding awards under a previous plan
that subsequently cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become
available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant and shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date,
then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.
Stock options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such
lesser periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. As at
March 31, 2023, <span id="xdx_90A_ecustom--OptionIssued_c20221001__20230331_zQWtabwz8zea" title="Option issued">3,916,000</span> options had been issued under the 2022 Plan and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_za2iRI7BF6Ka" title="Option available issue">6,557,952</span> options were available for issuance under the 2022
Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the status of Company&#8217;s outstanding
stock options is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zGhmkPXhQ9Gb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
<tr style="vertical-align: bottom">
  <td colspan="3" style="text-align: center"><span id="xdx_8B2_zncDT1zZs2Fd" style="display: none">Schedule of outstanding stock purchase options</span></td>
  <td style="text-align: center">&#160;</td>
  <td colspan="3" style="text-align: center">&#160;</td>
  <td style="text-align: center">&#160;</td>
  <td colspan="3" style="text-align: center">&#160;</td>
  <td style="text-align: center">&#160;</td>
  <td colspan="3" style="text-align: center">&#160;</td>
  <td style="text-align: center">&#160;</td>
  <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
  <td colspan="3" style="text-align: center">&#160; &#160; &#160; &#160;</td>
  <td style="text-align: center">&#160; &#160; &#160; &#160;</td>
  <td colspan="3" style="text-align: center">Number of Shares</td>
  <td style="text-align: center">&#160; &#160; &#160; &#160;</td>
  <td colspan="3" style="text-align: center">Weighted Average Exercise Price<br/>
($)</td>
  <td style="text-align: center">&#160; &#160; &#160; </td>
  <td colspan="3" style="text-align: center">Weighted Average Grant Date Fair Value <br/>
($)</td>
  <td style="text-align: center">&#160; &#160; &#160; &#160;</td>
  <td colspan="3" style="text-align: center">Aggregate intrinsic value<br/>
($)</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 38%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.3pt">Outstanding, September 30, 2021</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuzBCy6iGiC1" style="width: 10%; text-align: right" title="Options Outstanding at beginning">11,330,903</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3PxdH3c3Bkh" style="width: 10%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">5.74</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#8212;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJrudywlnHWl" style="width: 10%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">140,132,451</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrl6AoLbahe7" style="text-align: right" title="Options Granted">2,358,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpR5tlEDrGP5" style="text-align: right" title="Weighted Average Exercise Price Granted">10.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXA4H7ikh4S5" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">7.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqzKBxAWarQ8" style="text-align: right" title="Options Forfeited">(118,750</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zU3oWaBTWTdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited">6.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4IpSXM3CiS7" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited">5.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqVjeaHJc6G1" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised">(400,537</td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoQtupOyyLAc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">2.52</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHVz36IBp274" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised">1.88</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zM5qpTwDdW9" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised">4,201,015</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.25pt">Outstanding, September 30, 2022</span></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFXiw3owsBw8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at beginning">13,169,616</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXET1KCwX4ik" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">6.61</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zR1NM0Wrx97g" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">62,267,309</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxgkgXbaxH9h" style="text-align: right" title="Options Granted">1,863,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzFsud6fYvaa" style="text-align: right" title="Weighted Average Exercise Price Granted">9.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZ7sWM0phDt6" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">6.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJLx97GOqZHg" style="text-align: right" title="Options Exercised">(133,503</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zU48Vjf8083" style="text-align: right" title="Weighted Average Exercise Price Exercised">3.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHXv9VJsWv6c" style="text-align: right" title="Weighted Average Grant Date Fair Value Exercised"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.4pt">2 59</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHX4y89O55i" style="text-align: right" title="Aggregate intrinsic value Exercised">868,537</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpl3xaiUXDhd" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited">(57,500</td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5OJuXa1uuIl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited">11.73</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0W6R3TPfm06" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Forfeited">9.09</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.3pt">Outstanding, March 31, 2023</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsT8EkRNCRK5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at ending">14,841,613</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm5EPX5Pusl1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at ending">6.97</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zekX38HHuEIi" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Outstanding at ending">43,709,206</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.25pt">Exercisable, March 31, 2023</span></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending">9,937,362</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending">4.78</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending">43,099,822</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p id="xdx_8A8_zzJUVBBeEePg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at March 31, 2023 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zpLwDuPsADu5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8BF_z1eKRi0UsXF1" style="display: none">Schedule Of Share-based Payment Arrangement, Option, Activity</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><b>Range of exercises prices</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Number of Outstanding</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Weighted average remaining contractual Me</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Weighted average</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Number of vested</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Weighted average</b></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>From</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>To</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>options</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>(in years)</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>exercise price</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>options</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>exercise price</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit">2.96</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Number of outstanding options">3,834,559</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zRaAerWvkkzi" title="Weighted average remaining contractual life (in years)">4.60</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price">2.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options">3,834,559</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price options vested">2.29</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">3.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">4.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options">2,022,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z5lJbEpxnPni" title="Weighted average remaining contractual life (in years)">4.82</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price">3.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options">2,017,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price options vested">3.28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">5.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">8.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options">5,307,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zD86a3Np2h0j" title="Weighted average remaining contractual life (in years)">6.72</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price">6.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options">3,345,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price options vested">6.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">9.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">13.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options">2,118,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zbp7pMbGF1mj" title="Weighted average remaining contractual life (in years)">8.87</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price">10.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options">312,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price options vested">11.94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Range of exercise prices, lower range limit">13.22</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Range of exercise prices, upper range limit">24.58</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">1,559,500</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zxeHhqNGWvle" title="Weighted average remaining contractual life (in years)">7.99</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price">18.48</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">427,500</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested">18.90</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbdo8FSt1zU" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">14,841,613</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbdgeOa5UYe7" title="Weighted average remaining contractual life (in years)">6.35</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price">6.97</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">9,937,362</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm9PpFXH0seh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested">4.78</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A2_zqGnFQPsf3Mg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;&#160;&#160;</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average grant date fair value of options
vested during the six months ended March 31, 2023 was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20221001__20230331_zgflxeD3c01f" title="Weighted average grant date fair value of options vested">3.67</span> (2022: $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20220331_zWjP57fERXu8" title="Weighted average grant date fair value of options vested">3.20</span>). At March 31, 2023, the weighted average contractual life of
options outstanding was <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331_zp2iDvKN79jb" title="Weighted average contractual life of options outstanding">6.35</span> years (September 30, 2022: <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zpWFArHrXTxj" title="Weighted average contractual life of options outstanding">6.40</span> years) and for options exercisable was <span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331_zpFR4PrUC4hh" title="Options exercisable">4.92</span> years (September 30, 2022: <span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zbfkxxCCX355" title="Options exercisable">5.1</span>
years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and six months ended March 31, 2023,
the Company recognized stock-based compensation expense of $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331_zwr5bLubUvv6" title="Share based compensation">3,970,064</span> and $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20221001__20230331_zONmp8T38Vz2" title="Share based compensation">9,316,572</span> (2022: $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331_znNZBc8riQo8" title="Share based compensation">4,439,456</span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220331_zXUB5WrouLN6" title="Share based compensation">8,348,230</span>), respectively,
in connection with the issuance and vesting 	of stock options and warrants in exchange for services. These amounts have been included
in general and 	administrative expenses and research and development expenses on the Company&#8217;s statement of 	operations as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zHd2yF3cv6Yg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BE_z3eIb511MQDb" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months end March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZcCk1tExeq6" style="width: 10%; text-align: right" title="Total share based compensation">1,256,845</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z88z9XC2Lula" style="width: 10%; text-align: right" title="Total share based compensation">1,577,831</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation">2,999,370</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation">3,249,557</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zs63jaqd34p8" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,713,219</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ztzAhJ2Uak1a" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,861,625</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">6,317,202</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">5,098,673</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total stock-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331_zA7bV7COo72e" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,970,064</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331_zI4O267A8sA1" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">4,439,456</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230331_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">9,316,572</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220331_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">8,348,230</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
</table>
<p id="xdx_8AB_zOSHWMv6YZXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20230331_zduzbrIwAZTd" title="Remaining stock based compensation">21,781,736</span> in stock-based
compensation is expected to be recorded over the remaining term 	of such options through fiscal 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each option award
granted during the three and six months ended March 31, 2023 and 2022 is estimated on the date of grant using the Black Scholes option
pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zVpUVP5hTl97" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BF_z8iSpRqKAhh4" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20221001__20230331_zxQ8jJ4bCTIk" title="Risk-free interest rate">3.69</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220331_zkCu7YnhAW5k" title="Risk-free interest rate">1.40</span></td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230331_zj9vhfofKnR4" title="Expected life of options (years)">5.61</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220331_znjpVNeM15Gf" title="Expected life of options (years)">4.90</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20221001__20230331_zRr20MOo3PR5" title="Annualized volatility">85.28</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220331_zbUFlI3Ryp71" title="Annualized volatility">95.88</span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20221001__20230331_z5M3XiYupIY4" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220331_zPucHQvEpIdh" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td></tr>
</table>
<p id="xdx_8A0_zOoYGMqz8fc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of stock compensation charges recognized
during the three and six months ended March 31, 2023 and 2022 was determined with reference to the quoted market price of the Company&#8217;s
shares on the grant date.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206941296000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_znYEvP3hVhT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zV0dfSXhuLel">Basis
of Presentation</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying unaudited condensed interim consolidated financial statements have been prepared pursuant to the rules and regulations of
the Securities and Exchange Commission (&#8220;SEC&#8221;) and accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly, certain information and note disclosures normally included in the annual
financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion
of management, the disclosures are adequate to make the information presented not misleading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments,
which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated balance
sheet as of September 30, 2022 was derived from the audited annual financial statements but does not include all disclosures required
by U.S. GAAP. The accompanying unaudited condensed interim consolidated financial statements should be read in conjunction with the audited
consolidated financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K for the year ended September
30, 2022 filed with the SEC on November 28, 2022. The Company follows the same accounting policies in the preparation of interim reports.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
results for the three and six months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the
year ending September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_LliquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_84C_ecustom--LliquidityPolicyTextBlock_zAiBDyICsCZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_znepwWF4jzGl">Liquidity</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its research
and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical
companies or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business
to continue to experience negative cash flows from operations for the foreseeable future and cannot predict when, if ever, our business
might become profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>












<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
condensed interim consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the Sales Agreement
and the Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development
activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_849_eus-gaap--UseOfEstimates_zEswO4DgKpm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_866_zz3cpcMGIZ69">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_ze8RHSFauRVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zJrCBuITl9dc">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


















<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zxVD0g3eukN" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_861_zMQJMVFo24xb">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2023 and September 30, 2022, the Company
did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Share</a></td>
<td class="text"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zFLs6IeSvEY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_86C_z6s1GDvjulTl">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2023 loss per share excludes <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230331_pdd" title="Loss per share for potentially dilutive common shares">15,001,613</span>
(March 31, 2022: <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220331_pdd" title="Loss per share for potentially dilutive common shares">11,510,319</span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFRCuf4NZQB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_860_zvFoPQmzZ3Ll">Recently Adopted Accounting
Pronouncements</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2021, the FASB
issued ASU 2021-10, &#8220;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&#8221; (&#8220;ASU&#160;2021-10&#8221;).
ASU&#160;2021-10&#160;increases the disclosure requirements for annual reporting periods relating to material government assistance transactions
on the entity&#8217;s financial statements and any significant terms and conditions of the agreements including commitments and contingencies.
The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The
adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company
receives from the Australian Tax Office (&#8220;ATO&#8221;) for its clinical trials in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_LliquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_LliquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206942629440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zE0fQQNmWDSj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td id="xdx_8BB_zTXxyNJLU5Ud" style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt">&#160;Schedule of accrued liabilities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49E_20230331_z5Z9pzbGdPYh" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49C_20220930_zt7rlsV1Aj69" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">March 31,</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">September 30,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; text-indent: -10pt">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr id="xdx_403_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued clinical site and patient visits costs</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">2,168,950</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">2,031,105</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedBonusesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,572,500</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,297,337</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--FixedContractAccruals_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed contract accruals</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">82,666</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">417,414</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--MilestoneBasedContractAccruals_iI_pp0p0_zi1lOKAzRrMa" style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">Milestone based contract accruals</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,041,930</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">137,337</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">1,956,792</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">2,061,760</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzEQ3_zRGal2oAj7t1" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt">Total accrued liabilities&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">6,822,838</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">5,944,953</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206937047584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zvfUcIM49MZc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B7_zvmoXTwM6Uoj" style="display: none">Schedule of share purchase warrants outstanding</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">Number</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td><td>&#160;</td>
    <td style="text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="padding: 0pt 0pt 0pt 10pt; width: 20%; text-align: right; text-indent: -10pt" title="Number">150,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 20%; text-align: right" title="Exercise Price">3.17</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="text-align: right; width: 40%"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zoTANGKC0ck9" title="Expiry Date">May 6, 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="text-align: right" title="Exercise Price">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_ztGbnKtTdM1h" title="Expiry Date">April 21, 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230331_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number">160,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of outstanding stock purchase options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zGhmkPXhQ9Gb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
<tr style="vertical-align: bottom">
  <td colspan="3" style="text-align: center"><span id="xdx_8B2_zncDT1zZs2Fd" style="display: none">Schedule of outstanding stock purchase options</span></td>
  <td style="text-align: center">&#160;</td>
  <td colspan="3" style="text-align: center">&#160;</td>
  <td style="text-align: center">&#160;</td>
  <td colspan="3" style="text-align: center">&#160;</td>
  <td style="text-align: center">&#160;</td>
  <td colspan="3" style="text-align: center">&#160;</td>
  <td style="text-align: center">&#160;</td>
  <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
  <td colspan="3" style="text-align: center">&#160; &#160; &#160; &#160;</td>
  <td style="text-align: center">&#160; &#160; &#160; &#160;</td>
  <td colspan="3" style="text-align: center">Number of Shares</td>
  <td style="text-align: center">&#160; &#160; &#160; &#160;</td>
  <td colspan="3" style="text-align: center">Weighted Average Exercise Price<br/>
($)</td>
  <td style="text-align: center">&#160; &#160; &#160; </td>
  <td colspan="3" style="text-align: center">Weighted Average Grant Date Fair Value <br/>
($)</td>
  <td style="text-align: center">&#160; &#160; &#160; &#160;</td>
  <td colspan="3" style="text-align: center">Aggregate intrinsic value<br/>
($)</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 38%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.3pt">Outstanding, September 30, 2021</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuzBCy6iGiC1" style="width: 10%; text-align: right" title="Options Outstanding at beginning">11,330,903</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3PxdH3c3Bkh" style="width: 10%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">5.74</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#8212;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJrudywlnHWl" style="width: 10%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">140,132,451</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrl6AoLbahe7" style="text-align: right" title="Options Granted">2,358,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpR5tlEDrGP5" style="text-align: right" title="Weighted Average Exercise Price Granted">10.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXA4H7ikh4S5" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">7.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqzKBxAWarQ8" style="text-align: right" title="Options Forfeited">(118,750</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zU3oWaBTWTdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited">6.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4IpSXM3CiS7" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited">5.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqVjeaHJc6G1" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised">(400,537</td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoQtupOyyLAc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">2.52</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHVz36IBp274" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised">1.88</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zM5qpTwDdW9" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised">4,201,015</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.25pt">Outstanding, September 30, 2022</span></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFXiw3owsBw8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at beginning">13,169,616</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXET1KCwX4ik" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">6.61</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zR1NM0Wrx97g" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">62,267,309</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxgkgXbaxH9h" style="text-align: right" title="Options Granted">1,863,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzFsud6fYvaa" style="text-align: right" title="Weighted Average Exercise Price Granted">9.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZ7sWM0phDt6" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">6.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJLx97GOqZHg" style="text-align: right" title="Options Exercised">(133,503</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zU48Vjf8083" style="text-align: right" title="Weighted Average Exercise Price Exercised">3.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHXv9VJsWv6c" style="text-align: right" title="Weighted Average Grant Date Fair Value Exercised"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.4pt">2 59</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHX4y89O55i" style="text-align: right" title="Aggregate intrinsic value Exercised">868,537</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpl3xaiUXDhd" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited">(57,500</td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5OJuXa1uuIl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited">11.73</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0W6R3TPfm06" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Forfeited">9.09</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.3pt">Outstanding, March 31, 2023</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsT8EkRNCRK5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at ending">14,841,613</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm5EPX5Pusl1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at ending">6.97</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zekX38HHuEIi" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Outstanding at ending">43,709,206</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.25pt">Exercisable, March 31, 2023</span></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending">9,937,362</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending">4.78</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending">43,099,822</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule Of Share-based Payment Arrangement, Option, Activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zpLwDuPsADu5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8BF_z1eKRi0UsXF1" style="display: none">Schedule Of Share-based Payment Arrangement, Option, Activity</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><b>Range of exercises prices</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Number of Outstanding</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Weighted average remaining contractual Me</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Weighted average</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Number of vested</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Weighted average</b></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>From</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>To</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>options</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>(in years)</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>exercise price</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>options</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>exercise price</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit">2.96</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Number of outstanding options">3,834,559</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zRaAerWvkkzi" title="Weighted average remaining contractual life (in years)">4.60</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price">2.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options">3,834,559</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price options vested">2.29</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">3.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">4.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options">2,022,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z5lJbEpxnPni" title="Weighted average remaining contractual life (in years)">4.82</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price">3.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options">2,017,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price options vested">3.28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">5.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">8.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options">5,307,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zD86a3Np2h0j" title="Weighted average remaining contractual life (in years)">6.72</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price">6.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options">3,345,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price options vested">6.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">9.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">13.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options">2,118,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zbp7pMbGF1mj" title="Weighted average remaining contractual life (in years)">8.87</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price">10.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options">312,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price options vested">11.94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Range of exercise prices, lower range limit">13.22</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Range of exercise prices, upper range limit">24.58</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">1,559,500</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zxeHhqNGWvle" title="Weighted average remaining contractual life (in years)">7.99</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price">18.48</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">427,500</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested">18.90</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbdo8FSt1zU" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">14,841,613</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbdgeOa5UYe7" title="Weighted average remaining contractual life (in years)">6.35</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price">6.97</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">9,937,362</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm9PpFXH0seh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested">4.78</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zHd2yF3cv6Yg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BE_z3eIb511MQDb" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months end March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZcCk1tExeq6" style="width: 10%; text-align: right" title="Total share based compensation">1,256,845</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z88z9XC2Lula" style="width: 10%; text-align: right" title="Total share based compensation">1,577,831</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation">2,999,370</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation">3,249,557</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zs63jaqd34p8" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,713,219</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ztzAhJ2Uak1a" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,861,625</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">6,317,202</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">5,098,673</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total stock-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331_zA7bV7COo72e" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,970,064</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331_zI4O267A8sA1" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">4,439,456</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230331_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">9,316,572</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220331_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">8,348,230</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zVpUVP5hTl97" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BF_z8iSpRqKAhh4" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20221001__20230331_zxQ8jJ4bCTIk" title="Risk-free interest rate">3.69</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220331_zkCu7YnhAW5k" title="Risk-free interest rate">1.40</span></td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230331_zj9vhfofKnR4" title="Expected life of options (years)">5.61</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220331_znjpVNeM15Gf" title="Expected life of options (years)">4.90</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20221001__20230331_zRr20MOo3PR5" title="Annualized volatility">85.28</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220331_zbUFlI3Ryp71" title="Annualized volatility">95.88</span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20221001__20230331_z5M3XiYupIY4" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220331_zPucHQvEpIdh" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206942580880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="nump">15,001,613<span></span>
</td>
<td class="nump">11,510,319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206937019568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 749,681<span></span>
</td>
<td class="nump">$ 835,513<span></span>
</td>
<td class="nump">$ 1,483,271<span></span>
</td>
<td class="nump">$ 1,646,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredGrantIncome', window );">Deferred grant income</a></td>
<td class="nump">916,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">916,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 1,099,134<span></span>
</td>
<td class="nump">$ 1,146,955<span></span>
</td>
<td class="nump">2,215,753<span></span>
</td>
<td class="nump">$ 2,263,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=avxl_AnavexMember', window );">Anavex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 497,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember', window );">Michael J Fox [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 995,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_AnavexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_AnavexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206936993424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_AccruedClinicalSiteAndPatientVisitsCosts', window );">Accrued clinical site and patient visits costs</a></td>
<td class="nump">$ 2,168,950<span></span>
</td>
<td class="nump">$ 2,031,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">1,572,500<span></span>
</td>
<td class="nump">1,297,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_FixedContractAccruals', window );">Fixed contract accruals</a></td>
<td class="nump">82,666<span></span>
</td>
<td class="nump">417,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_MilestoneBasedContractAccruals', window );">Milestone based contract accruals</a></td>
<td class="nump">1,041,930<span></span>
</td>
<td class="nump">137,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">All other accrued liabilities</a></td>
<td class="nump">1,956,792<span></span>
</td>
<td class="nump">2,061,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities&#160;</a></td>
<td class="nump">$ 6,822,838<span></span>
</td>
<td class="nump">$ 5,944,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AccruedClinicalSiteAndPatientVisitsCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AccruedClinicalSiteAndPatientVisitsCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FixedContractAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FixedContractAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_MilestoneBasedContractAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_MilestoneBasedContractAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206938926736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 03, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SalesOfAgreementAmount', window );">Sales of agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,407,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,407,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_FairValueOfInitialCommitment', window );">Fair value of the initial commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Third-Party Payor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncurredExpenses', window );">Incurred expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member] | Cantor Fitzgerald And Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,066,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SoldForGrossProceedsAmount', window );">Sold for gross proceeds amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,803,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,265,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member', window );">2019 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Value of shares obligated to purchase</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued for offering, shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">2,159,080<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,075,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,152,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,080<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues4', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,847,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FairValueOfInitialCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FairValueOfInitialCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncurredExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncurredExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information related to number of shares obligated to purchase prorata basic.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfSharesObligatedToPurchaseProrataBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PercentageOfGrossProceedsFromSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information related to percentage of gross proceeds from sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PercentageOfGrossProceedsFromSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SalesOfAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SalesOfAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SoldForGrossProceedsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SoldForGrossProceedsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information related to value of shares obligated to purchase initially.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206937731600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member', window );">Purchase Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">May  06,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member', window );">Purchase Warrants 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">Apr. 21,  2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206938770944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1) - Equity Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at beginning</a></td>
<td class="nump">13,169,616<span></span>
</td>
<td class="nump">11,330,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at beginning</a></td>
<td class="nump">$ 6.61<span></span>
</td>
<td class="nump">$ 5.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at beginning</a></td>
<td class="nump">$ 62,267,309<span></span>
</td>
<td class="nump">$ 140,132,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">1,863,000<span></span>
</td>
<td class="nump">2,358,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">$ 9.36<span></span>
</td>
<td class="nump">$ 10.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Granted</a></td>
<td class="nump">$ 6.64<span></span>
</td>
<td class="nump">$ 7.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="num">(57,500)<span></span>
</td>
<td class="num">(118,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">$ 11.73<span></span>
</td>
<td class="nump">$ 6.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice', window );">Weighted Average Grant Date Fair Value Forfeited</a></td>
<td class="nump">$ 9.09<span></span>
</td>
<td class="nump">$ 5.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(133,503)<span></span>
</td>
<td class="num">(400,537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice', window );">Weighted Average Grant Date Fair Value Exercised</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value Exercised</a></td>
<td class="nump">$ 868,537<span></span>
</td>
<td class="nump">$ 4,201,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at ending</a></td>
<td class="nump">14,841,613<span></span>
</td>
<td class="nump">13,169,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at ending</a></td>
<td class="nump">$ 6.97<span></span>
</td>
<td class="nump">$ 6.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at ending</a></td>
<td class="nump">$ 43,709,206<span></span>
</td>
<td class="nump">$ 62,267,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable at ending</a></td>
<td class="nump">9,937,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable at ending</a></td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value Exercisable at ending</a></td>
<td class="nump">$ 43,099,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206938142304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 4 months 6 days<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">14,841,613<span></span>
</td>
<td class="nump">13,169,616<span></span>
</td>
<td class="nump">11,330,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.97<span></span>
</td>
<td class="nump">$ 6.61<span></span>
</td>
<td class="nump">$ 5.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">9,937,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 2.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">3,834,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">3,834,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">2,022,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">4 years 9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">2,017,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 8.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">5,307,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">3,345,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 6.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">9.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 13.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">2,118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">8 years 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 10.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">312,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 11.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">13.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 24.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,559,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">7 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 18.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">427,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 18.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206936802544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 3,970,064<span></span>
</td>
<td class="nump">$ 4,439,456<span></span>
</td>
<td class="nump">$ 9,316,572<span></span>
</td>
<td class="nump">$ 8,348,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">1,256,845<span></span>
</td>
<td class="nump">1,577,831<span></span>
</td>
<td class="nump">2,999,370<span></span>
</td>
<td class="nump">3,249,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 2,713,219<span></span>
</td>
<td class="nump">$ 2,861,625<span></span>
</td>
<td class="nump">$ 6,317,202<span></span>
</td>
<td class="nump">$ 5,098,673<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206934749744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 4)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.69%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 7 months 9 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">85.28%<span></span>
</td>
<td class="nump">95.88%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140206938506656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Incurred office lease expense</a></td>
<td class="nump">$ 30,070<span></span>
</td>
<td class="nump">$ 16,488<span></span>
</td>
<td class="nump">$ 60,140<span></span>
</td>
<td class="nump">$ 21,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution amount</a></td>
<td class="nump">$ 56,230<span></span>
</td>
<td class="nump">70,940<span></span>
</td>
<td class="nump">$ 99,876<span></span>
</td>
<td class="nump">$ 93,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_WarrantsOutstandingWeightedAverageExercise', window );">Warrants outstanding weighted average exercise</a></td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OptionIssued', window );">Option issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,916,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.67<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">$ 3,970,064<span></span>
</td>
<td class="nump">$ 4,439,456<span></span>
</td>
<td class="nump">$ 9,316,572<span></span>
</td>
<td class="nump">$ 8,348,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining stock based compensation</a></td>
<td class="nump">$ 21,781,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,781,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">Stock Option Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member', window );">Stock Option Plan 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Option available issue</a></td>
<td class="nump">6,557,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,557,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OptionIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OptionIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WarrantsOutstandingWeightedAverageExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WarrantsOutstandingWeightedAverageExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in lease obligation from new lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>e4668_10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avxl="http://anavex.com/20230331"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avxl-20230331.xsd" xlink:type="simple"/>
    <context id="From2022-10-01to2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_custom_MichaelJFoxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_custom_AnavexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_custom_AnavexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-03-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_ThirdPartyPayorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2021-10-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_PurchaseWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_PurchaseWarrants2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-10-01to2023-03-31">0001314052</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-10-01to2023-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-10-01to2023-03-31">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-10-01to2023-03-31">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-10-01to2023-03-31">Q2</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0079"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0080"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0090"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0092"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl0156"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0157"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2021-10-012022-03-31"
      id="xdx2ixbrl0159"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:OtherFinancingExpense
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0172"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:OtherFinancingExpense
      contextRef="From2021-10-012022-03-31"
      id="xdx2ixbrl0174"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0223"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedUnder2023PurchaseAgreement
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:InitialCommitmentShares
      contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:InitialCommitmentShares
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-01-012022-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2022-01-012022-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2022-10-01to2023-03-31"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-012022-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2021-10-012022-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2021-10-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012022-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NoncashFinancingRelatedCharges
      contextRef="From2021-10-012022-03-31"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:IncreaseDecreaseInDeferredGrantIncome
      contextRef="From2021-10-012022-03-31"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2022-10-01to2023-03-31"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-10-01to2023-03-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2022-10-01to2023-03-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-10-01to2023-03-31">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-10-01to2023-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-10-01to2023-03-31">001-37606</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-10-01to2023-03-31">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-10-01to2023-03-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-10-01to2023-03-31">98-0608404</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-10-01to2023-03-31">630 5th Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-10-01to2023-03-31">20th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-10-01to2023-03-31">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-10-01to2023-03-31">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2022-10-01to2023-03-31">US</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2022-10-01to2023-03-31">10111</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-10-01to2023-03-31">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-10-01to2023-03-31">689-3939</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-10-01to2023-03-31">Common Stock Par Value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-10-01to2023-03-31">AVXL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-10-01to2023-03-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2022-10-01to2023-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-10-01to2023-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-10-01to2023-03-31">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-10-01to2023-03-31">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-10-01to2023-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2022-10-01to2023-03-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-05-08" decimals="INF" unitRef="Shares">80837723</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">153466962</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">149157861</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4737661</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">3192580</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">981774</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">354162</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:Assets contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">159186397</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">152704603</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">6281742</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">3824777</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">6822838</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">5944953</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">916763</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">443831</us-gaap:DeferredIncomeCurrent>
    <us-gaap:Liabilities contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">14021343</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">10213561</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">80235398</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">80235398</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">77942815</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">77942815</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">80236</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">77944</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">416727598</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">387976881</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">-271642780</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">-245563783</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">145165054</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">142491042</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">159186397</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">152704603</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">2882568</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">2915158</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">6199604</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">5982109</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">11306591</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">8604589</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">23373510</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">17261028</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">14189159</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">11519747</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">29573114</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">23243137</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">-14189159</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-11519747</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">-29573114</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">-23243137</us-gaap:OperatingIncomeLoss>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">25000</avxl:NonOperatingIncomeFromGrants>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">749681</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">835513</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">1483271</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">1646243</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">1465221</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">7578</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">2732839</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">12488</us-gaap:InterestIncomeExpenseNet>
    <avxl:OtherFinancingExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">-964344</avxl:OtherFinancingExpense>
    <avxl:OtherFinancingExpense
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">-964344</avxl:OtherFinancingExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">-118678</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">268645</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">247305</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">324008</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">1131880</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">1111736</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">3524071</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">1982739</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">-13057279</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-10408011</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">-26049043</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">-21260398</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">50000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">29800</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">29954</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">59780</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">-13107279</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-10437811</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">-26078997</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">-21320178</us-gaap:NetIncomeLoss>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.17</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.14</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2022-10-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.33</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2021-10-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.28</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      unitRef="USDPShares">78304363</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">76248603</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2022-10-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">78138940</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2021-10-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">76121792</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">78032135</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">78033</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">393581544</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-258535501</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">135124076</us-gaap:StockholdersEquity>
    <avxl:InitialCommitmentSharesShares
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75000</avxl:InitialCommitmentSharesShares>
    <avxl:InitialCommitmentShares
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">75</avxl:InitialCommitmentShares>
    <avxl:InitialCommitmentShares
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">844425</avxl:InitialCommitmentShares>
    <avxl:InitialCommitmentShares
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">844500</avxl:InitialCommitmentShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2075000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2075</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">18150425</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">18152500</us-gaap:StockRepurchasedDuringPeriodValue>
    <avxl:CommitmentSharesShares
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9080</avxl:CommitmentSharesShares>
    <avxl:CommitmentShares
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">9</avxl:CommitmentShares>
    <avxl:CommitmentShares
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-9</avxl:CommitmentShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">44183</avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">44</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">181149</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">181193</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3970064</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">3970064</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-13107279</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">-13107279</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">80235398</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">80236</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">416727598</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-271642780</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">145165054</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">76155187</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">76156</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">354759781</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-208468231</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">146367706</us-gaap:StockholdersEquity>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">39700</avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">40</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">123386</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">123426</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedUnderSalesAgreementInShares
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">966801</avxl:SharesIssuedUnderSalesAgreementInShares>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">967</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">12489713</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_custom_ShareProceedsReceivableMember"
      decimals="0"
      unitRef="USD">-403696</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">12086984</us-gaap:StockIssuedDuringPeriodValueOther>
    <avxl:LessShareIssueCosts
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-374720</avxl:LessShareIssueCosts>
    <avxl:LessShareIssueCosts
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-374720</avxl:LessShareIssueCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4439456</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">4439456</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-10437811</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-10437811</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">77161688</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">77163</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">371437616</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_custom_ShareProceedsReceivableMember"
      decimals="0"
      unitRef="USD">-403696</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-218906042</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">152205041</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">77942815</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">77944</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">387976881</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-245563783</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">142491042</us-gaap:StockholdersEquity>
    <avxl:InitialCommitmentSharesShares
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75000</avxl:InitialCommitmentSharesShares>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">75</avxl:InitialCommitmentShares>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">844425</avxl:InitialCommitmentShares>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">844500</avxl:InitialCommitmentShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2075000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2075</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">18150425</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">18152500</us-gaap:StockRepurchasedDuringPeriodValue>
    <avxl:CommitmentSharesShares
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9080</avxl:CommitmentSharesShares>
    <avxl:CommitmentShares
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">9</avxl:CommitmentShares>
    <avxl:CommitmentShares
      contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-9</avxl:CommitmentShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">133503</avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">133</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">439304</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">439437</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">9316572</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">9316572</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-26078997</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">-26078997</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">80235398</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">80236</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">416727598</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-271642780</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">145165054</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75918465</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">75920</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">348328048</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-197585864</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">150818104</us-gaap:StockholdersEquity>
    <avxl:SharesIssuedUnderSalesAgreementInShares
      contextRef="From2021-10-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1066389</avxl:SharesIssuedUnderSalesAgreementInShares>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1066</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">14802398</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012022-03-31_custom_ShareProceedsReceivableMember"
      decimals="0"
      unitRef="USD">-403696</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">14399768</us-gaap:StockIssuedDuringPeriodValueOther>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-537806</avxl:LessShareIssueCosts>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">-537806</avxl:LessShareIssueCosts>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares
      contextRef="From2021-10-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">176834</avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2021-10-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">177</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2021-10-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">496746</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">496923</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">8348230</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">8348230</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-21320178</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">-21320178</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">77161688</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">77163</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">371437616</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_custom_ShareProceedsReceivableMember"
      decimals="0"
      unitRef="USD">-403696</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-218906042</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">152205041</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">-26078997</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">-21320178</us-gaap:NetIncomeLoss>
    <avxl:NoncashFinancingRelatedCharges
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">844500</avxl:NoncashFinancingRelatedCharges>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">9316572</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">8348230</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">1545081</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">-2667844</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">627612</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">109056</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">2456965</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">-2107893</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">877885</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">-619386</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <avxl:IncreaseDecreaseInDeferredGrantIncome
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">472932</avxl:IncreaseDecreaseInDeferredGrantIncome>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">-14282836</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">-13140439</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">18152500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">14399768</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">521441</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">439437</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">496923</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">18591937</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">14375250</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">4309101</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">1234811</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">149157861</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">152107745</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">153466962</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">153342556</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <avxl:CashPaidForStateAndLocalMinimumIncomeTaxes
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">139577</avxl:CashPaidForStateAndLocalMinimumIncomeTaxes>
    <avxl:CashPaidForStateAndLocalMinimumIncomeTaxes
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">141374</avxl:CashPaidForStateAndLocalMinimumIncomeTaxes>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-10-01to2023-03-31">&lt;p id="xdx_808_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zOTbS0vR8uEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 	&lt;span id="xdx_82A_zwdqtS4RVzRe"&gt;Business Description&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Anavex
Life Sciences Corp. (&#x201c;Anavex&#x201d; or the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company engaged in the
development of differentiated therapeutics by applying precision medicine to central nervous system (&#x201c;CNS&#x201d;) diseases with
high unmet need. Anavex analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical
trials for the treatment of neurodegenerative and neurodevelopmental diseases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s lead compound ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 is being developed to treat Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease
and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic
disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#x201c;MECP2&#x201d;), and Fragile X syndrome.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccounting contextRef="From2022-10-01to2023-03-31">&lt;p id="xdx_808_eus-gaap--BasisOfAccounting_zZq4uf2Shwha" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 	&lt;span id="xdx_82F_z0wmo129n8G2"&gt;Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_znYEvP3hVhT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zV0dfSXhuLel"&gt;Basis
of Presentation&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
accompanying unaudited condensed interim consolidated financial statements have been prepared pursuant to the rules and regulations of
the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and accounting principles generally accepted in the United States of America
(&#x201c;U.S. GAAP&#x201d;) for interim reporting. Accordingly, certain information and note disclosures normally included in the annual
financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion
of management, the disclosures are adequate to make the information presented not misleading.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
accompanying unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments,
which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated balance
sheet as of September 30, 2022 was derived from the audited annual financial statements but does not include all disclosures required
by U.S. GAAP. The accompanying unaudited condensed interim consolidated financial statements should be read in conjunction with the audited
consolidated financial statements and notes thereto included in the Company&#x2019;s annual report on Form 10-K for the year ended September
30, 2022 filed with the SEC on November 28, 2022. The Company follows the same accounting policies in the preparation of interim reports.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
results for the three and six months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the
year ending September 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--LliquidityPolicyTextBlock_zAiBDyICsCZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_znepwWF4jzGl"&gt;Liquidity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of the Company&#x2019;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its research
and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical
companies or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business
to continue to experience negative cash flows from operations for the foreseeable future and cannot predict when, if ever, our business
might become profitable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;












&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management believes that the current working capital
position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months after the date that these
condensed interim consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other than our rights related to the Sales Agreement
and the Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development
activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zEswO4DgKpm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zz3cpcMGIZ69"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_ze8RHSFauRVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zJrCBuITl9dc"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#x201c;Anavex Australia&#x201d;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


















&lt;p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zxVD0g3eukN" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zMQJMVFo24xb"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2023 and September 30, 2022, the Company
did not have any Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zFLs6IeSvEY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_z6s1GDvjulTl"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2023 loss per share excludes &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230331_pdd" title="Loss per share for potentially dilutive common shares"&gt;15,001,613&lt;/span&gt;
(March 31, 2022: &lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220331_pdd" title="Loss per share for potentially dilutive common shares"&gt;11,510,319&lt;/span&gt;) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFRCuf4NZQB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zvFoPQmzZ3Ll"&gt;Recently Adopted Accounting
Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In November 2021, the FASB
issued ASU 2021-10, &#x201c;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&#x201d; (&#x201c;ASU&#160;2021-10&#x201d;).
ASU&#160;2021-10&#160;increases the disclosure requirements for annual reporting periods relating to material government assistance transactions
on the entity&#x2019;s financial statements and any significant terms and conditions of the agreements including commitments and contingencies.
The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The
adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company
receives from the Australian Tax Office (&#x201c;ATO&#x201d;) for its clinical trials in Australia.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccounting>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-10-01to2023-03-31">&lt;p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_znYEvP3hVhT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zV0dfSXhuLel"&gt;Basis
of Presentation&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
accompanying unaudited condensed interim consolidated financial statements have been prepared pursuant to the rules and regulations of
the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and accounting principles generally accepted in the United States of America
(&#x201c;U.S. GAAP&#x201d;) for interim reporting. Accordingly, certain information and note disclosures normally included in the annual
financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion
of management, the disclosures are adequate to make the information presented not misleading.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
accompanying unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments,
which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated balance
sheet as of September 30, 2022 was derived from the audited annual financial statements but does not include all disclosures required
by U.S. GAAP. The accompanying unaudited condensed interim consolidated financial statements should be read in conjunction with the audited
consolidated financial statements and notes thereto included in the Company&#x2019;s annual report on Form 10-K for the year ended September
30, 2022 filed with the SEC on November 28, 2022. The Company follows the same accounting policies in the preparation of interim reports.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
results for the three and six months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the
year ending September 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <avxl:LliquidityPolicyTextBlock contextRef="From2022-10-01to2023-03-31">&lt;p id="xdx_84C_ecustom--LliquidityPolicyTextBlock_zAiBDyICsCZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_znepwWF4jzGl"&gt;Liquidity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of the Company&#x2019;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its research
and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical
companies or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business
to continue to experience negative cash flows from operations for the foreseeable future and cannot predict when, if ever, our business
might become profitable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;












&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management believes that the current working capital
position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months after the date that these
condensed interim consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other than our rights related to the Sales Agreement
and the Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development
activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</avxl:LliquidityPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-10-01to2023-03-31">&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zEswO4DgKpm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zz3cpcMGIZ69"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2022-10-01to2023-03-31">&lt;p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_ze8RHSFauRVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zJrCBuITl9dc"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#x201c;Anavex Australia&#x201d;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


















</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2022-10-01to2023-03-31">&lt;p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zxVD0g3eukN" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zMQJMVFo24xb"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2023 and September 30, 2022, the Company
did not have any Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-10-01to2023-03-31">&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zFLs6IeSvEY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_z6s1GDvjulTl"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2023 loss per share excludes &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230331_pdd" title="Loss per share for potentially dilutive common shares"&gt;15,001,613&lt;/span&gt;
(March 31, 2022: &lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220331_pdd" title="Loss per share for potentially dilutive common shares"&gt;11,510,319&lt;/span&gt;) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">15001613</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-10-012022-03-31"
      decimals="INF"
      unitRef="Shares">11510319</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-10-01to2023-03-31">&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFRCuf4NZQB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zvFoPQmzZ3Ll"&gt;Recently Adopted Accounting
Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In November 2021, the FASB
issued ASU 2021-10, &#x201c;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&#x201d; (&#x201c;ASU&#160;2021-10&#x201d;).
ASU&#160;2021-10&#160;increases the disclosure requirements for annual reporting periods relating to material government assistance transactions
on the entity&#x2019;s financial statements and any significant terms and conditions of the agreements including commitments and contingencies.
The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The
adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company
receives from the Australian Tax Office (&#x201c;ATO&#x201d;) for its clinical trials in Australia.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2022-10-01to2023-03-31">&lt;p id="xdx_805_ecustom--OtherIncomeDisclosureTextBlock_zERf2jW9hKlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Note 3	&lt;span id="xdx_822_zc1qQrqm7K6d"&gt;Other Income&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Grant Income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As of March 31, 2023, the
Company had received $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_pp0p0" title="Research and development incentive income"&gt;995,862&lt;/span&gt; in a research grant awarded by the Michael J. Fox Foundation for Parkinson&#x2019;s Research. The grant will
be used to fund a clinical trial of the Company&#x2019;s lead compound, ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 related to Parkinson&#x2019;s disease.
Of the total, $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230331__dei--LegalEntityAxis__custom--AnavexMember_pp0p0" title="Research and development incentive income"&gt;497,931&lt;/span&gt; was received during the six months ended March 31, 2023, and $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20210930__dei--LegalEntityAxis__custom--AnavexMember_z5rWjDX54Ph7" title="Research and development incentive income"&gt;497,931&lt;/span&gt; was received during the year ended September
30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The grant income was recorded
to deferred grant income when received and is being amortized to grant income as the related research and development expenditures are
incurred. During the three and six months ended March 31, 2023, the Company recognized $&lt;span id="xdx_907_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20230101__20230331_zXpvre4MlpK" title="Grant income"&gt;0&lt;/span&gt; and $&lt;span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20221001__20230331_zFOthGqAh2zd" title="Grant income"&gt;25,000&lt;/span&gt;, respectively (2022: $&lt;span id="xdx_901_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20220101__20220331_zXZpFiQ0bYr1" title="Grant income"&gt;0&lt;/span&gt; and $&lt;span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_c20211001__20220331_pp0p0" title="Grant income"&gt;0&lt;/span&gt;,
respectively) of this grant on its statements of operations as grant income. At March 31, 2023, an amount of $&lt;span id="xdx_90B_ecustom--DeferredGrantIncome_c20230331_pp0p0" title="Deferred grant income"&gt;916,763&lt;/span&gt; (September 30, 2022:
$&lt;span id="xdx_90F_ecustom--DeferredGrantIncome_c20220930_pp0p0" title="Deferred grant income"&gt;443,831&lt;/span&gt;) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to
other income. The Company will recognize this income on its statement of operations as the related expenditures are incurred to offset
the income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Research and development
incentive income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Research and development
incentive income represents the income earned by Anavex Australia, of the Australian research and development tax incentive credit (the
&#x201c;Tax Incentive Credit&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;During the three and six
months ended March 31, 2023, the Company recorded research and development incentive income of $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20230101__20230331_z1FOcf6chj13" title="Research and development incentive income"&gt;749,681&lt;/span&gt; (AUD &lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20230101__20230331__srt--CurrencyAxis__currency--AUD_zVsN0Ahfr2mb" title="Research and development incentive income"&gt;1,099,134&lt;/span&gt;) and $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20230331_zL0yXHqtsWdg" title="Research and development incentive income"&gt;1,483,271&lt;/span&gt;
(AUD &lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20230331__srt--CurrencyAxis__currency--AUD_zdVDiI9JGhd5" title="Research and development incentive income"&gt;2,215,753&lt;/span&gt;), respectively (2022: &lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20220101__20220331_zrupM5QNdMC7" title="Research and development incentive income"&gt;835,513&lt;/span&gt; (AUD &lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20220101__20220331__srt--CurrencyAxis__currency--AUD_z8Arf3BQHsj4" title="Research and development incentive income"&gt;1,146,955&lt;/span&gt;) and $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20220331_z7wpsblnBmN6" title="Research and development incentive income"&gt;1,646,243&lt;/span&gt; (AUD &lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20220331__srt--CurrencyAxis__currency--AUD_znILBhzasKOa" title="Research and development incentive income"&gt;2,263,317&lt;/span&gt;), respectively) in respect of the Tax Incentive
Credit for eligible research and development expenses incurred during the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Although the Company believes that it complies with all the relevant conditions of the program, the Company may be subject
to pre-issue review or audit by the ATO, and the ATO may have different interpretations of certain eligibility requirements. Currently,
the Company&#x2019;s tax incentive claims from 2018 to 2022 are open to potential review or audit by the ATO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</avxl:OtherIncomeDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012023-03-31_custom_MichaelJFoxMember"
      decimals="0"
      unitRef="USD">995862</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012023-03-31_custom_AnavexMember"
      decimals="0"
      unitRef="USD">497931</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012021-09-30_custom_AnavexMember"
      decimals="0"
      unitRef="USD">497931</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">25000</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:DeferredGrantIncome contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">916763</avxl:DeferredGrantIncome>
    <avxl:DeferredGrantIncome contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">443831</avxl:DeferredGrantIncome>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">749681</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-01-012023-03-31_currency_AUD"
      decimals="0"
      unitRef="USD">1099134</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">1483271</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012023-03-31_currency_AUD"
      decimals="0"
      unitRef="USD">2215753</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">835513</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-01-012022-03-31_currency_AUD"
      decimals="0"
      unitRef="USD">1146955</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">1646243</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-10-012022-03-31_currency_AUD"
      decimals="0"
      unitRef="USD">2263317</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2022-10-01to2023-03-31">&lt;p id="xdx_801_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zmqY9hLAfjwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Note 4	 	 &lt;span id="xdx_82E_zFwrf0lQpAs3"&gt;Accrued Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The principal components of accrued liabilities consist of:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zE0fQQNmWDSj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td id="xdx_8BB_zTXxyNJLU5Ud" style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt"&gt;&#160;Schedule of accrued liabilities&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20230331_z5Z9pzbGdPYh" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49C_20220930_zt7rlsV1Aj69" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;March 31,&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Accrued clinical site and patient visits costs&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;2,168,950&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;2,031,105&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccruedBonusesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation and benefits&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,572,500&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,297,337&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--FixedContractAccruals_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed contract accruals&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;82,666&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;417,414&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--MilestoneBasedContractAccruals_iI_pp0p0_zi1lOKAzRrMa" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;Milestone based contract accruals&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,041,930&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;137,337&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;All other accrued liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,956,792&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,061,760&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzEQ3_zRGal2oAj7t1" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;Total accrued liabilities&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,822,838&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,944,953&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2022-10-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zE0fQQNmWDSj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td id="xdx_8BB_zTXxyNJLU5Ud" style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt"&gt;&#160;Schedule of accrued liabilities&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20230331_z5Z9pzbGdPYh" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49C_20220930_zt7rlsV1Aj69" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;March 31,&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Accrued clinical site and patient visits costs&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;2,168,950&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;2,031,105&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccruedBonusesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation and benefits&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,572,500&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,297,337&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--FixedContractAccruals_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed contract accruals&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;82,666&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;417,414&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--MilestoneBasedContractAccruals_iI_pp0p0_zi1lOKAzRrMa" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;Milestone based contract accruals&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,041,930&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;137,337&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;All other accrued liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,956,792&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,061,760&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzEQ3_zRGal2oAj7t1" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;Total accrued liabilities&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,822,838&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,944,953&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <avxl:AccruedClinicalSiteAndPatientVisitsCosts contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">2168950</avxl:AccruedClinicalSiteAndPatientVisitsCosts>
    <avxl:AccruedClinicalSiteAndPatientVisitsCosts contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">2031105</avxl:AccruedClinicalSiteAndPatientVisitsCosts>
    <us-gaap:AccruedBonusesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1572500</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">1297337</us-gaap:AccruedBonusesCurrent>
    <avxl:FixedContractAccruals contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">82666</avxl:FixedContractAccruals>
    <avxl:FixedContractAccruals contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">417414</avxl:FixedContractAccruals>
    <avxl:MilestoneBasedContractAccruals contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1041930</avxl:MilestoneBasedContractAccruals>
    <avxl:MilestoneBasedContractAccruals contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">137337</avxl:MilestoneBasedContractAccruals>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1956792</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">2061760</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">6822838</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">5944953</us-gaap:AccruedLiabilitiesCurrent>
    <avxl:EquityOfferingTextBlock contextRef="From2022-10-01to2023-03-31">&lt;p id="xdx_80A_ecustom--EquityOfferingTextBlock_zK2pTZF4xKN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Note 5		&lt;span id="xdx_82D_zvJt3ZUU0ugc"&gt;Equity Offerings&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors (the &#x201c;Board&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s Board has the authority to issue
preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting
any series of the designation of the series.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sales Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald&#160;&amp;amp;
Co. and SVB Leerink LLC (together the &#x201c;Sales Agents&#x201d;), pursuant to which the Company may offer and sell shares of common stock
registered under an effective registration statement from time to time through the Sales Agents (the &#x201c;Offering&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon delivery of a placement notice based on the Company&#x2019;s
instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares by methods deemed to
be an &#x201c;at the market offering&#x201d; offering, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to
the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company
or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. The Sales
Agents will act as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable
state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has agreed to pay the Sales Agents commissions
for their services of up to &lt;span id="xdx_905_ecustom--PercentageOfGrossProceedsFromSales_dp_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z7Hdr97BdNc1" title="Percentage of gross proceeds from sales"&gt;3.0&lt;/span&gt;% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed
to provide the Sales Agents with customary indemnification and contribution rights. During the six months ended March 31, 2023, &lt;span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_do_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember_zO2zbhTGAo1j" title="Number of common stock sold"&gt;no&lt;/span&gt; shares
were sold pursuant to the Offering. During the six months ended March 31, 2022, &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_znZ0YhjsDob6" title="Number of common stock sold"&gt;1,066,389&lt;/span&gt; shares were sold for gross proceeds of $&lt;span id="xdx_906_ecustom--SoldForGrossProceedsAmount_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zxyLptqoQjQb" title="Sold for gross proceeds amount"&gt;14,803,464&lt;/span&gt;
(net proceeds of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z5lqCidGwX49" title="Proceeds from Issuance Public Offering"&gt;14,265,658&lt;/span&gt;). At March 31, 2023, an amount of $&lt;span id="xdx_908_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20230331_zoIiPkFxGqHf" title="Sales of agreement amount"&gt;142,407,882&lt;/span&gt; (September 30, 2022: $&lt;span id="xdx_90B_ecustom--SalesOfAgreementAmount_c20220930_pp0p0" title="Sales of agreement amount"&gt;142,407,882&lt;/span&gt;) was registered pursuant
to an effective registration statement and remained available to be sold under the Sales Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 3, 2023, the Company entered into a $150,000,000
purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;), pursuant to
which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $&lt;span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_pp0p0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zS6yotV9xMtj" title="Value of shares obligated to purchase"&gt;150,000,000&lt;/span&gt; in value
of its shares of common stock from time to time over a three-year period until February 3, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In consideration for entering into the Purchase Agreement,
the Company issued to Lincoln Park &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zHnm5s1hBbxd" title="Share issued for offering, shares"&gt;75,000&lt;/span&gt; shares of common stock as a commitment fee (the &#x201c;initial commitment shares&#x201d;) and
agreed to issue up to an additional &lt;span id="xdx_903_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z1sVAdXIpP6a" title="Pro rata basic number of shares obligated to purchase"&gt;75,000&lt;/span&gt; shares pro rata, when and if, Lincoln Park purchased, at the Company&#x2019;s discretion, the
$&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zUscKPRLCCv3" title="Proceeds from Issuance or Sale of Equity"&gt;150,000,000&lt;/span&gt; aggregate commitment. The Company determined the fair value of the initial commitment shares was $&lt;span id="xdx_909_ecustom--FairValueOfInitialCommitment_iI_c20230331_zSDQXyIJt879" title="Fair value of the initial commitment"&gt;844,500&lt;/span&gt; with reference
to the closing price of the Company&#x2019;s shares on the Purchase Agreement date. In addition, the Company incurred third party expenses
of $&lt;span id="xdx_90E_ecustom--IncurredExpenses_iI_c20230331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__us-gaap--ThirdPartyPayorMember_zKWbQaYjFZA1" title="Incurred expenses"&gt;119,844&lt;/span&gt; in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense on the statement
of operations during the three and six months ended March 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the six months ended March 31, 2023, the Company
issued to Lincoln Park an aggregate of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zz6TJrJSBSUf" title="Share issued for offering, shares"&gt;2,159,080&lt;/span&gt; (2022: &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_ziRnUQmbK2T9" title="Share issued for offering, shares"&gt;0&lt;/span&gt;) shares of common stock under the 2023 Purchase Agreement, including &lt;span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zH5D6LOehDP3" title="Number of shares issued for aggregate purchase price"&gt;2,075,000&lt;/span&gt;
(2022: &lt;span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z64bnbm9d63h" title="Number of shares issued for aggregate purchase price"&gt;0&lt;/span&gt;) shares of common stock for an aggregate purchase price of $&lt;span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zxsfRggGJ8K6" title="Number of shares issued for aggregate purchase price, value"&gt;18,152,500&lt;/span&gt;&#160;(2022: $&lt;span id="xdx_906_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z1C6MP1T5iEg" title="Number of shares issued for aggregate purchase price, value"&gt;0&lt;/span&gt;) and&#160;&lt;span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zF27NmC8jlp3" title="Number of shares issued for commitment"&gt;9,080&lt;/span&gt;&#160;(2022:&#160;&lt;span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20211001__20220331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zW2CgLvpd8ri" title="Number of shares issued for commitment"&gt;0&lt;/span&gt;) commitment
shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2023, an amount of $&lt;span id="xdx_900_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_do_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z5owmz6IyTGg" title="Amount of shares remain available"&gt;131,847,500&lt;/span&gt; (September
30, 2022: $&lt;span id="xdx_908_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_do_c20211001__20220930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zmR1jKfZKYCh" title="Amount of shares remain available"&gt;0&lt;/span&gt;) remained available under the 2023 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


















</avxl:EquityOfferingTextBlock>
    <avxl:PercentageOfGrossProceedsFromSales
      contextRef="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Pure">0.030</avxl:PercentageOfGrossProceedsFromSales>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-10-012022-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">1066389</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <avxl:SoldForGrossProceedsAmount
      contextRef="From2021-10-012022-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">14803464</avxl:SoldForGrossProceedsAmount>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">14265658</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <avxl:SalesOfAgreementAmount contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">142407882</avxl:SalesOfAgreementAmount>
    <avxl:SalesOfAgreementAmount contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">142407882</avxl:SalesOfAgreementAmount>
    <avxl:ValueOfSharesObligatedToPurchase
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">150000000</avxl:ValueOfSharesObligatedToPurchase>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:NumberOfSharesObligatedToPurchaseProrataBasic
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">75000</avxl:NumberOfSharesObligatedToPurchaseProrataBasic>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">150000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <avxl:FairValueOfInitialCommitment contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">844500</avxl:FairValueOfInitialCommitment>
    <avxl:IncurredExpenses
      contextRef="AsOf2023-03-31_us-gaap_ThirdPartyPayorMember"
      decimals="0"
      unitRef="USD">119844</avxl:IncurredExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">2159080</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-10-012022-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">2075000</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2021-10-012022-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">0</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">18152500</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2021-10-012022-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">0</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">9080</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2021-10-012022-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">0</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues4
      contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">131847500</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues4
      contextRef="From2021-10-012022-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">0</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2022-10-01to2023-03-31">&lt;p id="xdx_804_eus-gaap--CommitmentsDisclosureTextBlock_z1dSsYXExwY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Note 6 	&lt;span id="xdx_82F_zG9sw5dBR2fe"&gt;Commitments and Contingencies &lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"&gt;&lt;b&gt;&lt;i&gt;Leases &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;During the three
and six months ended March 31, 2023, the Company incurred office lease expense of $&lt;span id="xdx_90E_eus-gaap--CapitalLeaseObligationsIncurred_c20230101__20230331_zZhekqC2spK7" title="Incurred office lease expense"&gt;30,070&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--CapitalLeaseObligationsIncurred_c20221001__20230331_zERkFiZt4jz" title="Incurred office lease expense"&gt;60,140&lt;/span&gt;, (2022: $&lt;span id="xdx_901_eus-gaap--CapitalLeaseObligationsIncurred_c20220101__20220331_zW0xMJ6LaTn3" title="Incurred office lease expense"&gt;16,488&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--CapitalLeaseObligationsIncurred_c20211001__20220331_z5qWXxxCyY65" title="Incurred office lease expense"&gt;21,333&lt;/span&gt;) respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Employee 401(k) Benefit Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;The Company has
a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees.
United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal
Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees.
During the three and six months ended March 31, 2023, the Company made $&lt;span id="xdx_90C_eus-gaap--PensionContributions_pp0p0_c20230101__20230331_zvbghzCNQOK6" title="Contribution amount"&gt;56,230&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--PensionContributions_pp0p0_c20221001__20230331_zG5QutkUeVc6" title="Contribution amount"&gt;99,876&lt;/span&gt; (2022: $&lt;span id="xdx_90A_eus-gaap--PensionContributions_pp0p0_c20220101__20220331_zJ0TJ3eI48V3" title="Contribution amount"&gt;70,940&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--PensionContributions_pp0p0_c20211001__20220331_zuLN5HQirWg8" title="Contribution amount"&gt;93,622&lt;/span&gt;), respectively,
in matching contributions under the 401(k) plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;The Company is subject
to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be
no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will
not have a material adverse effect upon the Company&#x2019;s consolidated financial statements. The Company does not believe that any of
such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"&gt;&lt;b&gt;&lt;i&gt;Share Purchase Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2023 and September 30, 2022, the Company
had &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230331_zrRoiO2S0USc" title="Warrants outstanding"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zILBZQ2FOdWe" title="Warrants outstanding"&gt;160,000&lt;/span&gt;&lt;/span&gt; warrants outstanding at a weighted average exercise price of $&lt;span id="xdx_908_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_c20230331_zOsbPergO0I5" title="Warrants outstanding weighted average exercise"&gt;&lt;span id="xdx_909_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_c20220930_z2gRaPqbItTj" title="Warrants outstanding weighted average exercise"&gt;3.72&lt;/span&gt;&lt;/span&gt; as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zvfUcIM49MZc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8B7_zvmoXTwM6Uoj" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="padding: 0pt 0pt 0pt 10pt; width: 20%; text-align: right; text-indent: -10pt" title="Number"&gt;150,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 20%; text-align: right" title="Exercise Price"&gt;3.17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 40%"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zoTANGKC0ck9" title="Expiry Date"&gt;May 6, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="text-align: right" title="Exercise Price"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_ztGbnKtTdM1h" title="Expiry Date"&gt;April 21, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230331_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number"&gt;160,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A9_z8hNkttuMcZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;Stock&#x2013;based Compensation
Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;2015 Stock Option Plan&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 18, 2015, the Company&#x2019;s Board approved
a 2015 Omnibus Incentive Plan (the &#x201c;2015 Plan&#x201d;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the plan was &lt;span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_znucd8UstR88" title="Maximum number of common shares reserved for future issuance"&gt;6,050,553&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2019 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#x201c;2019 Plan&#x201d;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the plan was &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zNXFiKqSVkDc" title="Additional shares of common stock available for issuance"&gt;6,000,000&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2022, &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Option granted"&gt;406,453&lt;/span&gt;
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2022 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#x201c;2022 Plan&#x201d;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_z3HpFUr6ieje" title="Additional shares of common stock available for issuance"&gt;10,000,000&lt;/span&gt; additional shares of Common Stock will be available for issuance under the plan. Any awards outstanding under a previous
stock option plan will remain subject to and be paid under such plan, and any shares subject to outstanding awards under a previous plan
that subsequently cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become
available for issuance under the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant and shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date,
then the exercise price shall not be less than 110% of fair market value of the Company&#x2019;s shares of common stock on the grant date.
Stock options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such
lesser periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. As at
March 31, 2023, &lt;span id="xdx_90A_ecustom--OptionIssued_c20221001__20230331_zQWtabwz8zea" title="Option issued"&gt;3,916,000&lt;/span&gt; options had been issued under the 2022 Plan and &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_za2iRI7BF6Ka" title="Option available issue"&gt;6,557,952&lt;/span&gt; options were available for issuance under the 2022
Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the status of Company&#x2019;s outstanding
stock options is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zGhmkPXhQ9Gb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
  &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8B2_zncDT1zZs2Fd" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
  &lt;td colspan="3" style="text-align: center"&gt;&#160; &#160; &#160; &#160;&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160; &#160; &#160; &#160;&lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;Number of Shares&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160; &#160; &#160; &#160;&lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;Weighted Average Exercise Price&lt;br/&gt;
($)&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160; &#160; &#160; &lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;Weighted Average Grant Date Fair Value &lt;br/&gt;
($)&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160; &#160; &#160; &#160;&lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;Aggregate intrinsic value&lt;br/&gt;
($)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 38%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.3pt"&gt;Outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuzBCy6iGiC1" style="width: 10%; text-align: right" title="Options Outstanding at beginning"&gt;11,330,903&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3PxdH3c3Bkh" style="width: 10%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;5.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJrudywlnHWl" style="width: 10%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;140,132,451&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrl6AoLbahe7" style="text-align: right" title="Options Granted"&gt;2,358,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpR5tlEDrGP5" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;10.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXA4H7ikh4S5" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;7.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqzKBxAWarQ8" style="text-align: right" title="Options Forfeited"&gt;(118,750&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zU3oWaBTWTdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;6.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4IpSXM3CiS7" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;5.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqVjeaHJc6G1" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;(400,537&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoQtupOyyLAc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.52&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHVz36IBp274" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;1.88&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zM5qpTwDdW9" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;4,201,015&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.25pt"&gt;Outstanding, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFXiw3owsBw8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at beginning"&gt;13,169,616&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXET1KCwX4ik" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;6.61&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zR1NM0Wrx97g" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;62,267,309&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxgkgXbaxH9h" style="text-align: right" title="Options Granted"&gt;1,863,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzFsud6fYvaa" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;9.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZ7sWM0phDt6" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;6.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJLx97GOqZHg" style="text-align: right" title="Options Exercised"&gt;(133,503&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zU48Vjf8083" style="text-align: right" title="Weighted Average Exercise Price Exercised"&gt;3.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHXv9VJsWv6c" style="text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.4pt"&gt;2 59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHX4y89O55i" style="text-align: right" title="Aggregate intrinsic value Exercised"&gt;868,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpl3xaiUXDhd" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited"&gt;(57,500&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5OJuXa1uuIl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;11.73&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0W6R3TPfm06" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;9.09&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.3pt"&gt;Outstanding, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsT8EkRNCRK5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at ending"&gt;14,841,613&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm5EPX5Pusl1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;6.97&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zekX38HHuEIi" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;43,709,206&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.25pt"&gt;Exercisable, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"&gt;9,937,362&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;4.78&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;43,099,822&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8A8_zzJUVBBeEePg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following summarizes information about stock options
at March 31, 2023 by a range of exercise prices:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zpLwDuPsADu5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8BF_z1eKRi0UsXF1" style="display: none"&gt;Schedule Of Share-based Payment Arrangement, Option, Activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;b&gt;Range of exercises prices&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Number of Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Weighted average remaining contractual Me&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Weighted average&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Number of vested&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Weighted average&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;From&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;To&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;options&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;options&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"&gt;2.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;3,834,559&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zRaAerWvkkzi" title="Weighted average remaining contractual life (in years)"&gt;4.60&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options"&gt;3,834,559&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price options vested"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;3.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;4.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;2,022,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z5lJbEpxnPni" title="Weighted average remaining contractual life (in years)"&gt;4.82&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;3.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options"&gt;2,017,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price options vested"&gt;3.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;5.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;8.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;5,307,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zD86a3Np2h0j" title="Weighted average remaining contractual life (in years)"&gt;6.72&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;6.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options"&gt;3,345,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price options vested"&gt;6.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;9.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;13.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;2,118,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zbp7pMbGF1mj" title="Weighted average remaining contractual life (in years)"&gt;8.87&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;10.68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options"&gt;312,083&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price options vested"&gt;11.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Range of exercise prices, lower range limit"&gt;13.22&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Range of exercise prices, upper range limit"&gt;24.58&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;1,559,500&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zxeHhqNGWvle" title="Weighted average remaining contractual life (in years)"&gt;7.99&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price"&gt;18.48&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;427,500&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested"&gt;18.90&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbdo8FSt1zU" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;14,841,613&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbdgeOa5UYe7" title="Weighted average remaining contractual life (in years)"&gt;6.35&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price"&gt;6.97&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;9,937,362&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm9PpFXH0seh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested"&gt;4.78&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A2_zqGnFQPsf3Mg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The weighted average grant date fair value of options
vested during the six months ended March 31, 2023 was $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20221001__20230331_zgflxeD3c01f" title="Weighted average grant date fair value of options vested"&gt;3.67&lt;/span&gt; (2022: $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20220331_zWjP57fERXu8" title="Weighted average grant date fair value of options vested"&gt;3.20&lt;/span&gt;). At March 31, 2023, the weighted average contractual life of
options outstanding was &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331_zp2iDvKN79jb" title="Weighted average contractual life of options outstanding"&gt;6.35&lt;/span&gt; years (September 30, 2022: &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zpWFArHrXTxj" title="Weighted average contractual life of options outstanding"&gt;6.40&lt;/span&gt; years) and for options exercisable was &lt;span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331_zpFR4PrUC4hh" title="Options exercisable"&gt;4.92&lt;/span&gt; years (September 30, 2022: &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zbfkxxCCX355" title="Options exercisable"&gt;5.1&lt;/span&gt;
years).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#x2019;s stock for the options
that were in-the-money at March 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three and six months ended March 31, 2023,
the Company recognized stock-based compensation expense of $&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331_zwr5bLubUvv6" title="Share based compensation"&gt;3,970,064&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20221001__20230331_zONmp8T38Vz2" title="Share based compensation"&gt;9,316,572&lt;/span&gt; (2022: $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331_znNZBc8riQo8" title="Share based compensation"&gt;4,439,456&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220331_zXUB5WrouLN6" title="Share based compensation"&gt;8,348,230&lt;/span&gt;), respectively,
in connection with the issuance and vesting 	of stock options and warrants in exchange for services. These amounts have been included
in general and 	administrative expenses and research and development expenses on the Company&#x2019;s statement of 	operations as
follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zHd2yF3cv6Yg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BE_z3eIb511MQDb" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended March 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six months end March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZcCk1tExeq6" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,256,845&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z88z9XC2Lula" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,577,831&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;2,999,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;3,249,557&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zs63jaqd34p8" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,713,219&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ztzAhJ2Uak1a" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,861,625&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;6,317,202&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;5,098,673&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331_zA7bV7COo72e" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,970,064&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331_zI4O267A8sA1" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;4,439,456&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230331_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;9,316,572&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220331_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;8,348,230&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8AB_zOSHWMv6YZXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An amount of approximately $&lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20230331_zduzbrIwAZTd" title="Remaining stock based compensation"&gt;21,781,736&lt;/span&gt; in stock-based
compensation is expected to be recorded over the remaining term 	of such options through fiscal 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of each option award
granted during the three and six months ended March 31, 2023 and 2022 is estimated on the date of grant using the Black Scholes option
pricing model based on the following weighted average assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zVpUVP5hTl97" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BF_z8iSpRqKAhh4" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20221001__20230331_zxQ8jJ4bCTIk" title="Risk-free interest rate"&gt;3.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220331_zkCu7YnhAW5k" title="Risk-free interest rate"&gt;1.40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230331_zj9vhfofKnR4" title="Expected life of options (years)"&gt;5.61&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220331_znjpVNeM15Gf" title="Expected life of options (years)"&gt;4.90&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20221001__20230331_zRr20MOo3PR5" title="Annualized volatility"&gt;85.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220331_zbUFlI3Ryp71" title="Annualized volatility"&gt;95.88&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20221001__20230331_z5M3XiYupIY4" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220331_zPucHQvEpIdh" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8A0_zOoYGMqz8fc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of stock compensation charges recognized
during the three and six months ended March 31, 2023 and 2022 was determined with reference to the quoted market price of the Company&#x2019;s
shares on the grant date.&lt;/p&gt;

</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">30070</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">60140</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">16488</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">21333</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:PensionContributions
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">56230</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">99876</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">70940</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">93622</us-gaap:PensionContributions>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">160000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">160000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <avxl:WarrantsOutstandingWeightedAverageExercise
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">3.72</avxl:WarrantsOutstandingWeightedAverageExercise>
    <avxl:WarrantsOutstandingWeightedAverageExercise
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">3.72</avxl:WarrantsOutstandingWeightedAverageExercise>
    <avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock contextRef="From2022-10-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zvfUcIM49MZc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8B7_zvmoXTwM6Uoj" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="padding: 0pt 0pt 0pt 10pt; width: 20%; text-align: right; text-indent: -10pt" title="Number"&gt;150,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 20%; text-align: right" title="Exercise Price"&gt;3.17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 40%"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zoTANGKC0ck9" title="Expiry Date"&gt;May 6, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="text-align: right" title="Exercise Price"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_ztGbnKtTdM1h" title="Expiry Date"&gt;April 21, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230331_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number"&gt;160,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2023-03-31_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="USDPShares">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2023-03-31_custom_PurchaseWarrants1Member">2024-05-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2023-03-31_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2023-03-31_custom_PurchaseWarrants2Member">2026-04-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-03-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2022-10-012023-03-31_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      unitRef="Shares">406453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2022-10-012023-03-31_custom_StockOptionPlan2022Member"
      decimals="INF"
      unitRef="Shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <avxl:OptionIssued
      contextRef="From2022-10-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">3916000</avxl:OptionIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-03-31_custom_StockOptionPlan2022Member"
      decimals="INF"
      unitRef="Shares">6557952</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2022-10-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zGhmkPXhQ9Gb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
  &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8B2_zncDT1zZs2Fd" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
  &lt;td colspan="3" style="text-align: center"&gt;&#160; &#160; &#160; &#160;&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160; &#160; &#160; &#160;&lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;Number of Shares&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160; &#160; &#160; &#160;&lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;Weighted Average Exercise Price&lt;br/&gt;
($)&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160; &#160; &#160; &lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;Weighted Average Grant Date Fair Value &lt;br/&gt;
($)&lt;/td&gt;
  &lt;td style="text-align: center"&gt;&#160; &#160; &#160; &#160;&lt;/td&gt;
  &lt;td colspan="3" style="text-align: center"&gt;Aggregate intrinsic value&lt;br/&gt;
($)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 38%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.3pt"&gt;Outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuzBCy6iGiC1" style="width: 10%; text-align: right" title="Options Outstanding at beginning"&gt;11,330,903&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3PxdH3c3Bkh" style="width: 10%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;5.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJrudywlnHWl" style="width: 10%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;140,132,451&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrl6AoLbahe7" style="text-align: right" title="Options Granted"&gt;2,358,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpR5tlEDrGP5" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;10.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXA4H7ikh4S5" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;7.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqzKBxAWarQ8" style="text-align: right" title="Options Forfeited"&gt;(118,750&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zU3oWaBTWTdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;6.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4IpSXM3CiS7" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;5.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqVjeaHJc6G1" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;(400,537&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoQtupOyyLAc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.52&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHVz36IBp274" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;1.88&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zM5qpTwDdW9" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;4,201,015&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.25pt"&gt;Outstanding, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFXiw3owsBw8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at beginning"&gt;13,169,616&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXET1KCwX4ik" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;6.61&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zR1NM0Wrx97g" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;62,267,309&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxgkgXbaxH9h" style="text-align: right" title="Options Granted"&gt;1,863,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzFsud6fYvaa" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;9.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZ7sWM0phDt6" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;6.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJLx97GOqZHg" style="text-align: right" title="Options Exercised"&gt;(133,503&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zU48Vjf8083" style="text-align: right" title="Weighted Average Exercise Price Exercised"&gt;3.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHXv9VJsWv6c" style="text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.4pt"&gt;2 59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHX4y89O55i" style="text-align: right" title="Aggregate intrinsic value Exercised"&gt;868,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpl3xaiUXDhd" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited"&gt;(57,500&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5OJuXa1uuIl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;11.73&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0W6R3TPfm06" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;9.09&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.3pt"&gt;Outstanding, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsT8EkRNCRK5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at ending"&gt;14,841,613&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm5EPX5Pusl1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;6.97&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zekX38HHuEIi" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;43,709,206&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.25pt"&gt;Exercisable, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"&gt;9,937,362&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;4.78&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;43,099,822&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">11330903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">140132451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">2358000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">10.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">7.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">118750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.23</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">400537</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.88</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">4201015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">13169616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">62267309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1863000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">9.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">133503</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">868537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">57500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">11.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">9.09</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">14841613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">43709206</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">9937362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">43099822</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-10-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zpLwDuPsADu5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8BF_z1eKRi0UsXF1" style="display: none"&gt;Schedule Of Share-based Payment Arrangement, Option, Activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;b&gt;Range of exercises prices&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Number of Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Weighted average remaining contractual Me&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Weighted average&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Number of vested&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Weighted average&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;From&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;To&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;options&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;options&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"&gt;2.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;3,834,559&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zRaAerWvkkzi" title="Weighted average remaining contractual life (in years)"&gt;4.60&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options"&gt;3,834,559&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price options vested"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;3.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;4.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;2,022,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z5lJbEpxnPni" title="Weighted average remaining contractual life (in years)"&gt;4.82&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;3.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options"&gt;2,017,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price options vested"&gt;3.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;5.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;8.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;5,307,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zD86a3Np2h0j" title="Weighted average remaining contractual life (in years)"&gt;6.72&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;6.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options"&gt;3,345,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price options vested"&gt;6.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;9.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;13.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;2,118,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zbp7pMbGF1mj" title="Weighted average remaining contractual life (in years)"&gt;8.87&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;10.68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options"&gt;312,083&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price options vested"&gt;11.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Range of exercise prices, lower range limit"&gt;13.22&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Range of exercise prices, upper range limit"&gt;24.58&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;1,559,500&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zxeHhqNGWvle" title="Weighted average remaining contractual life (in years)"&gt;7.99&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price"&gt;18.48&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;427,500&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested"&gt;18.90&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbdo8FSt1zU" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;14,841,613&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbdgeOa5UYe7" title="Weighted average remaining contractual life (in years)"&gt;6.35&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price"&gt;6.97&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;9,937,362&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm9PpFXH0seh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested"&gt;4.78&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">0.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.96</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="Shares">3834559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="Shares">3834559</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">4.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="Shares">2022500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">P4Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="Shares">2017500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">5.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">8.98</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="Shares">5307054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">P6Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">6.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="Shares">3345720</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">6.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">9.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">13.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="Shares">2118000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">P8Y10M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">10.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="Shares">312083</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">11.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">13.22</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">24.58</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="Shares">1559500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">P7Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">18.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="Shares">427500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">18.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">14841613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember">P6Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">9937362</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">3.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">3.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-01to2023-03-31">P6Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012022-09-30">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-01to2023-03-31">P4Y11M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012022-09-30">P5Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">3970064</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">9316572</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">4439456</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">8348230</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2022-10-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zHd2yF3cv6Yg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BE_z3eIb511MQDb" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended March 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six months end March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZcCk1tExeq6" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,256,845&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z88z9XC2Lula" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,577,831&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;2,999,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;3,249,557&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zs63jaqd34p8" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,713,219&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ztzAhJ2Uak1a" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,861,625&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;6,317,202&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;5,098,673&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331_zA7bV7COo72e" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,970,064&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220331_zI4O267A8sA1" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;4,439,456&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230331_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;9,316,572&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220331_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;8,348,230&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1256845</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1577831</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">2999370</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">3249557</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">2713219</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">2861625</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">6317202</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">5098673</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">3970064</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">4439456</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      unitRef="USD">9316572</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012022-03-31"
      decimals="0"
      unitRef="USD">8348230</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">21781736</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-10-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zVpUVP5hTl97" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BF_z8iSpRqKAhh4" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20221001__20230331_zxQ8jJ4bCTIk" title="Risk-free interest rate"&gt;3.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220331_zkCu7YnhAW5k" title="Risk-free interest rate"&gt;1.40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230331_zj9vhfofKnR4" title="Expected life of options (years)"&gt;5.61&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220331_znjpVNeM15Gf" title="Expected life of options (years)"&gt;4.90&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20221001__20230331_zRr20MOo3PR5" title="Annualized volatility"&gt;85.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220331_zbUFlI3Ryp71" title="Annualized volatility"&gt;95.88&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20221001__20230331_z5M3XiYupIY4" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220331_zPucHQvEpIdh" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-10-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.0369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-10-012022-03-31"
      decimals="INF"
      unitRef="Pure">0.0140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-10-01to2023-03-31">P5Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-10-012022-03-31">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-10-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.8528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-10-012022-03-31"
      decimals="INF"
      unitRef="Pure">0.9588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-10-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-10-012022-03-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>38
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M -]7$J9#^V*NM-V_,&;_ E!+ P04    " #D@ZE6@$9B7M,"  "K"   &
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M[P/[NUH\B'E4I9Z:]$L2V_7=2(Y(K)=JF]I/YNEWW0@**KZ%2<OZDSSML0+
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M/N85#1,>Z=6;F-%BCR4\8E$<C^VUI%?3!);38&+D;8)MR=D1+$AB2FK8#.^
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M0V_V\IYZRWMG0XG;GW:M/(Y3;E9LJ9T$8$G<%=6L] ELK<]*8Q_SBG(A(KV
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M:&5E=',O<VAE970Q,"YX;6R-5<N.TS 4W?<KK(!819-GTP=MI78 @<2@:CK
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MS-!NH-' F^JE04Y6%)1;9[ J(>?.?OO>2/? /F^WPL@JMR<3!U1:FZ0MPD5
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MWIN*/ZZ41,ZC!7A/-DI?Z(#N]X(O_PM02P,$%     @ Y(.I5GC(]@_5 @
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MAA?CS".JZU/=Q,C6]89"&NPT;EAC:P=E _#[1DISG-@-^I_%XB]02P,$%
M  @ Y(.I5E)S^\X>!@  M0\  !D   !X;"]W;W)K<VAE971S+W-H965T,34N
M>&ULO5=9<]LV$'[GK]A1XDP\@U X>":V9V3G:!_<>&PW>>CT :8@B6,>*DA9
M=G]]=T&)DA-%=C.=OD@$L,>WP+>+Q=&RMK?-S)@6[LNB:HX'L[:=OQT.FVQF
M2MWX]=Q4N#*I;:E;'-KIL)E;H\=.J2R&DO-H6.J\&IP<N;D+>W)4+]HBK\R%
MA691EMH^G)JB7AX/Q& ]<9E/9RU-#$^.YGIJKDS[^_S"XFC86QGGI:F:O*[
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M'V.':+M'8C=HZ[E[F-W4+3[SW.<,W]7&D@"N3^JZ70_(0?]2/_D'4$L#!!0
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M;$;M NA^J<BL;N,2]-.^^ -02P,$%     @ Y(.I5J/VU4\/!   1!<  !D
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MY6<XA>IIBK3BC%UUMSHG>IV?CFS<G_@707':LX8I#I_>$[Z*,X$2NE20WOE
M]19>G.<L+B3;Y <6YTQ*EN9?UY0L*-<%U.]+QN3+A:Z@.E4[_@]02P,$%
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MV E9YL=DA2!/B^:7WA\;T4M0=<P)^)B APGA2 (Y)I"::(.LIG5%)9U->'D
MO(I6U:J#NC=UMF*3%M4TWDFN[J8J3\XNRSQ/I9H7*0 MEN"R+&1:K%FQ2)D
MKZZ8I&DF 'H-WH"W/W:I_ ENMO4$?+UF^9SQ;^K&I[LK\.K/UQ-/*D1576]Q
M'/VB&1V/C!Z":S7>1H"WQ9(M#?F7]GR$+04\U8JV'_BA'Q?86O&:<A<0]#?
M$!,3('OZ'=NJ=%BG8PL<TDX/J>N1D7HWJY5@LIH1<"[4D0!?_U,AX(-DN?AF
M:GA3SS?7JQ:%,[&E"S9UU+]>,+YGSNRO/U (_S&1_4W%'E'W6^J^K?JLD9D
M-SLII))FU0,JP9RMTZ)0)R;R3<6@KE@M8/L9(BA,0A1.O'V?F"$0$0(32-K
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M#C>Z$8,P!GJ_X%R=)N: IK6GOP%02P,$%     @ Y(.I5BP9YYIZ!@  42P
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MI^7'#<$1H;*!^'V5Y_SP13HXWB*>_0]02P,$%     @ Y(.I5E$,J*XP P
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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MV"! ;.!D@P"S@:,- M0&SC8(<!LXW"! ;N!T@P"[@>,- O1&KC<*T!NYWBA
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M\9]D?7=N^=>?S.U:&*GLP9]U_R5FGU!+ 0(4 Q0    ( .2#J58'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ Y(.I5OS!.%3N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ Y(.I5IE<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #D
M@ZE6@W%+3?8%  ",(   &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ Y(.I5F%UQ2K*!   SA   !@
M         ("!.0X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( .2#J5: 1F)>TP(  *L(   8              " @3D3  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #D@ZE6.");I_,%  !,&P
M&               @(%"%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ Y(.I5O(WZ>2&"@  J%4  !@              ("!:QP  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( .2#J59\ V?CN 4
M -\5   8              " @2<G  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " #D@ZE6J:_/H4\#   :!P  &               @($5
M+0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ Y(.I5K.$
M6L*Q#0  >"0  !@              ("!FC   'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( .2#J5;IF)C 200  -0)   8
M  " @8$^  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #D
M@ZE65?-;S.T"  !Z!@  &0              @($ 0P  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( .2#J583S,@^3@8   L/   9
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M970Q-2YX;6Q02P$"% ,4    " #D@ZE6;*RP(H,"  #Y!0  &0
M    @(%Z<   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M .2#J5:C]M5/#P0  $07   9              " @31S  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ Y(.I5E,=8YWS @  EP@  !D
M             ("!>G<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " #D@ZE69FQ5NU$&  !A*P  &0              @(&D>@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( .2#J58B;F0:Z@(
M &0*   9              " @2R!  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ Y(.I5NLQ &&<!   EA,  !D              ("!
M380  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #D@ZE6
MB=]ZTR0(  "M1@  &0              @($@B0  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( .2#J58/GRMRDP,  $H0   9
M      " @7N1  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ Y(.I5B\KOWW2 @  Y@<  !D              ("!194  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #D@ZE6+!GGFGH&  !1+
M&0              @(%.F   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( .2#J591#*BN, ,  .X2   -              "  ?^>  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ Y(.I5I>*NQS     $P(   L
M         ( !6J(  %]R96QS+RYR96QS4$L! A0#%     @ Y(.I5K-FV7FI
M @  <!$   \              ( !0Z,  'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( .2#J59^V5 B/ $  +(/   :              "  1FF  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( .2#J58KT'*.<@$
M )\0   3              "  8VG  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     A "$ W@@  #"I      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>97</ContextCount>
  <ElementCount>180</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>25</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Interim Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Interim Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Interim Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Interim Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Interim Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Interim Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Interim Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Interim Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Interim Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Business Description</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescription</Role>
      <ShortName>Business Description</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Equity Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferings</Role>
      <ShortName>Equity Offerings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BasisOfPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilities</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BasisOfPresentationDetailsNarrative</Role>
      <ShortName>Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/BasisOfPresentationPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Equity Offerings (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingsDetailsNarrative</Role>
      <ShortName>Equity Offerings (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferings</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Commitments and Contingencies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails3</Role>
      <ShortName>Commitments and Contingencies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Commitments and Contingencies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails4</Role>
      <ShortName>Commitments and Contingencies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="e4668_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="e4668_10-q.htm">e4668_10-q.htm</File>
    <File>avxl-20230331.xsd</File>
    <File>avxl-20230331_cal.xml</File>
    <File>avxl-20230331_def.xml</File>
    <File>avxl-20230331_lab.xml</File>
    <File>avxl-20230331_pre.xml</File>
    <File>e4668_ex31-1.htm</File>
    <File>e4668_ex31-2.htm</File>
    <File>e4668_ex32-1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img_001.jpg</File>
    <File>img_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="381">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>43
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "e4668_10-q.htm": {
   "axisCustom": 0,
   "axisStandard": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 381,
    "http://xbrl.sec.gov/dei/2022": 31
   },
   "contextCount": 97,
   "dts": {
    "calculationLink": {
     "local": [
      "avxl-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avxl-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "e4668_10-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "avxl-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avxl-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "avxl-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 287,
   "entityCount": 1,
   "hidden": {
    "http://anavex.com/20230331": 32,
    "http://fasb.org/us-gaap/2022": 40,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 77
   },
   "keyCustom": 41,
   "keyStandard": 139,
   "memberCustom": 17,
   "memberStandard": 8,
   "nsprefix": "avxl",
   "nsuri": "http://anavex.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://anavex.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Accrued Liabilities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://anavex.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Equity Offerings",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://anavex.com/role/EquityOfferings",
     "shortName": "Equity Offerings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://anavex.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Basis of Presentation (Policies)",
     "menuCat": "Policies",
     "order": "13",
     "role": "http://anavex.com/role/BasisOfPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Accrued Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "14",
     "role": "http://anavex.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "15",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Basis of Presentation (Details Narrative)",
     "menuCat": "Details",
     "order": "16",
     "role": "http://anavex.com/role/BasisOfPresentationDetailsNarrative",
     "shortName": "Basis of Presentation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2023-01-012023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Other Income (Details Narrative)",
     "menuCat": "Details",
     "order": "17",
     "role": "http://anavex.com/role/OtherIncomeDetailsNarrative",
     "shortName": "Other Income (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2023-01-012023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:AccruedClinicalSiteAndPatientVisitsCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Accrued liabilities (Details)",
     "menuCat": "Details",
     "order": "18",
     "role": "http://anavex.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:AccruedClinicalSiteAndPatientVisitsCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:SalesOfAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Equity Offerings (Details Narrative)",
     "menuCat": "Details",
     "order": "19",
     "role": "http://anavex.com/role/EquityOfferingsDetailsNarrative",
     "shortName": "Equity Offerings (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:SalesOfAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Interim Consolidated Balance Sheets (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://anavex.com/role/InterimConsolidatedBalanceSheets",
     "shortName": "Condensed Interim Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "20",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "AsOf2022-09-30_us-gaap_StockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Commitments and Contingencies (Details 1)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
     "shortName": "Commitments and Contingencies (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "AsOf2021-09-30_us-gaap_StockOptionMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Commitments and Contingencies (Details 2)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
     "shortName": "Commitments and Contingencies (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-012023-03-31_us-gaap_StockOptionMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2023-01-012023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Commitments and Contingencies (Details 3)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
     "shortName": "Commitments and Contingencies (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Commitments and Contingencies (Details 4)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
     "shortName": "Commitments and Contingencies (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2023-01-012023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalLeaseObligationsIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2023-01-012023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalLeaseObligationsIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Interim Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://anavex.com/role/InterimConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Interim Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2023-01-012023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Interim Consolidated Statements of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://anavex.com/role/InterimConsolidatedStatementsOfOperations",
     "shortName": "Condensed Interim Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2023-01-012023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "AsOf2021-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Interim Consolidated Statements of Changes in Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "Condensed Interim Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "AsOf2021-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Interim Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "avxl:NoncashFinancingRelatedCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Business Description",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://anavex.com/role/BusinessDescription",
     "shortName": "Business Description",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://anavex.com/role/BasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Other Income",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://anavex.com/role/OtherIncome",
     "shortName": "Other Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4668_10-q.htm",
      "contextRef": "From2022-10-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 25,
   "tag": {
    "avxl_AccruedClinicalSiteAndPatientVisitsCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued clinical site and patient visits costs"
       }
      }
     },
     "localname": "AccruedClinicalSiteAndPatientVisitsCosts",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_AnavexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anavex [Member]"
       }
      }
     },
     "localname": "AnavexMember",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_CantorFitzgeraldAndCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to cantor fitzgerald and co.",
        "label": "Cantor Fitzgerald And Co [Member]"
       }
      }
     },
     "localname": "CantorFitzgeraldAndCoMember",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_CashPaidForStateAndLocalMinimumIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for state and local minimum income taxes"
       }
      }
     },
     "localname": "CashPaidForStateAndLocalMinimumIncomeTaxes",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CommitmentShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares"
       }
      }
     },
     "localname": "CommitmentShares",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CommitmentSharesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares, shares"
       }
      }
     },
     "localname": "CommitmentSharesShares",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_DeferredGrantIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredGrantIncome",
        "verboseLabel": "Deferred grant income"
       }
      }
     },
     "localname": "DeferredGrantIncome",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_DisclosureEquityOfferingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offerings"
       }
      }
     },
     "localname": "DisclosureEquityOfferingsAbstract",
     "nsuri": "http://anavex.com/20230331",
     "xbrltype": "stringItemType"
    },
    "avxl_DisclosureOtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income"
       }
      }
     },
     "localname": "DisclosureOtherIncomeAbstract",
     "nsuri": "http://anavex.com/20230331",
     "xbrltype": "stringItemType"
    },
    "avxl_EquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to equity offering sales agreement.",
        "label": "Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "localname": "EquityOfferingSalesAgreementMember",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_EquityOfferingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityOfferingTextBlock",
        "verboseLabel": "Equity Offerings"
       }
      }
     },
     "localname": "EquityOfferingTextBlock",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_FairValueOfInitialCommitment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of the initial commitment"
       }
      }
     },
     "localname": "FairValueOfInitialCommitment",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_FixedContractAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed contract accruals"
       }
      }
     },
     "localname": "FixedContractAccruals",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_IncreaseDecreaseInDeferredGrantIncome": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred grant income"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredGrantIncome",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_IncurredExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Incurred expenses"
       }
      }
     },
     "localname": "IncurredExpenses",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_InitialCommitmentShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Commitment shares"
       }
      }
     },
     "localname": "InitialCommitmentShares",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_InitialCommitmentSharesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial commitment shares, shares"
       }
      }
     },
     "localname": "InitialCommitmentSharesShares",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_LessShareIssueCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: share issue costs"
       }
      }
     },
     "localname": "LessShareIssueCosts",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_LincolnParkCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to type of legal entity.",
        "label": "Lincoln Park Capital Fund, LLC [Member]"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLLCMember",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_LliquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity"
       }
      }
     },
     "localname": "LliquidityPolicyTextBlock",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_MichaelJFoxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael J Fox [Member]"
       }
      }
     },
     "localname": "MichaelJFoxMember",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_MilestoneBasedContractAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone based contract accruals"
       }
      }
     },
     "localname": "MilestoneBasedContractAccruals",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NetLossPerShareBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "NetLossPerShareBasicAndDiluted",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_NonOperatingIncomeFromGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NonOperatingIncomeFromGrant",
        "verboseLabel": "Grant income"
       }
      }
     },
     "localname": "NonOperatingIncomeFromGrant",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NonOperatingIncomeFromGrants": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income"
       }
      }
     },
     "localname": "NonOperatingIncomeFromGrants",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NoncashFinancingRelatedCharges": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash financing related charges"
       }
      }
     },
     "localname": "NoncashFinancingRelatedCharges",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NumberOfSharesObligatedToPurchaseProrataBasic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to number of shares obligated to purchase prorata basic.",
        "label": "Pro rata basic number of shares obligated to purchase"
       }
      }
     },
     "localname": "NumberOfSharesObligatedToPurchaseProrataBasic",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_OptionIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option issued"
       }
      }
     },
     "localname": "OptionIssued",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_OptionPrice1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 1 [Member]"
       }
      }
     },
     "localname": "OptionPrice1Member",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 2 [Member]"
       }
      }
     },
     "localname": "OptionPrice2Member",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 3 [Member]"
       }
      }
     },
     "localname": "OptionPrice3Member",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 4 [Member]"
       }
      }
     },
     "localname": "OptionPrice4Member",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 5 [Member]"
       }
      }
     },
     "localname": "OptionPrice5Member",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OtherFinancingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other financing expense"
       }
      }
     },
     "localname": "OtherFinancingExpense",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_OtherIncomeDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherIncomeDisclosureTextBlock",
        "verboseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeDisclosureTextBlock",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/OtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_PercentageOfGrossProceedsFromSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to percentage of gross proceeds from sales.",
        "label": "Percentage of gross proceeds from sales"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsFromSales",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "avxl_PurchaseAgreement1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to purchase agreement.",
        "label": "2019 Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreement1Member",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 1 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants1Member",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 2 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants2Member",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ResearchAndDevelopmentIncentiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveIncome",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SalesOfAgreementAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales of agreement amount"
       }
      }
     },
     "localname": "SalesOfAgreementAmount",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareProceedsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Proceeds Receivable [Member]"
       }
      }
     },
     "localname": "ShareProceedsReceivableMember",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued upon exercise of stock options"
       }
      }
     },
     "localname": "SharesIssuedPursuantToExerciseOfStockOptions",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued upon exercise of stock options, shares"
       }
      }
     },
     "localname": "SharesIssuedPursuantToExerciseOfStockOptionsInShares",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedUnder2023PurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under 2023 purchase agreement"
       }
      }
     },
     "localname": "SharesIssuedUnder2023PurchaseAgreement",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedUnderSalesAgreementInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Sales Agreement, shares"
       }
      }
     },
     "localname": "SharesIssuedUnderSalesAgreementInShares",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SoldForGrossProceedsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sold for gross proceeds amount"
       }
      }
     },
     "localname": "SoldForGrossProceedsAmount",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued for commitment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues3",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues4": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued for aggregate purchase price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues4",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues3": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Number of shares issued for aggregate purchase price, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues3",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues4": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Amount of shares remain available"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues4",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockOptionPlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to type of plan.",
        "label": "Stock Option Plan 2015 [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2015Member",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_StockOptionPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2019 [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2019Member",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_StockOptionPlan2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2022 [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2022Member",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ValueOfSharesObligatedToPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to value of shares obligated to purchase initially.",
        "label": "Value of shares obligated to purchase"
       }
      }
     },
     "localname": "ValueOfSharesObligatedToPurchase",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_WarrantsOutstandingWeightedAverageExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding weighted average exercise"
       }
      }
     },
     "localname": "WarrantsOutstandingWeightedAverageExercise",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
     "nsuri": "http://anavex.com/20230331",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "currency_AUD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars"
       }
      }
     },
     "localname": "AUD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r232",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r220"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued liabilities - Note 4",
        "verboseLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails",
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r245",
      "r246",
      "r247",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r55",
      "r56",
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total share based compensation",
        "verboseLabel": "Share based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Loss per share for potentially dilutive common shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r69",
      "r76",
      "r87",
      "r94",
      "r114",
      "r116",
      "r118",
      "r120",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r176",
      "r178",
      "r182",
      "r220",
      "r252",
      "r253",
      "r287"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r29",
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in lease obligation from new lease.",
        "label": "Incurred office lease expense"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r28",
      "r86",
      "r215"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r23",
      "r28",
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r23",
      "r67"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase in cash and cash equivalents during the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r11",
      "r72",
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies - Note 6"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Maximum number of common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r245",
      "r246",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r220"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 80,235,398 common shares (September 30, 2022 - 77,942,815)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r60",
      "r172",
      "r175",
      "r244"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense, current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeCurrent": {
     "auth_ref": [
      "r251"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred grant income - Note 3"
       }
      }
     },
     "localname": "DeferredIncomeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r66",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Basic and Diluted Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Remaining stock based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r42",
      "r84",
      "r90",
      "r91",
      "r92",
      "r95",
      "r96",
      "r97",
      "r99",
      "r104",
      "r106",
      "r109",
      "r121",
      "r137",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r180",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r186"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign exchange (loss) gain"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Axis]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major payor source of revenue for health care organizations."
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r16",
      "r68",
      "r73",
      "r82",
      "r114",
      "r115",
      "r117",
      "r119",
      "r209",
      "r219"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r71",
      "r80",
      "r241"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in working capital balances related to operations:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r9",
      "r94",
      "r120",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r177",
      "r178",
      "r179",
      "r182",
      "r218",
      "r252",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r70",
      "r78",
      "r220",
      "r243",
      "r248",
      "r285"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r40",
      "r41",
      "r124",
      "r125",
      "r126",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r23",
      "r25",
      "r27"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows used in Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r17",
      "r27",
      "r74",
      "r81",
      "r85",
      "r88",
      "r89",
      "r92",
      "r94",
      "r98",
      "r100",
      "r101",
      "r102",
      "r103",
      "r105",
      "r106",
      "r107",
      "r114",
      "r115",
      "r117",
      "r119",
      "r120",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r181",
      "r182",
      "r219",
      "r252"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows",
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expenses)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Offsetting Assets [Line Items]"
       }
      }
     },
     "localname": "OffsettingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsTable": {
     "auth_ref": [
      "r14",
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.",
        "label": "Offsetting Assets [Table]"
       }
      }
     },
     "localname": "OffsettingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r114",
      "r115",
      "r117",
      "r119",
      "r219"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Business Description"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BusinessDescription"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "All other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Share issue costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Contribution amount"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Public Offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Issuance of common shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r54"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r138",
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r138",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r58",
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "verboseLabel": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r57",
      "r83",
      "r289"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r43",
      "r77",
      "r213",
      "r214",
      "r220"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r84",
      "r95",
      "r96",
      "r97",
      "r99",
      "r104",
      "r106",
      "r121",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r180",
      "r210",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Number of common stock sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of general and administrative expenses and research and development expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r139",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share-based Payment Arrangement, Option, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of weighted average assumptions for fair value of each option award"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of outstanding stock purchase options"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Weighted average grant date fair value of options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Annualized volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Additional shares of common stock available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Option available issue"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options Exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted Average Exercise Price Exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Aggregate intrinsic value Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Option granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted Average Grant Date Fair Value Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value Outstanding at ending",
        "periodStartLabel": "Aggregate intrinsic value Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Number of outstanding options",
        "periodEndLabel": "Options Outstanding at ending",
        "periodStartLabel": "Options Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Weighted average exercise price",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding at ending",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted average exercise price options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of exercise prices, lower range limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of exercise prices, upper range limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value Exercisable at ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life (in years)",
        "verboseLabel": "Weighted average contractual life of options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Number of vested options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r13",
      "r42",
      "r84",
      "r90",
      "r91",
      "r92",
      "r95",
      "r96",
      "r97",
      "r99",
      "r104",
      "r106",
      "r109",
      "r121",
      "r137",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r180",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r109",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r42",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Share issued for offering, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r42",
      "r43",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued under Sales Agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r1",
      "r2",
      "r42",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Purchase shares, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r1",
      "r2",
      "r42",
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Purchase shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r38",
      "r220",
      "r243",
      "r248",
      "r285"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedBalanceSheets",
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ThirdPartyPayorMember": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services.",
        "label": "Third-Party Payor [Member]"
       }
      }
     },
     "localname": "ThirdPartyPayorMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r110",
      "r111",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Expiry Date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r221": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r222": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r223": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r224": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r225": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r226": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r227": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r228": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r229": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r231": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r232": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r233": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r234": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r235": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r236": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r237": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r238": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r239": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>44
<FILENAME>0001731122-23-000845-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-23-000845-xbrl.zip
M4$L#!!0    ( .2#J59)\@LMW@H   1G   1    879X;"TR,#(S,#,S,2YX
M<V3M7%MWV[@1?F[/Z7]@]=+T[)%E278V]MJ[QY:C'+6RK;6=6U_V0"0DH8$
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MV$1$*%7/IPU7>&HM4W==CF&-(]RYTTNQXXD@N<I?FJ.;'<<.GR/"!BZ>*TI
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M'\%?$PL8#N9*G-W5.6XVK-A;KL]^!IW[K8$$EP%[%%976&1OB5YP1V!4(/M
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M'N;..3XI4#Q*;ZC"47ZE?4:,OH?\B2B9X165?;N)]:3E7UN!G_\#4$L#!!0
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M)!K1=+0,H^!4IC4"%-:+F@]"*<6@B5(P.] AI4OL?/-9#[S(S3*P9XCBP33
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M;Z_>_O#F%4!9E,=)MOK;J\^WAXO;DXN+5Z H81;#-,_0WUYE^:M__9?_^E\
M^>>O_^WP$)PG*(T_@-,\.KS(EOE?P">X1A_ CRA#&)8Y_@OX&:9;^DO^'Q]O
M+LE?>78?P!]_>/MG" X/+5+[&65QCC_?7#2I/93EIOCP^O77KU]_R/)'^#7'
M7XH?HGQME^!M"<MMT:3VYNE-]0]7_VN:9%\^T/_<PP(!4DM9\>&I2/[VBN9;
M9?OU^(<<KUX?O7GS]O5__'1Y&SV@-3Q,,EI;$7I5:]%49'IOW[]__YI]K44%
MR:=[G-9Y'+^NX30IDZ^)1KZ#I$@^% S>91[!DC6V,1N@E*!_.ZS%#NE/AV^/
M#H_?_O!4Q*_JRF<UB/,4W: E8,7\4#YO"(&*9+U)*2CVVP-&2SF8%./75/]U
MAE:P1#'-Z#W-Z.V?:$9_J'Z^A/<H?06H).&'LESO>VE52J]=@[U&.,GCLVPW
MU$-M3_!)W\'E"PK0U7=>A+N\A.E.X+N:SF%_0KO5>*OGOJ:)G4>[U71'<Q;8
MI0AY=/7*ZS6E/UZ2/_4@HJ>2#& HKD'2)#06F.7 !H8J[2;U/.JEFU)KGF.Q
M['1D9&DN87'/$MX6ARL(-R2#HZ/7*"V+^I=#^@NKA.J'W^C8B-8H*\_^ODW*
MYY-\O2$C?U86BZ>DJ/-B!?W;*TN=U\."4.T%KDL#<62HDDKB=923 6U3'J:\
M\KGZ$N=K:RA5_>66"K^E]TT^O-()%$6!>F(8%?D61VA4FW=+-::&*Y3KE&A1
MUPUEAY]O7_T+%P6M+/B52O^?O[YN<_!",8)HG6>W91Y]^0FM[Q%6%%HBYY)*
M2IA=^@A"P5!&A6Q($RX'F"#XE8OZY\@BCA/JJL+T&B;Q178"-PD9@;5\,>BX
MY(X5_"Z/M K!<,H&Y9!?K0Z@2F2*!"JUR=@&'Y]22J'C-\=\'O('^LMOMP\0
MHVN<1PC%Q0V*4/(([U,DY9"-@@L"V0.G[#%+>Z>.-<0A;Y@.J)5 JQ6.D;I!
M)4PR%)]!G"79JM!:)Y6P2[.D!]RU1W))[VRR@C=D4BT,:NF0&)2RJ3&9$S_?
M89@5,**VLOCXW/VB<;W')."6:6,+UF>?K79 C!P)660I$P-,;B)773$P_I1$
M#Q"E_W:>/ZD'0XF0LP%0"; 9] 0)[T30PAHV=B4'_@T0R7G,48&B'U;YX^L8
M)=P2D3^T!HC\Y;=+M(+I658F4@LCE7#!  TTVOR2S][;7HUIV/!,"G"Q>3OY
M(H./2-._^]^==6T9K*97=S]Z;U05(F&"PT1F]BD*7';\"?*WMBN3O_QVLL48
M99&L'XN?7;2U"A1MZN$W[RVM "2LE%0B<ZRCU=8ZJO+@C5W_K6WL^I??%I]/
M!Z7H?W+1R#(PM(&[OWMO7 D8H0=OBQ+#-($'X#1/4X@+[Q.#.Y+VU7*!B2>Y
M8@N_FCF 0M:ENZ^%V_7LI8+>.6*#3EPW)4RYSS$LDT<$.CH 9G'O[U?E \*@
M?( 9Z"O-.O[SY?^KY1)A,N>]A2DJ%BN,&"2U5V"CY<Q7L"]"XT&85;R3;1Q.
MQ:Y.K0F8*FATYUY3/8$9$3U/RM]7B)C,>)'%)[F:3EIQ9SRR -T02",;!G/,
M  5+Q31 JP*(#C%%<W/EFI3Y 1:H(>=;-5'4LLY88H+;4$0E& 8_#.B&Y#AZ
M\_8]J'7<V9'+)(OR-+N&^$NU&W2^S>++RQ,U18PJSIAB";XAC$$^#-[8@136
M,[@67;7\TNSK4<4#0%3#66C_GPBFY<,)Q.@*KV"6_,X.0MZ@1Y1MT2VK1=T)
M%WMUEU[WV$)U'7%;7>_DW!'PD*A<'5!]T$W@ %1)@"J-4$[)W#TDF&\:7,/G
M'&OW%A6R3F> .KB]&:!,,!B6Z= -*<5D#_E^#9,.Q]Q=$Z#TK+O&I/5%7%)%
M!J[+D.[W8(@A 37D Q5A-PSFG=BSDUI7&VJ\:([$@?NCYDB+6MC=<183X/8H
MBTK2.PVLX E'6-B9.JX &#NHRNS'G@24[\?PXWT _'AOS8_W8?/C_7A^O'?.
MCZ.C$?QHA?WQ8PA8S8]:,E!^#.#9\./H*!PO8_$5XIBNF6O<C(&,TT.X,GB]
M0[== >\4T:$2=JRH#*!"\_H:]<+0+Y#N9Y2%Q0J>(.I\ 4\!5EB_&\AY)X %
M.,'EK!?N:G'PUM6J;IVC9O!0BGJCA&K@4,B%20G]H"%2(J 1XQ3AY)%M?EYD
M18FW=*GY)BF^: 80O8K+\<0&?'=XT<E[9]8(D$.&M2J@U0EEV:SC8VF7S"1R
M;N\I*F#V[R8.A()AC0J9:K>:N[#!F"%VM^0C,9(QO1V)LH(M!;-?B\6V?,AQ
M\CN*/V<QP@.?O?CX?/:$<)04Z!HG$;JAISQT5V/GR,DI4>>KJA[5I\\FG,XR
M6]F$[E8) R8-F/B\$X0**\U.,S>023GS =40&_=/%/%.'CVN8</7:P2LV6>?
M G1@:;Q_F92/1E?Y_*)(<(VN]_1[C3Z=DV]N]&.K1C_VV>C'YD8_#K31C^T;
M_=AAH[^S:O1W/AO]G;G1WP7:Z._L&_V=PT;7["S*I'PTNFHO410)KM'UNX>]
M1I]NU_#%DZ>++,K7J(E(4P>5TTR"M!HN)S,6T+N3$HVX=R[98QSRBFN 1@74
M.J$LX?#HD>DBBQ?Q.LD2>CF'KC:=/=')DSQ^QTA=EZ0;59PN_:P4@R'B&+1#
M2E:Z_.9,3QM4ZN&8OQM4(%+%#Z2@I^@1I?F&Q>6RX*:5IML@#=9%Z4=G,*H%
MPTI[K&(\!J[)2-G1G9>1YEO[)_DCPHM[VD&B<E!JR7=7-_:EL.K[^KV/WKFA
M0B3>\",R9%"LI%PW]&D>L9T5NLLO*4'_LZMFEH&J6[G[+8A&E@ 2]K(J$7:6
MPG$#+TC&,<W\/(4K"?S!=U=-+(55MW'O8Q"-+$,D')>I90 5\M7,IZB(<,)F
M=;IR],2<-[H$I-#V'9FP*" "4S.A(^O)L-^@5>7GTCB=U6Q,8\84\JY-OQ;V
M<"R0"@=!&AN$RM&BJ]3.I#WQ:)%E6YC>H$V.=?3IB[EFC0SDD"Q=F: X(@&F
MI :7!5S8$R/^UQ;B$N'TV4@*0=(U+Q10A]08B 7%#CDV)4$:<;\<84$*$WZ'
MTD 24=3Y=$,!5IAZ#.2"XHD"G'I*TLC[9<KM TI3>G0%9F:#(A-VS18UX"%?
M1,F@&*.$I^0,TP"52CBT.7NDWCEQDRP+VY'W21X!MHX_C7"P%!HBM&014P-4
MSQ.3.B\'&3@D2+IFCP+JD#<#L: 8(\>FY H7!TS>/TG.LMB*(HV<'X(,8,KI
M40D%2(X^,A,USN@&BC]BG"=%!%..Y9S\)@MTK)%U31 EW"%)!,&@B*)"IR0+
M5Z@YPU2\$N8_$<1V=.E(^B&+ %5.E48L0*(,L9EH0N6]D(0' >Z@5H\X:E%G
MF[(&L,W^K$(N"*(8P,FC-/>)XFD$.F-AWL^3%'W:2LZ%R$5<<4,%KN;$\'L0
M7%" $N[!\/CZ5 YP02\M7^\29"6-"J0LSE#,+0/D(/LLZ,L$Q 0I, 4;6ED6
MI,D+(TZ(9<(PO<AB]/3OZ%E9+D'.+2<4,/ND& @%Q HY,@4M*F' I $1]T*,
M:YRL(7Z^32+#4"$*NJ6&"FB?&T.I@,BA@*9@1R4-;B].?(XD=_#I(B9$398)
M/ZMM8(E2WBU9#+#[G%$(!T0=/4(%@X@2Z&OY)!(]_(\W>>>XPTF^)0;P^22/
MU1Z*0<LMJ:R*T*>65B4@@MG@5-"LIWK SZ2 '(,J 4!3\,*X11R3BBJJ_UTF
M&7JK++]4UBV[-'#[G)((!L0D-3H%?RK)@_H/@.J JRP4TAR-*.J1?](<V9+F
M*&C2'.U"FKNO>2"D.1Y1U&/_I#FV)<UQT*0YWHDTI.&]VIH3^AX/OLN_R@YG
M*R6]4$:$*B5,*Q8>701L)K)0!>K/4!6?-&&.U16^QOECDD5JEUDE[H4P"M!2
MU@QDPZ..'*")/XU#7.MYM37<*3=VDEK,CY7I@Y2;&"X3'DGZP(S&A4O[I,1U
M7I0P_=_)1CL1EPM[H8<4L)0D/<GPJ"*#9R(,UP%$R<?$NJ(KW="07B4;?'=W
M!5@"J[T"W/D8! EDB,0KP'SUA NY;F;*48R@PB+T/SMK9 FHIHT[W\)H8A&0
MT,*L7Q,9'QV91EY)KQ_R3'U 0!1QU=(J<'5K#[\'T>(*4,*S=3D[:T;E/*W&
M/Y4H*^3FN_/-V<@^A-,,Y/6'(%IWB$:,?UI]=]R:O^"D)#F?Y.OU-JMV>63G
M!A5RKEI9"[-N<:E0$*VO0S9D0B4+^L*.:7&;ITF4E$FV^HE,/G$"9:62";DB
MA!I@S091(@@J*&$)3^@T@J"6=$R":XPH"1%I"'8)$-$XS^SY;DFY=,*N2&$&
M7)-#+1D$28SPA*<S,#J,.AJ J_#'UOW2YJ(HM@B/(H]$Q1.%E. 51!+D0Z23
M"J215%S1)[=N4;0EX^/SVZ/[NZ1,99-+4<39F*0 UXQ(@^]!<$,!2G@QEGX#
M^1*\/?KN_GM0:SEN_D_Y'88Q&1)OG]?W>:J(/B65<D4"#<2:!Q*1(*B@QC5D
MPZ<<5** R_J(3M4#*RG.X+LK DAAU4W?^QA$H\L0"9V_U]:>3/[94_1 7P51
M7$B0B[DV_3*00_/?E0F" AI@PJ2D$@6UK(\+">V0M3([ 2MO3L#*X 2L0G0"
M5K9.P,J;$U!GRT.$$+MT=9\F*Z@(3JB5=DT*#>0A/R2B05%%C4]I,QH5T.JX
MCFC)0IQ=9,L<KUG^Y^0/DE(JY)S%M-3!;():RH2"X(@.F1#6D@>=ZP@#*NV:
M%]LX*5',P9PG&<RB!*9->$39BKA9Q1E;+,$WQ#'(A\$A.Y "G;A:'<NP46Q#
M7;I>2N<','Y!:?KO6?XUNT6PR#,4\[44V4Z17M[MB1D#[/ZA&85P$'2R0:@X
M.D.5#K]0+5"K52MA7ICT<YYNLQ)B=I<<RRR30LXM<Q0P^XP9" 7$%#DR!4,:
M8<"E_5S0YM$C&B>+&CQI"!B]N./KVEK0@UO;4MF .*,%J+K#7<7\:'UCKN7I
MBF6)Z'L1R2,ZA26LL"G+JQ)W?:E2!WIXFU(F&Q"%M "5]R<;'1HJ!M:<\A8R
M!I\05VN5:TZ)#Z3<!XX1((JQ8QJ1@.@APZ6)((-!+>N%"[=KF*8?MT62H4(]
M$ VDW')!"K'/A9Y(0%R0X5)P@8F"6M8+%\[6"*_(\/8CSK^6#U5\5F79%-)N
MN:&%W.>(5#0@KNCP*3A3JP"N4X?4]4.>IS:@.(^RJ"ZI1-0Q;91@!YP1Y$(B
MC J<P)84172]Y5->@KL<?"X0*!_HVX<E/202=R/!\W1\O3021?1"!/?*LQAB
M&85TPLY?'5$"%MX>$22#()(1GOH=DD8#U"J.67-%.(R[\S@&XJ)$:^5M![.*
M*P;9@J]Y9)(/@DV6((67J*E:?W+-% '5]!G-J!O<7NWB]80<>\82@ /'N",1
M!$>4L%1N<?>M #^Q\[;W:1*=ISE4K[+T9!Q'S!/A#8+EM0(!,4!$I0J1QP0!
MD_32_A]A]@5O-V7T?(WS""%ZRJIHK)5I_<U2VRUG1A6ISR8KU8!X-@:O@H%M
M$J"3QD%GQ/*YF$</C=-H;GGTY?8!D@J\VI8%'4$),/4JN%;)\?:"10$&FPP:
MC8"H9P%3M>' - %3/0!<&72T/<W/BC8*((H_/M^@)<+TWL$=>BH_DHR^:&88
M%KJN9V_6Q1E.YHR*09!P+%K55*\ W03 /3TC5B4!?J6) );*M.^7+V%QS\JY
M+0Y7$&XX,U%:%O4O+46K'WYK3H]<+9LC)=<Y7]A0O&@_3M4%07<I#.7G&#WO
M]-P!K'!@L5:E1UW;$T2U-OBUUO?/RT51H+(P,' HY))K<H!=5O4E@N&/%)9P
MVHP)!<*"RE.T(H,@ZYX3"K@B-0:"@3%$CD[QM(MWIIS XF&1Q?1_9W_?)H\P
MI:/PHCR!&#\3[^]GF&Z']RE&ZKIDTJCB=)EEI1@,T\:@%9A'E !Q[4%$_X!:
M=>]<I*[?&MW!)T0FS1$BN.Z%NSP&69=<T\+M<DLJ& R7=.B&W"&RA"GT7!$E
M4 F? &Y4_//G&J,-3.*SIPW*"D3Z!UOL[UEE11U8:;KDUHBB=)EFH18,[^RQ
M2L(04$V N&K!R)BSC9VH.CT)0_+#M.Z"#T]+[5HY94>9ES"]-#I4JKN'5!L$
MXG!?)O ^2<EL$!6$R6PM[2%/8X0+.CZ7SP8?W%[=)5G&%JI+)UO=8,S12,!"
M%+Y6G9FC;@+_!'@2(;'4;FZH4_#$1(M9HEHZ1+:-FB^"CJ)W.E7'<HIK^$P=
M0+V+I1)V.OII ?=&0ZED,/31PA/6I"IAL.'2(? &;U$L]@%U:57RCMFCAST@
MD%PX) YI$4IH1.5!VAGI#NDQ3P3>>:?4*=TEPBCFDUD]G12R+JFDA=NED50P
M& KIT D[?)4L6+%G:Q.F4A/HV#N!.MW /&1[<WX,WDY8LS<1F'P*%Y)+0P]#
M)"7;B:;KJSD[=(RR2$T+K8;3I6\S]-Z"MUH\&/MBQB@^<M!HL&E83Z>V-G_R
M3K-K7%E#-DW4[;%()1VO1*J@#E8>AV+!T$B-3=P;V234)!54$"RVY4..D]]1
M_.'MFX,W;]B_8%.GQJ4.B%N-P2--%/SW-S^\>?,6;! &!3U'Y9UGG5-AVHT\
M0<RUX9*!'%JKKDPPW%( LR;6T9N661$_B6>D%?CSFX.CXS\>'+__<Z/#C^U]
M=TOJ&M$[#.#XS0&@?"!&[Y__^>#]NZ.#/[_]X_?>&;F(8W9F!J;7,"&.8U4Q
MG6I435<L%)W.!JT+TIL6&K6"8;8U5&&BV"@"NDUSF&0@XKK>V7>#2IAD*#Z#
M.*/GJLF<=KO>IO2L(9F?T.CZBLJP473)/ON"=-EGU@J&?=90)<L4M2"(N:1W
MVHF["8I2RP3='@15 >T?^QQ*A37Q5.*3SS]#WZJ1;D?MN(L5U@;B+AN'85'-
M$JUQX2/</</^Y(E?#VG]5ZL9EZCD;P*K*H!Z+CO4"&:(M((I.3O3G[U6,P?8
M* ;&N&N(KS [@!^S"=8UPJRH5I6B5O;'0%.!U$Q4:0;*2 -<(S.;";!W1@J7
MZXP&4*OA:7'%QO1IQ(-AF1FC;%6X75@)S^)U2C32W%EI>N+;&$-GH18B_T::
MN!/Y E](_.,]BD4SMK9MM;17N]:'K+5I7#1$/DGP6=FRA&F$QR-U>  [%:^,
M4H0&L)$/EUOFL !2@N4SQ0/8_9I0<R?7<(15*>W^JI 2LGA92! -AE%Z?)(+
M0_283WN!.J"KTE<;A"$]'5!=03'=FM;(N^22$7:734KA8/AD0B@$<*OEF^L_
MWHGT(\H(IG21Q8MXG60)Q4\OR54E4A3<J.625)9%Z%++H!(,P>QP#FE6:;%U
M6=C3\TZW&U0@4I?T O I>D1IOJ&654\V@X[;K4L+^/U=2XU",#2S03DD6:W#
M6!:W6MXI)AAE6^/M>2BT&@+#VD%2P9-O&>7AC7Y- ;BO=YD+H?VUDE[X(D*5
M,J85"Y0S D"UMY3F$P?ZWX4KG_(L[V.OKW_K76\+/9<\LBY&EU5&I6"&,END
M\MC*U<V.[VH#]>(SA_#Q*:54.GYS?/R6T8G^0E$.^L$Y::0?Z>V2H0&RD'=!
M'VO8E#9&8>]TL44HN-:="T S<4/NC#712SA067$L%9VQ951!&MI8:87!GS%0
M;=UGRJTJ3,TT+)M@R;)$I-K*GC7]A-1KEBIQMXN6>M#]54NYK'>260(4URVY
M>$6@ Y"A%\_*%+:*C9I54,EF%B#K*@I!9[9("[2Q/5(I[S0P0I/[,LM:N)YN
M>;<DYSE&R2KC=VVC9_::#GWJ+\]^A$E&9P(?T9+(W,$G14\8E8)+>[-#T;HF
M:(2Z=SKNCGG(TRH%PL_H@?Q._&XZT?L>K(B^=[(J)Q)C)QZ!3.]&3>O"6C(P
MP50L-W5F=).,@1-M_M*>0><9_'KOEI2IFH3D6=5C.E$-SY[(I#7',;'E^)D^
M\U.0RB T*$G-I:PZ^%BOW?"<*4?WF]"S5IVXD3U+=F%UK?D+.NR<Q&]EZWG@
MGB4,-CA_3 H:B9S\M5Z *6E&WOMK%12D*7ME=3ZB#"V5M^U,2DZ/!5D5H'<P
M2*OAAKOO.7<SM*)G$W7LM4*K.-9! \!6CO%!'7K3.^-(YS#N1 QDG#H7,G@]
MAZ(K$):EDT%3VB868CI?;S!Z( 2ABS%!;$'4%TKKH[J&G0>UN$O2F$!W^:.2
M#6;28P H(Q3EVW1A-50;"JBD^=2P/L(BB>BR9))N2^$PM)6&NTT%*^CMMH)6
MW#M1[#$.N<*D^'(PE_-N;GXAL_,' F3Q2)S!%>(/C%XMA<.X!C,T/AF7YFG7
M0G;-UM@TO+/TA<"'U*V3 9"G S*6$'UQ:/HSV H+:%L4"].X<U+.;.8+"]L8
MTQW3<<I? NT^+Y#,MYN@#.%;X>;\^9WF29&AD)<7V.Y4CXCT)8*Q?E)8ZO?3
M?F5B_L_^-X@NDPRQ!1A3^3J"7H@A )62HY$*CR!#:!J24%'V('NA9<JLU;YC
M()PCIQ5/ID1)'I.:PZ5NWJ[!*=ANM$HR.CT#]Y!\B-!!('=4;2\4>KY%:'5U
MT.]]05O26-X7E#"&.ZPS.:G=.[*?,T)I*G)-*N$!%FBQPH@9$9F78ZOIS 4=
M5Y3&X[13\SX"C,<J# G=V\U@2]5I3,MCL*D2 +!.82:R761)F?"@ASRL,(<D
M*ZE2U!F=#& ;_BCDPB",'IRX$<&D02L^K_%1H!O-BE"X,8XA>\ 3*[9$0[9,
M-61-$RGR!M7V+3[=8C*R7K,16Q?!V4+/>1Q)FV((WK1.R3OQQB(50ES5P]8>
ML$UJTL8HAL(WT<39:^T%X[0F;T"YF7US&S_)HX-D](S"=(DL?2%7/I"]\^/=
MZ[%T=T+V<T8Y. (%',[%B:4IMC K[_*S)X2CI$!72V:VKC;L$)QI=FC6]S(O
MMRV6='9N4@Z#8CL@-LS4-SD]D<[UV0XF>_8BYTD$P,6+3&VT=DLG2&X.B[D3
M1^M$]H^K ^0OX6Q8$T1>?&'6P>XLZ1Q(O9YSA]VF&(*_KE/R3M&Q2&T6/&]A
M2GY:S+S0*:S3LFR;7&T-IE;5W[JZOC#JA76YGG>:[0!V!Z;-[#M>HH([LZP(
M)WDA#]L@%7/&) W(AC42F3 8H@8FO%Y/)#]4CXLQ2H"(2GL?[1;Q_]T6_#G'
MNUSQ(!4KX3U=%"&S'WH7@=VYN4%_WR9%4J);A!^3"'$#?(.B?)6Q5'2KJ?-G
MZ_:E,C>5V'_G;-X\O7<PQP45#\M0YY2ER2Y9U(EZ.BXS\E*+VT,RNN:3XU+=
M:=FWPTC''LZ5G&7:ZV8:E,-:/V.G3D:<0PKO6(^/TV"F!E""--5_,#/@ZIS@
MU?($%@_G:?[5%+E9K^+E.*<&O/1@IT0^&"-J 5)]V#-? JH$F%9(X<&)T:?
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M?C!2UQE1QA:G88^MHG='<1>TJHNH4:4/B */Q[;A28!'ED8@[RA4<#_FV;9
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M9IG$-$P-;O]MR4PU8KQ?PWPZ$-/(7$OZ? ,/RM4YY62^:1/BZ;G]#SW@-O@
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M[VL^BLH36#Q<XYR&*(X_/G\NZ/W<9M*\B,KD4;EB;*\=4%/N %J8PJ(2T#1
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M29V;GB/=GR[)G\C/]4_D/S2"%/GE_P%02P,$%     @ Y(.I5OB7!SY;)
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MQ;9HEM%Q+O[2#+NB*11PG!1)'7M]0YWZ+*%^3M(Y"TGHB2/5NF"3 G5C+Z@
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M'QD:ZVAX*:O0GY206KDM2+".DP>\E-[-\#CSZU;$K^5])Y3J.-!Z/+O_$G(
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M',(.FDMJF8WE[(?.II"!9T1T][[/G;ZB[68[DUW5M*I;\[+.DE"P4:[9B2R
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MD#UGS]1?;FR6="H,1-$6>Y6Q- <MQXY0_L0$?0D/E\%&(+A-G;!#LRQQAV&
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M,EW;<BM(T0V[:7&_CO+M>7YS:+=-VNP+E/J/NRAU"QB<&O/J]8_KAV)?MBY
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M 3WU,<UK$D=DNMUR?/2&>XOZHH&ZL@*>C*@H\"W9AS?@W[\CF;@WX-6TL?T
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MRME?[5YGNA^Q#J&V] $V(<9>/81LEN&*JPNR$N@BK$/J?;D/(<JM7A=E8\I
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MCH6ENK1)RZ*EFIU?I=GZ"$M7LMB6%9I3GU5N:32YT$OYWUF^G8A5VH87*5.
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MWF>/CZRP49X1-30C:52P5 S1NR'J8ZI\75'6'5&RY K>F!<ULL:#!@+X$!F
M7_T. 0UF\;)OYC@^,OH80F*1&H &L0^#-GCS DNSS3QZ@F_ O8= 5+*"8JJ?
M-NTL/?6G47M$-J6IEIN.@E.">15')V6F.KF_'>(&5XLM<"/DE]'71@K@#,:7
MQ&TRI=#]2+7VPZD)\:!U?+1Z1,>>&32!@4EF8,Z&S4>,-JTLHXE@VDM@%TAH
MYJN;"!AC4;<O<7<Y<7SDLJ(+P8\TA1;,/QGF6GNT6,87K><LZMG3P]@*;=U$
MKXH')VYFE2#NEHS=.,U:LERIFK7S::(A;I#=GG;'1Z ;(\7TI(CZ.K8R08;\
M3,)OLV_8DD*WAY"S.V19#,UTK89,EU<)EG6:3+*-A3.^V1=A*1+'1#7(#0P=
M*O#6I,='CCP265DP#<)+D(?X@F]:7G.ER&#?P*BL"(T\MR4&OM*:E.7SBW&M
M8E3^Y),>B/O$0UF(YO#PZ>=E]G[R">*A*P=/ER<'&$ <? 145A3JW?JM6&Z.
M$4GZJ.=F.RUWUUXRW!2Y-\MO[1#0JYL\*U$'5D P3&!IG "!6A^9^E,&MG:Y
MK=M?ID/A;I>L/;#J@>< KX+33NQ:=Z2 6\\@N>OYA)D.& @Z'8=D-,E@XI T
MLK MGB$J5C72[+8&<08(_&29A*?LO#RF+>Y( Q.ZI#]B=80A;&AJ9/< ,^@)
M6Y$(0=AYA;A+8_=ARYG21KKG/K39E=NRQ];*W;9WT&AY S%+,HQ!@"4/Z72#
M!RQ^S[+QUE6E=-6W)G$G<-<34H%C8$S*X5!W9(YT;)_\H2P"/P 6#!,]];%*
M:4P(QE!@IX ,2'$A4)%6RP(=NS*MKMO%JC!7K@5&&]/3NMAK57FA"A:'SSX5
MRII<+DAQF$Q:>>29?@&<)95DI<!*LAD,SJ_;#]=_?^;.:RX"KZ/$K+1>B=F4
M:.76I'MY56X__RUU?DT;Y^RQ^&Q11O:G%/G61.>O[LI"EAUQ/3^E2'K-V7*-
M\^*::TT*S?R7W*>K4?&W[^;%@9>IA2>%T)H\?S__A@<*OBH5$D**X,JV\(B=
MMR:_/EWGNGC0J-W("4',OQAN :GE:.GFKY_-7GU2_!K#TF59"Z\-VX&)^C9-
M;+6Q(H-784>@U),<Z:0J9/X*V>,C>A6@E:=Q?,!NE^0MK#3N@*2O_-S7^;MH
M[5R3G9W"8\WV3U4 %7&\$U6+7=!#*\-+L[DV?"2#N$GJR6VK*EG>W9"TPS-H
MMHVZIEYG%]POZAYKADGRZ(X#;<H#FCPDA[!')O&WK'VD^?(46H"BVL[U.XNW
M-)$&TP^LIGMH-"2$I(E'KV_>%X$D]/IMXCUCX-> ;@J0(768%'P^!3S21W!8
M;$]6(FF#XR/*CO8]2882SY3N57BG[I@DZ24.2,H)!<09].I'T!::$:1,?B39
M3@D/[=P#!5I$ZHCF'V"4+HRKZ<:TI $ &9G4VU: 6/9%PY2'F+3Q9[PTE$;3
M%)?M^\Y1DK&S85I/MUGE![83M*"YF 4DEKPI#@R7@PKYEL[GB@B\#?XT6>/$
M1U%6J.L\X_X3EM"D)+TX:4P0LM+'E$73RS2&"C%:#JGH3#8O04A4KP %XOMN
MA\YZ##/<T/H74%25ABCTU-/,C=,T6TK#NS)P%%M,<GA3!R[T26\K]SOTAN:\
MNS2!#H9*>R+1+EFW4>XM8R5\'5U5-:I>.MV+HK:"G% BXC7-BP/I'=/E\IJ
M-3)HA'5\1.K1Z#X5#;;<9]QXUIE,:]M9?9KB=^)/A025H@$STG&Q/B ;6#,R
M2XJ0B'(X,UL#6>+E@NMNMQ%1(?H&8D.TODTVKBW(@&0$8@(2&9&"S9#?'/S
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MS,RN$!#!<A')CK)5ED(7 4I\$$_"A_N1U+.%I0T.HC6DJ.MTMY;0&"^51%O
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M%'UO';5L!MFNFJY6/:IC(@0RTK1 VX8*?2$II6?X Y)H97'(:K/8&]DAH%4
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M5'#=E-/J3D(QY]<Q<U'JI3'OD)-397,<R=3IJ7$A**@(%A;/'R?1N1$NF^S
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M'1<'Q5,=!/X4X;3Y)& OL'R6+HF/=M_L$T04TT![, ?!0!I0X01NV'E0=,_
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M/*TVOM#:AOOU[N?/L3F9B,X/QEAFSU B'S&\@]-CZ@N\*SN>T?U3#UQ<PT1
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MV^LUX#R#BGD-."_8XJH7FNLSM7)B1M%KP/E1YM=O%G!>A!E642O5FMHHKT7
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ML@^*?F3KP NP HU]SH-EHPME!*YC.;=TI /'=H!]D'E,CTP&9GZ373<(1$B
M<\:W'6"%GUC=AT@\L-8-OS^R=O:&1SL=DX5=*+,"'R^'/'URL'=>%ER]X<R#
M%CX3IG!<%'CQ[S'?YI(A?>MJ L!Z[\#=AGL:_AI<5;Q*\4_"/X!W[C37I(-&
MR42W+E;[(0<<)&&D$H $SU(W."Y2^)/\M^%'T;\53+(I!\ K3\-6L1R;1PU!
MS3$\XJ=!R5RJ#J9H($6I>$25Z+N8&H-%[&JJ33QI$8>O-0?@V[C=_[Z!'VZ*
MQ5+AQ_#V#7C@_G_?O%'^O:@JT565$X--\'\K_U7.6$B;0H'[4KH!A [*F</]
M]E_;6_N:UZ?V13:AI9A]1HA6]/(G5=R.3CTCS*7:&:MHA4Z63)^ S&A8PR4P
M'1(+8*%@6PT/1<:((@,(F#%O!]I.B?(/0]]QE;>7QT<G[8O2.T4(Y0@\SRJT
M^ <(3PWV3A>$!;.*Q1^X%%=Y\ 8M*!L3Y:Z&93,!UAIU^V#WN(YM8*]G)O/)
M4#$'N&8LKW:I(33\/OJ.,Q@$>&IXV(7P;?AXRP,3Q;YSK#MN>KF:C0'*(8<)
M\@@PW7063[$#LMTQ5D;:>'N+)>ZP7@_>VP?5YX!(]4Q1'6 .\ F\3)T"<4A3
M V-9@<T 1?=]PV;40NNNH!S;"E.*H.COX* H$$$V$L\["!-)G RX/4[X $P?
M@F[W23);(YG"%/#@,4-#)UD>P6QI)4C+2Z C?$+'8 F&(@FKJL4>JYQC.@3.
M03G@D=3MK2MG@!)PV!\I;\\/KM[!F6@45O2Z=(P*&(N&.%L)%*W#LW7',W9T
M8X@%8G"&.181B&3W%LQ19B\S^]@-N7!["Z-28%!W.1 E/&QF2G1<S;0W11D]
M)5+3?(W44*2F^1JI62Q?9IH.Z1V6DX9$.6%(/-NR8D&"%;U=;J\^YYMHR9<@
M].%V;V]=&"/XZ*5B8!ZEH&+H <-A!4Q?E90VF#?EVE]*J?2V].[/4J-4*[)M
M\CST1@L_"O#L"=7^/E*WJPCW+']_)Q@+"F,PZ*KQ?!K^%K0<>H#,5=[> K.U
MVP<=#&ZT,#M\^-D<=#2+Y7@PY25(!<J6$F4]I@1993+9&D-#-S7?9=YXGD^/
MSP/G!\T "PP?8"=O@+4I&-CD"TF^#LR@< .1BX_?P)IQDL68V</ J$?F&QJ'
MN L1!: 53CJ<4EQ"+'4R&((&6&8<!!8^WZ)!0.^ )\T*V^$W@6GIP1 LCE[T
M 'A38#$L5Y\VE_$*L$*'1A?KG# $HQ*<N,LJF&4+$AXMK%PT<LR.0^8G/$_K
MFGH8Z[@X#>$+VUL49>*MBG1#0\1VCQ&0@RSTD1=:GCPK%@_Z,&O=@P/26*N(
M:!7:[2T6TS-S%K>*?Z<4,_^$,X0WCN!4-&K/!#8I\+V'!]I#2Q4_.^\YL5RF
M2"Y2H%%$C6(4 BY%)(J)'.EJ".?'#)V*L <+]X$@"@<KJ&A/+A 'K%6=V;W1
M?<"MDX6O<=X<:%UX)3@5W8 [%J$A28R"=35=/%H+L5H>VJ&4_L;@9W@3,2\1
M;D*1""D011%SL]7@B1AB38<.-EG0$#>J9L?\$$7=QQ#;"-<547],[,LR([%+
M-QA9CDEM.< JXM 18I2>V7%-< O 5X$[>6M1II3ETS%V%/$ =BH!^PO<:L>#
M_[@C=C6NM" \%=HW? TY@@6 R7NAF&-XPC]MY]ZFUA%:0!Q$F V$]8";I"'1
M>Y8V&(2)>_ D7.?6,K6"\C5$>W!+G[M!#'?"AC'Q/\$2;AV$_WC@W?\T<N.N
M#&:'0#J->:($M2,G+[K+_'25MV;!*,@7]QWQ$0(L!/N2X.CZ"( );WKX'/G*
M#Q !SH-\>& B4(L+Z(/9Q#C7TD8I\38Y##<I*UF$BC7J^!U<H-:K"T0N4.O5
M!5I"G)@9HER$"-,S*4K8AU"@['A<WRN[82)LH1;KBG+QJ.ZH.P:9@ZF9.@PR
M;6^1!#-MD'M#1T1Y1,8P3/71H#T?^%\!VP HXL=R4_#3D$??6/>2>Q"4\3>&
M20TF-CL@]'JFCS8CV&5I2],4K)^>7 EL)5>QF@2#HJR;@!CF!:GZ&JC\OF%A
MM@[LJJ@8F<PN2BH(0Q?S,!IK#H9!59N,0BQ#C#7@$ N.TJA13(\L/7(.1' ,
M=Y.].A:RW#L[N5+9H1BQ&.C &"#B5=B(:CB)#\/F G(+OBPH'FJ8R3=G8D#1
MXB8CAB-MA6$<<E82W@K*C'/S "P*AQERE&X6@%I2HW";C >>AL3K$QU-/-H7
M+BDBF""T\C8^Z+-4_&.G7/R#['BF<073O4-JP$=QD:1(!?"6.FE)AQI[7A.>
MURK^(3$-(8,Y)HY&IH5LB29C=.3;6W#FO#J?$Y_K=.IORI: N3QAIL)!@#5C
M8+ 3KM&]8;"#DG:_?]JF!X"'P/+TPGN! \I/.T?V'KT&;B=Q1Q2CG79CF"FJ
MRF;< !T&,&*Q"^O0,04N$4&D.^S?9*-CMUZ/H>X0X-/CV$Y)+DRB'-)RE5.N
M ?IT;)ZDN(K2Y8IH"*0 UN)F/XD1B46P!8YA]<C?8E<O8LB^0^0;@&5']J;%
MZS7P DT[ "9I&!#W*TA3!*@*I"1#?P;8&6ML<$?=EFS5- \KS/W+-K7.4R+<
M',Y&#.@49S<UN"-N(B* ^1?BE+S-H#L2YJ\9F(%=)7VI=JAX]@;9$WN"C:]8
M>O'L#B?R&O<;9RJ@;33!A?N,GS8_67HL5PT42W7*J_'"3K)TSOMX;\H1  S<
M;SQ150AM'E>A&H>V"(#XRJYPM"W-8T_R:>HY?+36@)<86(F! C'WNF&JS=+!
M3M_!.;A4!C!Q&-M;0E*A,D$+" 3[CJ6!NE5<6 ]8&Q@X8 (/94J V3IPN1%^
M@T,7^MCS#.>DLCRG@64M^*^X;&<=M5'),:43 ?M!P+.61_@QXV%HL58_(ZE'
M4K[XAD55RDJTB^E)0R_,6E,U7.!UP22PT?H0^<,PT,'*FU"C>GV,39 E,%F"
M0P)=#[J&"!V2692($G$+1D^-(4B^/[/+Z$-4 <*T'M>D]-H^F RHH>"T.AY&
MB#(":EQP4^STK.L[G$\;+/]+,2#D+E;3!AOEF$2$M*,BW-X2D<7SCR$PD$QS
M_CE]9&MHC88?VX_P@R$:$%<_<0\4?@T8E8$88 N;!+C06.,TFQ=G[;#&<G@T
MW 7HF\/0S,D[:R(BL>T B!"X4I-86 O_G<<+]]#6PL5B;4E,=;.X'BL$), #
M%5. %H3#$U<Q+.F1V3>RU5@E=VC(,=--5L&1;4I8%$N*SG/LQ C8.BP7LD8<
MWQPG)JI^L+09?R&W,HLSET3\Z70]#;N/42R*<6-'/XT9NW#-M8YCF2 \WK)G
ME5H[I6KU760<(GI"W"PY!!=B0B@.3H@2X-S>#HT$BUO+_CWU\H2+XR!BQ.,\
M3\!A$73=\&#5%6'U;"Q((<*R0Z-*)2]T;</+LKT%MX5]A&20AE T0X_X43!H
MI&[PN[7R#K(DUR+":V3/D?L4^AJ5K>3;_LP&9X7 H!?0"L?1%JP9HD:A6UH^
M-O/E0IQ=>SQR,/4(\4);Q?*P(9#)T:EP"7]'8^!(,K6#6Z 1YBR+:G3Y1'\$
MQ!FQRM)0B$Q0[AZ1I6+VO-BC3FWU/"^$R9(O,-5E%\%BI%NH[.SMK:.H3<F^
M@:<@7(OWAF;!,TGHEO[B 5_"9"M'CJ-[B6K34#@3XINBL*B8$0%-N2#869NM
M&R=I#S:=Z]L*%?VZXO0Z_ZXHNA-T+&,')+ZMJYAWZ!H=9P?/S74L"^4L.^'I
MBC_;PZ'&>"3.3(G#2DWF,DN+X<QDLU<KM6(KY$$)H>X:\: /::D[PZ9.4:BO
M=G3-1! U8J<15B4<PRE[P*M2;0J+3C*X2G_"_P'K BWNG0CWG_LP1$]1LI>3
ME.U57'[G)_L](MAJ95 UF+G!I!:PVBE<;;@6-'M$4Y6# !O1D-@.KT!A>^M\
MBJ$7V76224<F8J8R%$:>RFC,M;(>OX63-BOW()0VO8YNXB7.WPEOX5[XPLN@
M0Z-Y@#V!!82ETMYO7^[ AZ)R[TPW!9[%B[+Q:6#PC5C3='Q-6^H+W%/VB04^
MP6] 9$9OVKO<:>]_BAE0H7^WSUUJY4(C7T \^#(8X!-WG0>#*09.098FW-X*
M,[=A[<;^Q<[E;@AT1[DJ"HQ%%EC8Z>&!L9!A'D=-W!-FP\<"NJ@G#!'!8SUO
M?$KU4M *XZJ4)0[C35'\1@0S4^(X4@@&_GJ'"'4LDXHB6MP2RPUO9EB=\K5
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M[IUYQ^^Q:PPM+A8*RGLD(7S'EZ:"\V&$(DG S"@:[ <' 'Q.[4B!^WD\AJJ
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MDW Q^&1,L2$LC^"0H,13^#."1BY<YU:^4HJPL""_X6E#(D97HQP;\!AP8-M
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M;;K8%:JEDG@<=7O4V &]@(?D1<Z)]%QX,-#ST;0G&P"9),=CW2E7FB)WH6[
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M" #R8>RAT8EQY?H:JFXD+V'O$R*3B? YO(J"WG8%LX&;AHEA;<"&'80U]UH
M"CO[,W@*%KLQ+;UO= WV^%2Q)Q;Y;B*:*VJY(++[?7:+0K8=&]+V32P]\TT
M$<#I)Y]CE] =+"X<!(=PW*$Q9GHONP5QF>P1<-C:S#) ><VV'E(K)2;.RS(&
MY^TA5)\L4N9)*ZCGT\RN;XK;0JCYZVNGL/F0A@?TH>:^]KZ),=AO?(=<5O5[
M=B(6XY9*%R]*M9S+XU>U$7JN2-<_\=D2U%QO(P?O.SK*AA6GZH9%$%H]GLV*
MG"ZP')0(E$.HLLH>-%D?0;G<BQM*RE8AIE%'[!O89:Y4BI+&B%U(F"FF] B[
MYO!3@6GXQ-0BM#^EBX04_^@L&4<K;$<TP7E ]_V4$C$L TX&^O!F7<A8E^GH
MI+S![R,&8,#.TMI6G)RVESZ)92@'$EBE76*4DTU!B5>FE%&^4H)8TS"_S:.L
M);*]0U"D;"K#*2#Y9:94Q(URR!"6YY:T8<"C'\)>\8]^P:\"-257(?$ #;OB
MM%"!$Z%A$KASEF25?%%S:KH4HL49EG2@F-\J[[RC0VQ$LE[@*(+=C]]KB]2W
M%=_>I9S]^4]G/SK[\Y_._E=T]M?8QQS;-)E$K]_Z4-C?ZO=)HXA%X-Z3:_Q0
MFRHDX3)8,2,[PT'B54B7I*J,$YTIM:"LQC8DHOK$?A=UA=>8AFM#/,5[& !(
M:$_Y?]IH_ ^[4M-XP9R>5Y4#'7;]AGSC\0]#7!C2M1;YQR?D;+3A^,CK"C[Q
M.?<MNPH!BA76+/R!BL[>[")>!OV6:YFX>-+EDOYM;^C8_H"<\V(+L$9,7D+%
MVV#_VN#VJ:"OP(FZVK+]; PY+[K)]LV9DA-XS"0S48AE>Z!B""<H.%V@FHCM
MK=^E@K28>QP-*MWA)4"A9SPPA.)1\<3& PTL./GU-7;OCG1FL?; D\J^@JI<
M!]$NA6O/DYW0=O2\4I0O,[ ]0I1C9&*YFEB-%_/I2LY>^BJS<R6'+KA!M.!A
M"4^%7/=S/,4(^P( >$P;)9N:%@0^7>[O9K\UM8FL-(939E.0YIR2MQ\K81R#
M?7[BP(?(XD+G[H7P)GO1P-%(N^'N >&;2J1XQ XMO;YV@2N??7:^"T"B^'M8
MCH6%9>S)V5S$+")VM)S.. %Q,$W-\::I&;$7B:RX5S\R"?3<L\U!:X]^A.YE
MH"+=X:X)2M%"I8Z)#=OQ,(!AN#+(,XH^-A7#8?-S1ECTI.%9(-'CF&,'C@'.
ME,E:R<\',@<?Z^L]A%7&TX0?.#Z\AW]#+WC(1A@0]/DAD&]LQ67+!=1RWNF2
M%8SAB=B)<0N6C!($9G8#7&FV][QM NY*+IT)_#8#!Q+>@L)<DNU2RLZ<FT.^
M>&81MQ),VG0AL!Q.G0)62:I'.@G#@0;CFY%E]!DIX/W#!2'E%F&)* 1]5]WB
M8LHNWV $!6<J?&^1;T1J,TH6\GSILMK[LK17(LLDAIK*%(NI7*F<W,NY^X-&
M:(SV>55X6/K\-5*SG@#QUOI0>LRFY*.W>'U-8CVD5W%G!M#OJZWES*I)X'F&
M3&MG5]%&53,QT?%TJ.M,4:PX#OAH1U1B\)+J_(*I_<%=$3+0LH$4-CJT.^ ,
MU0%Y5MH=BC[CPZ +.7IXM3(5QKB!4 T3GB11@X3FL)27E':XH0FJ'3.VT 5K
MB4@T^<LA*9I="[,>8&J6;ODZCXX1P:9X-($\.Q)0O2D0X%)!N7,$^MR>409-
MB\0JY)$&_FK0!4C;PDN%8H@O*=)?BTP6\4GMI-%NU"H'2J56:YTUVXWF#^6H
M=="H->JGS\@D;Y0?>!TZ]Q(RZ6PA!")"7QLCU!O!C85J=4BE@?&).?U:MVL[
M/10T%%1C__8I[LW+!T#4#Z@3!V0D=[L 7Q$DBIQ9!MKQ'D;# $>?:;1,SR [
M'S5Y9NL;(_PU@<J[_FA,*B;1,&<W; 4 *!B \B @'_H<7R4E8T,$[(4?#-DK
MT%C)Z%E?@_B#:;M^H'3APF)($ZA>=32.-Q!.EO'_D*G=MH/@ C"*8Z#;#&\C
MM <2:YGHD$EMZ'<ZL::DTXOZ"3E#*0T1-Y_8&@4#99B@NT$HCZZT@>^ FY\V
M-*4<H:3N0',;RX9Z@@&ILNP80SE,FPL!33@MF8H9"W0-3GSAZ48RGK";A&7Y
MB+N)G0O8X>\ ^(.:V=@/PO^0;"B2^9,@+A@Q[1NF"$^CHE2OP:>:]AT]FRV]
M>&^/MWF03%:?U&OU9EN2U.MK1R>M)OM'K7[(?O.< GME]N7(Y!@_P/+L_F[:
M'D#%"+?1B=Y%B,F0G(\<VV)_)V=8D!!FH+]"=X4*4!.W@=+@ET%-O@QV@LO@
M5+X,P*^## &9$X8;<,#QRI,KI<)CDJK1^\]?VG\SF3S$D##UM-&N'S(S7CD^
MJS"Z;%?:C?.Z4FENPP\.Q+^W&Z>U@];IV4G]5*E46V=MY;!RLE]OKZ^=-$[W
M3]//B-+[2E[[!3O/J%!*$7N'AU^('GX^K=1:S?9)Z^ 4#Y[)I5I]&\[Z71TK
MF\%VH!$I/$S%<;*.P#+O@:;T$<7P4M'DPF<T&:/)A<]H\MNEY L=JV<Q*!&:
M/^!.(VY7."@>9_; C0 *,1LBZE>6S!<P=1PT$_&-P.=@6 "21FYE!U PG"#Z
MQ8?G&@7&@;!0Q^AR0T^HRZ%C,9*):"!,(?!4+T53=C'9+ #8XHF)@=4(:C>W
M!# BQKM@*NY8[S*+@6QCH9<'26IA] -6X@;P;X_N 0;4Y/6S"3/#PQ_Q1$SR
MLH]&/L#346B+MH$ZI5&P$6WWH:'WF86)Z<+@M>HS\X9'G'GXC.KX)2N>/Y-"
M@$1 (,,E V0H6RMY32$WR\'@4' P(46LO$KW"XS1U1QFPL.>0EHNL^2@ $TC
MAUU(@ZX_AO".*P(E@3$'T3\#SD'@=,;/,HR,1D]M]LE*Z PSCI5'E(($ LPX
MYS\D5B7R$&Y$,9_PA)4Y+(]V:D_O&]2I$/-ZU]?4G*:HA:_ZMSG<B&^)2:$[
MGO:$2N^Z4)0GT$$9&QP3O(,YG6%/'Z>5:EC!Q!Z6CH&+B65W+LD/L&ANQB"/
M+K<E%.0(]AI+HM@"H_&A#\<Q'.<Q=+&@+8G525QWI%K,T)JDPV8,\/+%QF]S
MR[83:+HSP1\H_9>1'-*=90=^+&Z^&WRC!;W2/H?$[HA]9@8-%"G!W08'% JC
MX'8+F6M]38XSG^"MQ[D>J@(<]I<>^T^1:@0BUW'DW@=/,+(+7,*+HBSA"XRK
M\(W4S"6Z<]?XSOA.H# F;-)B8),>54[:2J.!3B!5_4=IM7?K)TJCN=,Z.:RT
M&ZWF"[&6-+5GME1G+'<K:H*K:>6@_J-R0+9W?;O1_/'.C.\E\9#7UVXLILTQ
M#K1"[E$P&LCXW60ZG2G"Z  CD>*A""PBLD'=@X0/]FD/D(<APL%KE.'*!&$1
MQ@E%37DJ3'AD/\:B:*Q*8&R-X42_XQH]@VG<H"9#!3#E0>'O^_Q%?+[/TV/8
M])A>X$%=@\B5BE4/2PL N25_@U0 *ANS'3<E;G8,@\H%6C957$MIEY#"%M9A
M26%0!?[ G+>@WJKP/T)C$C5FH+U#M3$30X :%*QQB"4ZDL'#&\OR)\5NSM@M
MD44D7GEY^.<_YE KQ;BYDE; +ZKL5&KMULD*<O*LV%-(!-)]C0F8CN'>* !"
MSRA6:D-H!/F?)_# #CT@.>V/&)$IC932\'2F&U<$22X1BTITD(=:OV1(ZL_'
MHUZ:\LI1RLNFE;/F2?U'X[1=/ZEO*Z>5@_JITMI1ZL=GC?9/V($S2!JHDZ?W
M[+0.O^27SDK2J:1S/F:- <Q!PASC_2WN*!$7,[T0S(9*%]RP3)1'N'G&;B+=
M/594&M:2YL(WU]?@54A"!J0R3'KEOAM(15!$5ZW8+$L;^ZM+H&HF$6C:KN]4
MS@[:I\K94:O)*++9:)U(A+F*1-BTK1>,$[WT$:F)<-!AHUEGLF.GSD2&%/I;
MS:.1@WDKS$C9Z"D5TB]H&'VRSG/78A8_HV<8/2M^1L]>0UCDHL*BF%;JE[N-
M:J/]XB(B[(HB=T&)=TEY\KA2ZY,%+5(>Z8K":(6>B*&C_ZUTXMC]8CSH#"$P
MSQUJ+5)(;R'FN?@QX)V+G\8<'=B2Q#4>=%HD[EG]'M%B>&-KLH@[CK+YK_+H
MJTT?S1;Y34*.3^*](ULD5L5_R1<R[]>"@^9M2JG\Y$W!!3ZZOFW,2L2,TO@:
M'V]V,.]P?WFU_/>TDL1OGY<HON:^+76LO[J6YYUM!7:>E\4UK*[MC#G8(0:6
MJE-3F[B)Y;SG$\REU;=Q<IHR=/3^?_X:>M[X[\W-R6229B9L>F#?;5:<[M"X
MT]U-O3?0G,V>YFF;:D[-9PK9S4PFHV[E5#6;S3()F\T4LYMZ+I<I_E>_SVVH
MZ:$W>FP'YI/$5R/X)QGEF.V)M[YG*T(: MX_=R4NF8JLS,E$5KG7)^+HR=.O
MO@6GI'T$HLRN/%%F2H5,;BNSQ8A2+9<W=:*6W'^7HDDNB!83(.8+SW6\A+14
M&3N&J:A$2+D/14AP/^6_K<[UU$ X!$KKWH9,#^$@/,$Z7Q!1W%,W57:I4.PC
M75;Y]W-9Y>#O[$=Z/E<JL,LJO]QE=2*CD7"BD/M"4)5  NR\0]C3'=V;0$1$
MAC!+H('/@"=?ZA[,A_?@PBRBX"J,M,'9UKO\+A1M-@+Y%2QGZX-*,#6S0B+L
M4(3:,-5(ZWH?2D*IF?<KHACS+B6C9J#-SI9+KR*6X$0^Y=++6/[J*IG^' 97
MVU#S7[5OFY@]1W^OP:D(C)4/):YR:EK]W[=Q?$)>Z?EBL036N[J<M(D<'D(L
M#QVH_AY#<M6AX;J F952CH;;Z8_$G^QDLV_W9+._=+*G[%)P-*5JZY;A=H<?
MZ3A1W&972=QR ',F<0L9Y0-+V"R3L&^5$;//+6()P3/*IA]*[)*YIJZ0O799
M/3GX2 S)3B?=:)Z^$99<.%4X&H7-M5UIUNK*=JMV!G ;'^F@3FN[*W-0[<IE
MJ]DZ_*G4+]OUYFD#,@1KN_7#RD<ZL%KE8)4/C$V_=G: &6G*0:.Y7ZV<UC_2
M\6W7=U;Y^-CT&\W&ASV]@TIUE4^/3;]^\"$/[NBDOLH'QZ9_RA23Q\7F)J;8
M/4<&W[/F(/ZOLH,^7:@;@HJ;YTFU?HT$WO]E4_<=9F8-GWWZ;SLI>>LS*1F3
MDK<^DY)GTN7+Y_(NE["+^Q#*\D@N,,K7B4YRF;H"S"8??+"OC0QS^K=28[_L
M.(9R .\!T#W6BOY_V9U"OER<(<&76Y@H.36LGCV!.<S(S Z!]TX;/YJ5=EA7
MLT#2_]99X_]R2(VS]@5_!A#Y\.&-7#%*BB]%:4<QT'^.T4-).XD>C>MKLYLT
MTIN4S&%YU!+9-Z=*5_-=Q$!!$"4,4A(H$P=Y@H)P:#"A#S6S3X6"O)<V/9 2
M/1[96_#!]37-]X8VHBZM^L70^;?2K)S7+YF.L5-GQG6CWJS53Y5:Z^0HK;QT
MM<^K"YCG+!;@GRV V%JLXVVZFW.]NW-55/GS8I]^3VV?H\Y&/H_O_>IXC[F\
ME]Z#%YL 0(O5 QBE%H$IO-;P7X\"J*;$'+Z]UB2@^_+?V)^L3!D62PW\7$;&
M')R&R*6321<,ZR/)AGDAV/<O$6(K3RFUHPK[OQ^5U^*&D"-#W*X_)Q7".4#(
M3\*Y_D!"@AMT27-N-CK3<VE(3QPVN7W"E'ADM&0LNQ3'P9$L/$BOVA!6GFQL
MRG,";U-T&;D9IF8.3<VD,8\O)"QY>9KPL8B-)O8<K%+^_[)5&IGT*VF.FQV[
M-T4:''HC\]_H+I[JGK#R[WOW_RB-;?S+?S.EZG_9MW6+$$)QMOB>OO?0N_BA
M'C4>NL>;@\O<;J934.NWC>G$9P0P.1A<3?/58:-:.!V?;UY4LWNE>M$IY+3<
MS7;Q>M.^:V6/[CK#@\;>S=W9]_)!^_1LV]#USOE#:9I7V^/;?GMG^[:W7=OZ
MKN<:6]>[G?UB_63K>F?_W#FK]?;W)KV+NZM,9;.3JX^L3J_V?;-J[;<'D[W&
MX4TWYW2_GUT>[WS?M8^OQX</Q6KYN[-;+EZT<M7OZM'55J8]VIGFCNZV<Y5B
MRSJ\N?3&YY5!KV*WM>]7%_:PE_UQLNO?_[P[V3/='^?'9=MJMXO;V\[N5O]:
M/2I7O=[6>/+SOF-D>]=WVS?:];%^MWW6O\[9_<N=D?70TJP#JWVL7=:NCTX+
MVH%=M$J3O6/3>A@5#W?=S9.:L:ENU6UKSVT-F[V;R_*X8[:\C+]_,>VKAT[?
MOFD.;XKZ][91G@RZSN'%Z=G0O3H\N-ZK-@<_MHZO\_</]:V37+MT8/B7E>G/
M\]JX:Y?&C:WCJ_SE_;&Q66D6].G>P]W/R\)AZ;"S>>#6=37_P]_NMH[ZK;-2
M>^_AN#6XW\SO;9U7;^V3PYJ_.[VR<UKSKN+L[W=O]G[Z8__P[$>AWBCM.X4=
M[_:AG<MNN=7<WCE;H+99/#GQO'+.:U_N[_N[VS\M]>9P_T*[>1@6VH[3OG%O
M6],'[<1BA] [.3H^'EU>;D_/BY=GF<O>J.1>>A6S5S^[/6B6K%RI=]_N=TJ>
M5QL<'MY<;]]5*[N=2>6@LEUM=RN3ZMC=RW>ZC89U[#4F/V^KW4[QI-"^J%XX
M-WK7^_F]<S+U"^.#NUKO]MQQZ^7&[O7DIMP>#+R'H_9/9](VAIGS_N7YA=-0
M_8:YL^]E#JZWO]^5*^=MQSW+= ^+^P>;G8OQ;O6H/MUMVYV=G'5K= [NVHV]
M^E[O=)I].&IXE?O]3O-V?&X?UG8K1=OI-QQ]NU>O?G^XLH?7>^W2?D$?EP_]
MO;/VWE7.;QT<J=VS_-2^'6S>VM7=XMZ>66Z8T^OKKGUW=^P,;@J7^8)E-MQI
M_SYG]/)FNW ]J@W\VX-#RQQMU8:UXN2^\* ^J%O^Q)F>#^V^76S62JJUHW<'
M^^7*U??:D=YRC@[.J^6#DZN?PZU&>7QYT7..S0>U<&)Z6\V.LU>Z81_;.]ZI
M7YU=7^K3\]I5?6N_=N#>;O>:^UN&?9W]>9PS:]/Z5;O3W,T/6I.S1J;N9,V*
M?5[*],J[V_7]0;,[T:WF]:V>,4^J_8YE_SQYV.X>^<[.WK3OY:XGHY/#:NF@
M4CV[^=Y\.&X_U+QA_OIJN%48GAENZ?OAX<6./CC</SL[K-]O;?^HMJ_L7N[2
M/6B:YNW%]TNW>>]N-[R;DX;6'-5K9_;HWC\_OKTY'YBW=KE5O"T>[YZ;M[O5
MR5VI;&?&Y_M7E_N3ZOU(J^X/?NZ,A\/^S?3PXGYX7CETCLYJ^UICNW=U[DQ^
M7D^]7&MH[1EE_\%RO),?W7'[_+QQO'=L76::_L^KD\M#]>ZJ>&:,<OJ6:[FF
M7E)/K>'0V>^J%7UXF/?OU,WMWO!NNV?I/[KEB\)>9FQ7KL>]ZO?\^62GW[GY
M[E^6<I5+K6Z=6,U:I3JLMWXT-B\'WE&NV"]W\^7AQ=;AYMW$WV)$F^GTK)Z5
M:QU<M79O,Z.;PG%55\VC?6WWXNAGX:33RF]?9>[.L]W1SZ%Y^UVU?GI5P]'V
MBC_MN^/"]L-4&]4-S=N_:A@G3?.B>IQ3\_UIL]K>;5P>'_NM;;5K&#?#8WW8
MO;/5XL#4-_5>Z[S6^7Y6[>V;/S+^3NNR4MH]NW2GD^TCYVBK?5NLJN>7%U73
MV#8&]JZ>R57T0:[*1'&%";)Z*YNI>7='M>']R7GV^_?KF^O#T0UC_9)YY?PL
M:E[^2MV9;C?O:KD?UF'MO%5L#<Q*Z39_N']CGI5;Y=+9?G7;O<L=N3>]\LZ=
M:FFY<[?\LZ5='NA:XR9SE1M6=\SZ]:73N[>SA[O'MV[C;N>'M7MSHU6N+O3:
MD5=NM+33?O5AY.W^.*QZ=X?9TI%1&W7/&E9^4#K=N:FV?TY:U;8].:KN;AY,
M'Z;%\67G_O[.S=Q?_V#K:5S?%SK-/>OZ9ZY9=_O7/UI'M<:DM3OJ9K2+776J
M'Q6VA_EAIE_8?6A5+PO[#V/VX<WA?DZ?%KM><WR6N^YN[5[M^-[=CYMJS>Q.
MMC-WNS_TCGZ_KS;KMSLU>[=Y?=J[Z%Z?MK5,LS<M3;T37<L>7>G[0U\]N#WW
M=C..T38WV2KLP\/3X>5553]Y..P^Z)O3P]/OCK$S&6N#[FWS:&NR<[%OE(;M
M7OVJ,N@?7VMZ<_]D^G,X]:JY[]WCFP-U?W1_<#,].KMW;K2FEQN6.NY^]: Q
MN;#\S<X@LU<^ZSQH/_:.^J/^WO;/5GGDG;CCP<G@Y][/VKZ9S_=*IXUJOF8,
M.@\%Y\QM[OTL%Z>77N;AYDXMG1_<CERCF^V>'6U>N9W]EC.^:#NETG33.*J=
MY8[_\Q]2!_Y_4$L#!!0    ( .2#J5;7QG+V6@<  &T?   0    930V-CA?
M97@S,2TQ+FAT;=U9;4\C.1+^CL1_\$4Z!%)#8#A.6LA$XB7L1F(8%J*5]J/3
M79WXZ+1[;'="]M??4W9W7@@,F3TRIYE!$XC;KBK74_54N=WZK??IIKV]U?JM
M<WZ%WX+_M7K=WDVGW6J&WWC:K!ZW+CY?_2D>>G_>=#XV4IV[4W%T6#C14R.R
MXI8FXEZ/9!Z%@4@\D%%I PNQ]*Y>-Y)FH/)3<=B BKOP\!_[^^):49:<BOLR
MH_T[.2"QO]]N777_$.<WW5]O/S9N.M>]QK*0?:<+F/"A<&>B&NEKY_3H5!P7
MKA&6+YB[;]5?A 4\OZ]-0B9(N,AD_"@@1EB=J63VL!86GA_-GT]4XH:\^<-_
M-MH[>=\69ZTFE+6KSX7]-)<V]*HK:B%WSZ:LZ^7: 1!V)AP]N7V9J0&^&C48
MNFI(Y0FQN,.#$Y7/=%ZT.T]#U5=.'!\='+6:%^U-F;'!;<;8&!E ?M&^[-SW
MNM?=R_->]_/MAK93JWO'_33:W4A<#HVRB,DA&?%)69NI?!!!FW$JG0HWE.[T
MG91M#(G_E):-;;2/#D17#.68A*&QH@DEV("RXO=2&C@OFXI[*K1Q0N?;6]?:
MC*!U_W>1:H-YA/^&2,@\$58]B1',&EI!B.!$?)(F'B):(_'A\,.QT*DXSZ'G
M2=RHE,1#K"B/8?FE-L6!V&5A.UGRI=1GA@9PKY&YVS%^8&^C'MB\CS\<B MI
MX1*=B]%4/.9ZDE$RH"BXV@0')YKL]E:NG8BA6:H<;IV*,G>F)&&==#1"/+,?
M)30"&R4SD<H80T;H$9C!Z3!O94).\+259LI31O*1/'8SF19C":Q1@#AC"F E
M/"-6)BY'F.>1*@&K$9.A JRVY(^Y@ D9JJ3P#D;*9B03Y 58V VQ15M0["UD
MN05LTPGV.<:R1/2GBX[XP<$^_@K8)%*5PYD,S-QYT?86)Y!VS"?S"2I'D@%'
M!4$JC[.2DPI1L>"J"/ JSM$"#N;@X*#)LCGZE=_M,]T(L$2QX(AGE)E#X %R
M#5R\/NLS.I9V*-),3VP=#_/,%)('(S\/9D8+L-K:FA5S?W!D_W4@>DM.V#&6
MZ<E6T%4% $'/WDP5OGO_=(4TY*& 9U4_(\^>A #H9\H..4EXV@@ISVG/WQ-E
MXTS;$NN8#(S. B2%T3$E&+9B%P@D!$R#FSM/\5#FZ%_.D6;<S0#2HV.YDR=
M\>SH9)?VO(2CDV1Q+ PJKI-Y" Q6)C@Q%^(EP,>&O:E5+"E-]T)L+VE-H;6N
M'XL1A7E<B-ZG=FX^2OS/\>'!OPOWBK)=N0=G60S"6YXQ7\ U.&@.;,1T'LO2
M?F7-\U@ K?9IKBH0M2X-!" GQ\KZ5,<LRKT<;E%F)+&]M<@TAC+ID:ZH>@Y0
M5+$0/U2@%!CC&VWIO*5]JQ(EC>(=J%!1//GE+*FT3/(^3:RO")X8M"58Y,!$
MQ"18H.-0<9E)9C1LS%LQKQ98$FK/8M'$7WWBB> <K*?D>V'[?0.I_SR0GF<L
M&.>5E%V)I_63?>VP0BB.54+;6X:DU;EDCI,6H<:- X>0-$F-)@),R;[*E)MR
M67E)+T>W!]YC&N)R:>I"X^&I]"GL""%4F@)197TAC&,<$+T%O@<94([REB&V
M\(0*CEJ>@@8KQ ^B6Q5@L)\S@N(]06.9E3Y;V;F4IN@,U!A>L:'\NY>+VQK\
M$[Z^7/1]P& AJ,.&UJ*O2_<5$][6%X7N(\C@SBE]NZL4_;HI\TE0^0(&G;'P
MGQ+R9*_VY2HH.%IL;U6UVS]Z$?IOH JN*#J.2\.N7R#O%Z2.M'48Y]/Y]E8*
M"R'I2SAN!CE#:6?5B=/5APDEGLG\%BJ2F8I,/5)6G6J>S8_6W=3KU/F#AL8K
M&D[^=OOJ7P_,0BF:IQ*G]@*:"UG%.;EV]$2KS49M&[HC=!Q.&SNK"GX ,D<X
M\CJBU;/);%]]C;K#SQ,% [V07800>,(R$>$W]SUUI-*74L%^WD=:YK$_!^W]
M7,THGPVYF"N@RRTW=_+^/8RBJ@^=G1PG)!^9ED,M];SL^P#_LJ$^)WX3RE7W
M%LY"JQD,_0E66IIE\&NPUMT#@@:PHL9'H398^,66(_A$_17>255D]^*9^@=-
M[O6:17YSE!ID2@2ODT]OX.;?S%0 H]_V7*ORL<[&Q(2;RT'UBLE4E$"C(M-3
MPM/)4 <:D$L!!+S_A_K!_6(5' ?_'R1ZYQ<W'7'9N;EYN#N_[-[^^K%QV/#?
M[\ZOKNKOWVS0PLW#[)HBUEDF"TNGHOZ+[UQ:O?M:_)CY%[6PMMGI(LRXJF=4
M8D_X/J-U_?FV]]*UR2'?J5P!Y5/Q24[%+^'U:ZO)\_FZZ.IUF;5S, <?]^N:
MM[AN9>!;!-4SGEWL])<O=M[:>],V7WY!?S>\>M4-A4SXA#+3>52XO^^/K]NW
MOG$;,T!1*CI/%)?<?(O/H=C#!O36BB^?/'D^4&S(23/]7G;MWH4S&/ABQ;B]
MM8QH^GS>((^\?4_W_NU"1NF*RO>ZE3U^]TO9=[ITW9#7ED'R*IM\71[NS_F:
M_;]02P,$%     @ Y(.I5ENUV"-1!P  %!\  !    !E-#8V.%]E>#,Q+3(N
M:'1MW5EM3R,Y$OX>*?_!&^D02!U"X%AI(8,4(,Q&RC L$ZTT'YUN=^*CT^ZQ
MW0G97W]/V=U)AX29S!S,B0&1T':YJEQ/O;G=^7/X87!1KW7^['6O\<WHIS/L
M#P>]BT[+?V.V54QW+C]>?V:?AI\'O7>-6*7VC+6/,LN&<BH,NQ5S=J^F/ W\
M0, ^"2WC!A9BZ5VY;LKU6*9G[*@!$7=^\K=FD]U(D41G[#Y/1/..CP5K-B\Z
MU_V_67?0?W_[KC'HW0P;ZTR:5F50X3BSYZP8&2EKU?2,G62VX9=7U&T:^8_
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M.!_I%>;CA>OYCH*:/;W)SE]MTQOPOP%02P,$%     @ Y(.I5H>BE<WBA
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M?1F_]TR%"C%IM426,%O'K@S"-!I)]>0+]_:'?_JM-*.P(G?JI:G,B2E$F!*
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MYVB6U[M4A16& PR9%K9?T_22(O3CE\4.:8C5PN41V/8\ 3@/_69/K*#'<@D
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M6^'\P0[CQP)EGY*0JEU(;)!376&"HGD>KALYTO 0<F,K?69@;9?E@O4BA=R
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M!':H.%%N''7V8[4Z'P)?!5L.&S9D_YBIX)\YK'BI_9M7GX&LBE74/-.GB[1
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M[WJ^1&/_!PNV>S<*/T$JK"F3H33[J#"MW\RP)/2C@^,Y! 9<=0;5 ;9,[T4
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M*36^;'RA9]4#$9!0.24_W0/Q%):?NVK2G5"UN;C(G2I_(!BS=5P$?7NZC1L
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MC'N]@@_8CN:'2-TBZ+W+BOWY3I0,Z!X:HTDD P(\7E::=59%*L4W[LW)U51
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MMPN-/076(_&W*R!D=VU$#O(_G 1K8OR^N,)'N93M$162QP,H,D^CO,;COT_
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M=K:B3?JQ'',4K'G'6VN#J""X?/=&M.(=!%CAPARWM*2;T4N9VCYQV2HD+Y)
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M@'OXZ_TK'YY/_TMZ!B0/_"]02P,$%     @ Y(.I5L GWW&B7   G&X   L
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MG*L IBH33 >S_.#T*(DJ]_@]!P(,#R@5W6[=AQ$D//C(08",Q(S_(150 5L
M()D59@I!D'H$O2A]JL]>,L[<-8Q2<)<J*A<@N#?>MYH\Q^.$.(CGP6-GO,B!
MCC[+G ^FTIR AT?0+BK0ZD*IH!$Z$F.H\J6H#7QEE,:[7PV;6-\4@Y2WN2M=
MEOICHW[I,JR<,WN"_^H!_5.)RH?C;V&&$Q)-C1^4"B@Y,XBK;.(8ZJYPB.P+
M_=M-1OO8VGH&%7/<S#CWC);*?PX4D)A8L5@D@:3PUQ8P)_5X>J/H/KLIZS,+
MF'&3A1DUG^F,&]ZQWUPC1\2M:N\/#_B1?WCKI+^>KX!'5SAX*N>[-;6.8\7#
M(V-A0D#' ?IP)?3E::N+/"U2 (>*L4%$T(K/VQP%U5IL<417T7BA"7&E>Y_C
MNC2@K[N^3+&V,7"V!R=[PS/_2!]W)>VCP=NQM<H4-S84^I)IEQ(#[;J..GK$
M0SC3Y.,-[S7,')7,<+H#FZ'H'!V<@#*5(G#C[F7YM!4NO!9AK[[,(()5Q("I
MAI A#T>#-Z8X//7&76*-.GB92.-H9F7[03:Q2:5Z*+Y(^]37SLE5N'(H!UL,
M)D#?8#4-#@)8<5R1N/5#D4N73O(2L+DFKC>9KUIR%/%2?C23Q)OW H6T:1+I
M8^&K8&L[STT^1+IL8G7T)I1KY,<U%;OK[<//[DI'JKU3UZYT8Y2W/Q5>-(Y1
M+UKJ.+V3ZBN_/#_J+:M3EL#IU?RSS%8)B '+1I-_19BLRB&QS*;9CQ2Y]EL^
M*1RX;*SKJ54]#>1+O.PH'SW7/%C]@M?O;X-1!K.G^0C<$6FCIO<&5*:5.#<4
M>YK>1\EP]+_6PY#2ODFE[3^QP[T@D%7^X.5B'IG A$93=8(?F\#0(--<LFYJ
M_;5<!E\!9*L6*=LVG!=]:F:<#*.C/1YX@<=PH NGO UG;C%<\M44UG;0>J?B
MXT1&E(RL<%/EQ:F0' X3?Y'RZ+5NU3F77565E_"2?^\:G+P[2P0'[!@GMP7"
M8<^3TZ_ZDFI2U-G!9Y%$EOY:?0*EO%N);4$D%*4D.0(FI8L]Y_S'7PJQ'0IY
M[()RSLP_?6O-+C#K/ .#&QA%Q6PH#V(:GGBL N]/YRC!6^2Q+.(H@RRAMB$
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M1R?IK#KW,2)$1[@&_Y@7 ($&K"C4$;;47)D0B?DBJF?SPIWORG"MINB9KB"
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M$*;D_X<4?<S+S_\!4$L! A0#%     @ Y(.I5DGR"RW>"@  !&<  !$
M         ( !     &%V>&PM,C R,S S,S$N>'-D4$L! A0#%     @ Y(.I
M5HD#8K%G"0  :&@  !4              ( !#0L  &%V>&PM,C R,S S,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( .2#J58=:YHQ1!0  #9+ 0 5
M  "  :<4  !A=GAL+3(P,C,P,S,Q7V1E9BYX;6Q02P$"% ,4    " #D@ZE6
M\Y$RG:\X  "7*0, %0              @ $>*0  879X;"TR,#(S,#,S,5]L
M86(N>&UL4$L! A0#%     @ Y(.I5OB7!SY;)   8F$" !4
M ( ! &(  &%V>&PM,C R,S S,S%?<')E+GAM;%!+ 0(4 Q0    ( .2#J5:X
MV$\VRAH! %+#"0 .              "  8Z&  !E-#8V.%\Q,"UQ+FAT;5!+
M 0(4 Q0    ( .2#J5;7QG+V6@<  &T?   0              "  82A 0!E
M-#8V.%]E>#,Q+3$N:'1M4$L! A0#%     @ Y(.I5ENUV"-1!P  %!\  !
M             ( !#*D! &4T-C8X7V5X,S$M,BYH=&U02P$"% ,4    " #D
M@ZE64*A<5O$%   (%P  $               @ &+L $ 930V-CA?97@S,BTQ
M+FAT;5!+ 0(4 Q0    ( .2#J5:'HI7-XH0  &ND   +              "
M :JV 0!I;6=?,# Q+FIP9U!+ 0(4 Q0    ( .2#J5; )]]QHEP  )QN   +
M              "  ;4[ @!I;6=?,# R+FIP9U!+!08     "P + +,"  "
%F (    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
